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The serotonin (5-HT) receptors, with seven subtypes and at least fifteen distinct 
members, mediate a wide range of physiological functions both in the central nervous 
system and in the periphery.
1,2
 All members of the 5-HT family except the 5-HT3 subtype 
belong to the family of aminergic G protein-coupled receptors (GPCRs).
3
 Over the years, 
various molecules have been reported which act selectively at 5-HT2 receptors.
4
 However, 
there are no ligands that exhibit complete selectivity for one subpopulation of 5-HT2 
receptors. Insight into how drugs bind to 5-HT2 receptors could contribute significantly to 
the development of subtype-selective agents with enhanced therapeutic effects. We have 
   
 xvi 
begun to address this challenge by the combined approach of chemical synthesis and 
molecular modeling. 9-(Aminomethyl)-9,10-dihydroanthracene (AMDA) a novel, selective 
5-HT2 antagonist that also has modest affinity for the histamine (H1) receptor has been 
reported by Westkaemper et al.
5
 A structure-affinity relationships (SAFIR) study of 
AMDA and its analogs was carried out by studying the effects of N-alkylation, variation of 
the amine-ring system linker chain length and constraint of the aromatic rings on the 
binding affinities of the compounds for the 5-HT2A and H1 receptors. The results of the 
docking studies carried out on the homology models of 5-HT2A and H1 receptors were 
consistent with the observed binding affinity data for both receptors. In order to explore the 
additional binding site interactions of 5-HT2A receptor, synthesis and testing of the ring-
annulated analogs of AMDA were carried out. A 3-methoxytetraphen analog of AMDA 
(26) showed high affinity (Ki = 21 nM) and selectivity (126-fold) for 5-HT2A receptor as 
compared to H1 receptor (Ki = 2640 nM). 
  Further, to test the utility of our homology models, and investigate the binding site 
specific interaction, a compound was synthesized and tested that lacks a basic amine and 
contains an acidic functionality designed specifically to interact with lysine K191
5.39
 found 
in H1
 
but not in 5-HT2A receptor. This compound would thus be both H1-selective and 
demonstrate that a basic amine-D3.32 interaction is not necessary for high affinity. The 
synthesized compound (34) lacking the nitrogen atom showed moderate affinity at the H1 
receptor (Ki = 250 nM), and lacked affinity for 5-HT2A receptors. The modeled ligand 
orientations in combination with the observed affinity data provide another example of a 
successful structure-based design strategy. 
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INTRODUCTION 
 
 
 
1.1 The Discovery of Serotonin 
5-Hydroxytryptamine (5-HT), commonly known as serotonin, is one of the 
evolutionarily oldest neurotransmitters.
7
 Its discovery and identification as an important 
monoamine neurotransmitter involved a multidisciplinary approach by several groups.
8
 
Serotonin was first described as enteramine, which was isolated from the gut in the 1930s 
by Ersparmer and colleagues and revealed to cause contraction of the uterus. In 1948 5-HT 
was rediscovered by U. C. Irvine‟s Page group based on its vasoconstrictor properties, its 
name being derived from the fact that the substance was produced in the serum (“ser”), and 
constricted or increased tone (“tonin”) in blood vessels.9,10 The chemical structure of 
serotonin was proposed to be 5-HT by Rapport
11
 which was then confirmed by Erspamer 
and Asero as identical to enteramine obtained from natural sources.
10,12,13
 Following this 
discovery, in 1953 Twarog and Page reported the presence of serotonin in the central 
nervous system (CNS),
14
 which was considered to be one of the major findings in the field 
of neuroscience. 
 
   
 2 
1.2 Serotonin Biosynthesis and Metabolism 
 5-HT is synthesized in the human body from the natural amino acid L-tryptophan. 
Tryptophan is converted to serotonin via a series of reactions (Figure 1). First, L-
tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) via the enzyme tryptophan 
hydroxylase.
15
 This reaction constitutes the rate-limiting step in the synthesis of serotonin. 
5-HTP is in turn converted to 5-HT via the enzyme amino acid decarboxylase.
16
 Serotonin 
is released into the circulation from the enterochromaffin cells found in the gastrointestinal 
(GI)  tract and rapidly taken up by platelets via the serotonin transporter (SERT).
2
 It is then 
stored in platelet-dense granules which comprise almost all of the circulating serotonin. In 
the central nervous system, serotonin is stored in secretory granules and released from 
serotonergic neurons into a synapse. Serotonin is metabolized at the presynaptic terminals 
by the monoamine oxidase (MAO) enzyme to 5-hydroxyindole acetic acid (5-HIAA) via 
oxidative deamination. Brain 5-HIAA is actively transported to the periphery where, along 
with peripheral 5-HIAA, it is excreted in urine.
17
 
 
1.3 Classification of Serotonin Receptors 
  In 1957 Gaddum and Picarelli started the subdivision of 5-HT receptors by 
studying the effect of 5-HT blockade in guinea pig ileum in the presence of morphine and 
dibenzyline. They proposed two receptor classes, 5-HT M and 5-HT D.
18
  In 1979 Perouka 
and Snyder used radioligand binding techniques to describe two classes of serotonin 
receptors, 5-HT1 and 5-HT2.
19
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               Tryptophan  
 
        L-erythrotetrahydrobiopterin       Tryptophan  
                                                               Hydroxylase  
 
                    5-Hydroxytryptophan (5-HTP)       
                 
 
                      Vitamins B6, B3,      Amino Acid 
                          Magnesium                   Decarboxylase 
 
                        5-Hydroxytryptamine (5-HT) 
       
    Monoamine Oxidase 
 
                       5-Hydroxyindole Acetaldehyde    
                                                       
    Aldehyde 
     Dehydrogenase 
                    
                5-Hydroxyindole Acetic Acid (5-HIAA)  
 
 
 
Figure 1.  Biosynthesis and metabolism of serotonin. Cofactors are shown left of the 
arrows; enzymes are shown right of arrows.
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Later Bradley et al.
20
 proposed the existence three families of 5-HT receptors, named 5-
HT1-like, 5-HT2 and 5-HT3, the latter corresponding to the M receptor. With the advances 
in molecular biology techniques 5-HT receptor genes were cloned, which further led to the 
identification of number of new receptors devoid of physiological counterparts.
1
 Based on 
the new findings and a constantly developing field, the serotonin receptor nomenclature 
committee proposed a new nomenclature system based on operational, structural and 
transductional information.
21
 To date, 5-HT receptors can be classified into seven families 
with at least 15 different subtypes. A majority of these receptors are G protein-coupled 
receptors, with the exception of 5-HT3 (5-HT3A and 5-HT3B) which are ligand-gated ion-
channel receptors 
3,22
 (Table 1).  
 
Table 1. Serotonin receptor classification.
23
 
 
5-HT1           5-HT2           5-HT3           5-HT4           5-HT5           5-HT6          5-HT7 
 5-HT1A             5-HT2A              5-HT3A                                        5-HT5A             
5-HT1B              5-HT2B              5-HT3B                               5-HT5B            
5-HT1D              5-HT2C   
5-HT1E               
5-HT1F               
Coupled        Coupled           Ion              Coupled         Complex       Coupled      Coupled   
 AC (-)              PI              Channel           AC (+)                                  AC (+)        AC (+) 
 
Second messenger system: Adenylate cyclase (AC), Phosphatidylinositol (PI) 
 
   
 5 
The 5-HT receptors and a large number of monoamine receptors that belong to the 
G protein-coupled receptor (GPCR) family are a part of type A family (rhodopsin-like) 
GPCRs.
24
 The presence of highly conserved residues in rhodopsin, β2-adrenergic receptor 
and other type A GPCRs suggests the possibility of serotonin receptors sharing certain 
structural and functional similarities with them.
25
 While the overall homology of GPCRs 
compared to rhodopsin is low (35%) in the transmembrane region, the presence of several 
highly conserved residues suggests an possible evolutionary relationship.
26
 The 
phylogenetic relationship of each serotonin receptor to others is shown in Figure 2. 
 
           
        
Figure 2. Scaled phylogenetic tree comparing all human serotonin receptors with bovine 
rhodopsin (BRHO).
3
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1.4 Serotonin Receptors: Clinical Significance 
Serotonin is a neurotransmitter that plays a role in large number of physiological 
processes including regulation of vascular and non-vascular smooth muscle contraction, 
platelet aggregation and mitogenesis.
27
 The greatest concentration of serotonin (90%) is 
found in enterochromaffin cells of gastrointestinal tract and the effects of 5-HT are seen 
greatly in the cardiovascular system and central nervous system (CNS). Serotonin 
receptors contribute to pathological processes related to cardiopulmonary problems,
28,29
 
irritable bowel syndrome,
30,31
 psychiatric illness (i.e., schizophrenia and mood disorders)
32-
35
 Alzheimer‟s disease,36,37 problems involving food and alcohol intake,38,39 and behavioral 
problems (i.e. aggression, impulsivity).
40,41
 Serotonin exerts its effects on neuronal and 
non-neuronal tissues by interacting with the various receptor subtype populations (Tables 2 
and 3). 
 
Table 2. Mental illness where altered serotonin neurotransmission has been implicated. 
(Adapted from Roth, B. L. and Shapiro, D. A., Expert Opin. Ther. Targets, 2001, 5, 685-
695)
42
 
 
Disease 5-HT receptor Prototype drug Agonist/Antagonist 
Schizophrenia 5-HT2A/2C Clozapine 5-HT2A/2C/6/7  antagonist
43
 
Depression 5-HT1A/1B/2A/2B/2C Mianserin 5-HT2A/2B/2C  antagonist 
Anxiety disorders 5-HT1A/1B/2C Buspirone 5-HT1A partial agonist 
Eating disorders/ 
obesity 
5-HT2C Fenfluramine 5-HT2C  agonist
44
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Table 3. Common medical conditions in which 5-HT-subtype-selective drugs have utility.  
(Adapted from Roth, B. L. and Shapiro, D. A., Expert Opin. Ther. Targets, 2001, 5, 685-
695)
42
 
 
Disease 5-HT Receptor  
 
Prototype drug Agonist/Antagonist 
Obesity 5-HT2C Fenfluramine  Agonist
45
 
Irritable bowel syndrome 5-HT3/4/5 Tagaserod 5-HT3 antagonist,  
5-HT4 agonist 
Migraine headaches 5-HT1D/1F Sumatriptan Antagonist 
Emesis 5-HT3 Ondansetron Antagonist 
Pain 5-HT2A/2B Amitryptiline Antagonist
46
 
 
Over the years, many studies have been reported with reference to the 
pharmacology, molecular biology and the development of selective ligands for these 
receptor subtypes.
22,47
 However, the following discussion will focus on the 5-HT2 receptor 
family due to its relevance to the current work. 5-HT2 receptors are one of the most 
extensively studied receptor types within the serotonin family. The structure and function 
of this group of receptors have been studied in great detail and drugs targeting these 
receptors have utility for treating large number of diseases
42,48
 (Tables 2 and 3).  
 
1.5  5-HT2 Receptor Structure, Function and Localization 
The 5-HT2 receptor family members comprise a closely related subgroup of G protein-
coupled receptors, functionally linked to a phosphatidylinositol hydrolysis pathway and are 
classified as 5-HT2A, 5-HT2B and 5-HT2C subtypes.
49,50
 While the 5-HT2A and 5-HT2C 
receptors are widely expressed throughout the brain, the 5-HT2B receptor is mostly 
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expressed in the periphery, with minimal CNS expression. Each 5-HT2 subtype has a 
classic G protein-coupled seven-transmembrane helical region connected by extracellular 
and intracellular loops. Most of the current understanding about the structural features of 
the 5-HT2 receptor family is derived from mutagenesis and molecular modeling studies of 
5-HT2A receptors.
3,51,52
 The general arrangement of residues in the binding pocket is 
similar to that of rhodopsin and large numbers of studies have identified key residues 
essential for agonist and antagonist binding to the 5-HT2A receptor.
53-56
 The binding pocket 
of the 5-HT2A receptor is lined with many aromatic residues with the presence of a single 
charged residue (D155) which acts as an anchor for aminergic drugs binding to the 
receptor.
57
  
The 5-HT2A receptor shares high homology with the 5-HT2C receptor subtype with 
overall amino acid sequence identity >50% and the sequence identity between 
transmembrane regions >75%.
21
 The 5-HT2A receptor is highly expressed in all layers of 
the cortex with the highest density in the neocortex.
50
 In the basal ganglia and forebrain, 5-
HT2A receptor has been localized to medium- and large-sized neurons in the lateral septal 
nuclei. The 5-HT2A receptor modulates GABAergic and glutaminergic transmission as well 
as monoaminergic transmission via various mechanisms and interactions.
49
 Given the 
extensive location of this receptor in brain areas that mediate cognitive functions and social 
interaction, the 5-HT2A receptor is implicated in diseases in which these functions are 
impaired. Some of the central disorders involving 5-HT2A receptors are schizophrenia, 
depression and psychosis. In addition, recent studies involving 5-HT2A receptor knockout 
mice have also implicated its role in sleep disorders.
58
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1.5.1  5-HT2 Receptors in the Development of Novel Antidepressant Drugs 
Depression is a common condition that has both emotional and physical 
aspects.
59,60
 It is often accompanied by variety of neurological, psychiatric and other 
mental illnesses.
59,61
 However, no single neurotransmitter abnormality has been identified 
that fully explains the pathophysiology of depression. Alterations in the serotonergic and 
noradrenergic function in the CNS have often been implicated in the pathophysiology of 
depression and the mechanism of action of antidepressant drugs but the specific 
impairment that underlies depression is unclear.
62,63
 The classes of antidepressants drugs 
that are commonly used include monoamine oxidase (MAO) inhibitors, tricyclic 
antidepressants (TCAs) and the monoamine reuptake inhibitors.
64
 There have been few 
reports suggesting that the depression is caused by the functional deficiency of the 
serotonin in the brain.
65,66
 Studies involving 5-HT2 receptors have indicated that 5-HT2A 
antagonism is often associated with significant antidepressant potential
67
 and that the long-
term administration of tricyclic antidepressants causes a decrease in the cortical density of 
5-HT2A receptors.
68
 Thus several clinically-effective antidepressants (mianserin,
69
 
mirtazepine,
70
 trazadone and nefazadone
71
) are thought to exert their action by 5-HT2A 
antagonism in addition to their action at other receptors.
72
 
In addition, a study involving the functional interaction between central 5-HT and 
DA systems has suggested that disinhibition of the mesolimbic DA system might be useful 
in the treatment of depression.
73
 Specifically, the 5-HT2 subtype has been indicated to play 
a role in the control of central DA activity because of the moderate to dense localization of 
both mRNA and protein for the 5-HT2A and 5-HT2C receptors in the substantia nigra (SN) 
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and ventral tegmental area (VTA) in the rat forebrain.
74,75
 Further, studies have shown that 
the 5-HT2C subtype is responsible for the inhibitory influence of 5-HT on the activity of 
mesolimbic and nigrostriatal dopaminergic pathways
76
 (Figure 3) suggesting that 5-HT2 
receptors could act as an potential targets for the development of novel antidepressant 
drugs.
73
  
 
Figure 3. Distribution of 5-HT2C and 5-HT2A receptors on GABA-containing and 
dopamine-containing neurons in the midbrain. 5-HT2A receptors are expressed on a 
subpopulation of DA-containing neurons, and on non-DA neurons whose neurochemical 
identity is yet unknown (indicated by question mark). 5-HT2C receptors are expressed on 
GABA-containing neurons in both substantia nigra pars reticula (SNr) and the ventral 
tegmental area (VTA).
73
 
 
 
 
1.5.2 5-HT2-Selective Antagonists as Potential Antipsychotic Drugs 
In the past, studies by Meltzer et al.
77
 and others have predicted that drugs with 
high 5-HT2A/D2 affinity ratios would be effective atypical antipsychotic drugs.
78
 Since 
then, several such atypical antipsychotic drugs (clozapine, olanzapine, risperidone and 
ziprasidone) have been approved for clinical use. Generally, atypical antipsychotic drugs 
have a complex pharmacology due to their action at multiple serotonin (5-HT2A, 5-HT2B, 5-
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HT6 and 5-HT7) receptors.
79
 In addition, atypical antipsychotics also interact with 
dopamine D4 and muscarinic (M1-M5) receptors. It is assumed that 5-HT2A rather than 5-
HT2C receptors play a major role in mediating psychosis, which suggests that the variable 
degree of 5-HT2A vs. 5-HT2C receptor selectivity between atypical antipsychotics may be of 
clinical relevance. In fact, antagonism of 5-HT2A as well as 5-HT2C receptors has been 
implicated in the therapeutic effectiveness of atypical antipsychotics.
80
 The role of 5-HT2A 
receptors in psychosis is supported by the report of MDL100907,
81
 amperozide, 
eplivanserin and ritanserin as compounds preferring the 5-HT2A receptor; however, 
development has been limited.
82
 Due to the multiple receptor affinity of the atypical 
antipsychotics they are often associated with side effects. Thus the development of 
selective 5-HT2A antagonists might provide an effective therapy for psychosis in addition 
to acting as pharmacological tools for the study of the 5-HT2A function.  
 
1.5.3 5-HT2 Ligands in the Treatment of Schizophrenia 
Schizophrenia is one of the major neuropsychiatric disorders that involve the 5-HT 
and DA neurotransmitters.
83
 It is diagnosed by its positive symptoms (auditory 
hallucinations, disorganized thoughts and delusions), negative symptoms (social 
withdrawal, lack of motivation) and cognitive dysfunction.
84
 The first-generation 
antipsychotics and the newer atypical antipsychotic drugs are the main line of treatment for 
schizophrenia.
85,86
 However, the negative symptoms and cognitive dysfunction are not 
fully treated by them.
87
  Recent studies have shown that the 5-HT2A receptor subtype plays 
an important role in schizophrenia by modulating dopamine release in the striatum and 
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cortex.
33,88
 In addition, the antiserotonergic properties of atypical antipsychotics decrease 
the dopamine activity in the frontal cortex that in turn may contribute to improvement in 
negative symptoms in schizophrenia.
89
 Recent studies have also linked the association of 
the T102C polymorphism in the 5-HT2A receptor gene with schizophrenia.
88,90,91
 The 5-
HT2A receptor is considered to be a major component of the atypical antipsychotic profile, 
and atypical antipsychotic drugs used in therapy are known to bind to 5-HT2A 
receptors.
92,93
 However, the use of atypical antipsychotic drugs is often associated with 
adverse side effects such as metabolic disorders, sedation, movement disorders and weight 
gain.
84
 One of the possible reasons for the side effects of these drugs is their multiple-
receptor (serotonin, dopamine, α-adrenergic, muscarinic and histamine) binding profile.94 
Thus the development of newer atypical antipsychotic drugs having selectivity for the 5-
HT2A receptor can potentially lead to clinically useful drugs for the treatment of 
schizophrenia. 
 
1.5.4 5-HT2 Ligands in the Treatment of Sleep Disorders 
It is well established that serotonin plays major role in the regulation of sleep-
wakefulness cycles (Figure 4), and that any disruption of serotonergic function induces 
modification of sleep and waking.
95
 Evidence from clinical studies has suggested that 5-
HT2 receptors modulate slow wave sleep (SWS).
96
 For example, the 5-HT2 receptor 
antagonist ritanserin promotes sleep and enhances slow wave activity in humans and rats.
91
 
This activity is likely mediated through the 5-HT2A receptor, as similar increases in SWS 
are observed with more selective 5-HT2A antagonists such as eplivanserin
97
 and 
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MDL100907.
98
 In addition, studies involving knock-out mice lacking 5-HT2A receptors 
have suggested that the 5-HT2A subtype is involved in non-rapid eye movement sleep 
(NREMS) regulation
58
 and that the ligands acting at 5-HT2A receptors might be useful in 
the treatment of sleep disorders. Thus by improving the quality of sleep and restfulness, 5-
HT2A modulators (antagonists/inverse agonists) can offer a significant advancement in the 
treatment of sleep disorders. 
inactive
active
5-HT
Hypothalamus
Synthesis of
sleep -promoting 
substances
via 5-HT1A
and 5-HT2
receptors
During Wakefulness
During Paradoxial sleep
inhibited
Via 5-HT1A
receptors
 Cholinergic
"PS-on" neuron
Nucleus Raphe Dorsalis
active  
 
Figure 4.  Schematic representation of the serotonergic regulation of sleep-wakefulness 
cycle. During waking, the serotonergic neurons of nucleus raphe dorsalis (NRD) are active. 
5-HT is liberated at the termini and activates postsynaptic serotonin receptors. This 
activation results in an increase sleep-like condition at the hypothalamic level and 
inhibition of cholinergic structures responsible for paradoxical sleep (PS) at the pontine 
level. During sleep, the serotonergic neurons are inactive, possibly due to a negative 
feedback loop via a sleep-promoting substance. This result in a reduction in both 5-HT2 
influence (facilitating occurrence of SWS) and 5-HT1A inhibitory control of cholinergic 
“PS-on” neurons, therefore facilitating the occurrence of PS.99 
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1.6 Clinical Relevance for Studying Serotonin (5-HT2A) and Histamine (H1) Receptors 
 
 Histamine is another monoamine which is known to regulate a wide variety of 
physiological responses.
100
 It acts as one of the primary inflammatory mediators released 
from mast cells following allergic challenges.
101,102
 It also acts as a neurotransmitter in the 
central nervous system (CNS).
103
 Histamine exerts its effect by interacting with four 
different aminergic GPCRs H1-H4
104
 (Table 4).   
Table 4. Histamine receptor classification. (Adapted from Fung-Leung, et al., Curr. Opin. 
Invest. Drugs, 2004, 5, 1174-1183).
105
 
 
Histamine 
receptor 
H1 H2 H3 H4 
Expression Ubiquitous Ubiquitous Neural cells Mast cells, 
eosinophils, 
dendritic 
cells and T-
cells 
Gα-protein 
association 
Gαq Gαs Gαi/o Gαi/o 
Signaling ↑Ca+2 ↑cAMP ↓cAMP ↑Ca+2 
Key 
function 
Bronchoconstriction 
and vasodilation 
Gastric acid 
secretion 
Neurotransmitter 
release 
Mast cell and 
eosinophil 
chemotaxis 
Agonists 2-Methylhistamine, 
Histaprodifen 
Dimaprit, 
Anthamine 
R-α-
methylhistamine, 
Imetit 
Imetit, 
Immepip 
Antagonists Diphenhydramine 
Cetrizine 
Pyrilamine 
Burimamide 
Cimetidine 
Ranitidine 
Thioperamide 
Clobenpropit 
Thioperamide 
JNJ-7777120 
 
Over the years various classes of H1 antagonist have been developed and used 
clinically
106,107
 (Figure 5). However, because of CNS penetration and central H1 receptor 
blockade their clinical use is hampered by various side effects, most notably sedation.
108,109
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 Figure 5.  Structures of representative H1 antagonists.
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This led to the development of second-generation antagonists (acrivastine,  
 loratadine, terfenadine, cetirizine, etc.) that exhibited less sedative potential due to the 
decrease in their ability to penetrate the blood-brain barrier.
107,110,111
 Some of these 
antagonists, such as doxepin, ketotifen, and epinastine that have a tri- or tetracyclic fused 
ring system also showed affinity at 5-HT2A, adrenaline α1, dopamine D2 and muscarinic M1 
receptors, indicative of their low selectivity for the H1 receptor.
112-114
 Among the various 
chemical classes of H1 antagonist, ligands that are zwitterionic (olopatadine, acrivastine, 
fexofenadine) showed an improved degree of selectivity for H1,
115-117
 suggesting a specific 
interaction of the carboxylate group on the ligand with the H1 receptor. Introduction of a 
carboxylate moiety thus provides one potential means of designing H1-selective 
antagonists with reduced sedative potential. 
There have been three reports suggesting that serotonin may be the primary 
neurotransmitter in the control of sleep states.
95,118,119
 However to date, drugs which 
modulate serotoninergic transmission by stimulating or blocking serotonin receptors have 
not been used clinically in the treatment of insomnia.
120
 Studies related to 5-HT2 
antagonists including the antipsychotics ziprasidone and risperidone have shown that these 
drugs increased slow wave sleep (SWS) and affect NREM.
96,121
 Nevertheless, the study of 
the clinical role of 5-HT2A receptors in sleep has been hampered by the lack of 5-HT2A 
selective agents. Thus there is a need for a selective agent for the determination of the role 
of 5-HT2 receptors in sleep as a lead to the possible development of a sleep drug based on 
5-HT2A antagonism. 
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 In addition to serotonin, histamine has been proposed to be involved in the control 
of sleep and wakefulness, as mentioned previously.
122
 Most common over-the-counter 
agents used to promote sleep are antihistamines. Development of improved antihistaminic 
drugs for the treatment of insomnia is hampered by the fact that these drugs have action at 
multiple targets including serotonergic and muscarinic receptors. There has been a recent 
report of the use of low-dose of doxepin (an antidepressant agent with high affinity and 
selectivity for H1 receptor) in the treatment of insomnia, suggesting a potential role for 
selective H1 receptor antagonists in the treatment of sleep disorders.
113
 In addition, the 
latest reports of clinical trial studies
123
 have also implicated the role of selective dual-
acting 5-HT2A/H1 ligands in the treatment of sleep disorders. As mentioned earlier, the 
majority of atypical antipsychotic drugs (clozapine, risperidone, olanzapine, ziprasidone, 
aripiprazole) used in the treatment of schizophrenia exhibit high affinity for the 5-HT2A 
receptor. However, they are often associated with the side effects such as weight gain. 
Results from a recent study have suggested that the histamine H1 receptor is the most likely 
molecular target responsible for atypical antipsychotic drug-induced weight gain.
124
 Thus, 
the study of factors relating to the selectivity between H1 and 5-HT2A receptors could also 
help in the design of next-generation atypical antipsychotic drugs with fewer side effects. 
 
1.7 5-HT2 Receptor Ligands 
The 5-HT2 family of serotonin receptors represents major target for drugs used in 
the treatment of a variety of diseases as mentioned earlier. As the 5-HT2 family of 
receptors has three members (5-HT2A, 5-HT2B and 5-HT2C), the development of subtype-
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selective compounds will be needed in order to avoid side effects and to enhance 
therapeutic value. Unfortunately not many ligands are available which exhibit subtype 
selectivity.
125
 Some of the ligands that act at 5-HT2 receptors are shown in Figure 6. The 
indolealkylamine ligands act as 5-HT2A agonists but are less selective as compared to 
phenylalkylamines such as DOB and DOI that exhibit low affinity at non-5-HT2 sites. 
However, phenylalkylamines also cannot differentiate among 5-HT2 subpopulations.
126
 
One of the most selective antagonist classes of 5-HT2A ligands are the N-alkylpiperidines,
4
 
(e.g. ketanserin); although ketanserin only shows about 10- to 15- fold selectivity for 5-
HT2A versus 5-HT2C receptors. Various analogs of ketanserin have been made, but not 
much selectivity has been achieved. The other 5-HT2A antagonists such as ritanserin, MDL 
100907,
81
 spiperone,
127
 risperidone and olanzapine demonstrate increased selectivity for 5-
HT2A.
82,120
 Various nonspecific tricyclic agents (tricyclic neuroleptics and antidepressants) 
bind at 5-HT2A receptors.
128
 A range of new compounds reported to have activity at 5-HT2A 
receptors is under clinical development.
129
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Figure 6. Structures of representative 5-HT2 ligands. 
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1.8 Understanding 5-HT2A Receptor-Ligand Interactions and Development of a 
Selective GPCR Ligand 
 The 5-HT2 family of receptors has three members (5-HT2A, 5-HT2B and 5-HT2C) 
and development of 5-HT2-selective compounds is expected to lead to drugs with better 
therapeutic indices. To date, very few truly selective 5-HT2 receptor ligands have been 
discovered and found to have clinical application. One of the challenges in the 
development of a subtype-selective ligand is the possible interaction with the multiple 
serotonin receptor subpopulations (5-HT1 through 5-HT7) and the serotonin transporter 
(SERT). In an attempt to develop a selective 5-HT2 ligand and understand how the 
molecules bind at these receptors, we decided to use receptor structure-based drug design. 
Integrating data from molecular models, site-directed mutagenesis studies and traditional 
SAR studies makes it possible to generate new and interesting leads. With the introduction 
of a structure of a true aminergic (β2-adrenergic) GPCR
130,131
 in addition to existing bovine 
rhodopsin structures, homology modeling techniques are better-equipped to produce 
biologically relevant GPCR models. 
 In an effort to develop a 5-HT2-selective ligand, we started with a simple 
nonselective structural template (phenylethylamine) having low affinity for the 5-HT2A 
receptor (Ki = 16,800 nM) and modified its structure so as to enhance affinity and 
selectivity. Initial investigations
5,51
 in our laboratory have led to the development of 
AMDA (9-aminoalkyl-9,10-dihydroanthracene; Ki = 20 nM), a novel 5-HT2 antagonist 
having moderate affinity at histamine H1 (Ki = 197 nM) receptors. Using structure-based 
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drug design methods and AMDA as a lead compound, testable hypotheses were generated 
and compounds were designed to test these hypotheses.  
 
1.9 Specific Aims of the Research Project 
Taking into account the lack of the experimentally derived 5-HT2 receptor structure 
and the need to understand the 5-HT2A receptor-ligand interactions, a set of specific aims 
were devised as follows: 
Aim 1) To design and synthesize ligands based on AMDA (9-aminoalkyl-9,10-
dihydroanthracene) and its pharmacophore as molecular probes for the study of the 5-HT2A 
and  H1 receptor binding sites.  
Aim 2) To test hypotheses relevant to the affinity/selectivity of the compounds at the 5-
HT2A and the H1 receptor using ligand SAR, homology modeling and existing site-directed 
mutagenesis studies.  
Aim 3) To use the information acquired in the above investigations for the refinement of 
homology models and test the utility of our models for the design of new H1- and/or 5-HT2 
-selective compounds. 
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MOLECULAR MODELING OF G PROTEIN-COUPLED 
RECEPTORS 
 
 
 
2.1 Introduction 
G protein-coupled receptors (GPCRs) are vital components of biological signaling 
processes in higher animals and humans, which constitute one of the most important set 
of targets for pharmaceutical industry.
132
 More than 1000 genes encoding GPCRs have 
been identified from the human genome sequencing effort. This represents a substantial 
part of human genome (~3%). On the basis of structural and sequence similarities, 
GPCRs are generally classified into 5 families: Class A (rhodopsin-like) is the largest 
group and contains receptors for classical neurotransmitters (biogenic amines and 
nucleotides) and a large variety of peptides and lipids, with class B (secretin), class C 
(glutamate), class D (fungal hormone), class E (cAMP)
133,134
 and class F (frizzled) 
comprising the remaining classes. The physiological function of a large fraction of these 
GPCRs is unknown; these receptors are referred to as orphan GPCRs.
135
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2.2 Central Role of G Proteins  
On activation, GPCR‟s trigger a cascade of intracellular responses through 
interactions with their associated heterotrimeric G proteins.
136
 The G proteins are a 
family of closely related membrane-linked polypeptides. By acting as a carrier they form 
central elements for the signal transduction between the receptors and the effector 
components (enzymes or ion channels) in the cytoplasm. At rest, they consist of a 
heterotrimer possessing a guanine nucleotide-binding α subunit (40 - 52 kDa), a β subunit 
(35 kDa) and a γ subunit (98 - 100 kDa). The β-γ complexes are presumed to be 
exchangeable from one G protein to another.
137
 G proteins are peripheral membrane 
proteins, in contrast to integral membrane proteins which span the entire membrane (e.g. 
GPCRs). Activation of the receptor promotes the exchange of a molecule of GDP with a 
molecule of GTP within the active site of the α-subunit. The binding of GTP causes the 
dissociation of the heterotrimeric complex, and both the GTP-bound α subunit and the 
released β-γ complex are then able to interact with intracellular or membrane effectors. 
The intrinsic GTPase activity of the α-subunit hydrolyses GTP to GDP, restoring its 
initial inactive conformation as well as its affinity for the β-γ complex (Figure 7). 
 
2.3 Common Structural Features of GPCRs 
GPCRs share a common structural motif of seven hydrophobic transmembrane 
(TM) segments, three extracellular loops (EL), an extracellular amino terminus, three 
cytoplasmic loops and an intracellular carboxyl terminus. They share the greatest 
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homology within the TM segments. Each of the TM regions is composed of 
approximately 20-30 amino acids. 
 
 
Figure 7.  Role of G Proteins.
137
 
 
The most variable structures among the family of GPCRs are the carboxyl 
terminus (12 - 360 amino acids) the third intracellular loop (5 - 230 amino acids) and the 
amino terminus (7 - 595 amino acids). Amongst these the greatest diversity is observed in 
the amino terminus. This sequence is relatively short (10 - 50 amino acids) for the 
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monoamine and peptide receptors, and much larger (350 - 600 amino acids) for 
glycoprotein hormone receptors and the glutamate family receptors.
137
  
The 7TM structure of GPCRs has certain structural and functional merits as noted 
by Ji et. al.
138
 The odd number of TMs places the N- and C-terminal segments at opposite 
membrane surfaces that allows glycosylation and ligand binding at the N-terminal 
segment (for non-aminergic GPCR‟s), and phosphorylation and palmitoylation at the C-
terminal segment for desensitization and internalization. Also, seven TMs may be the 
minimum necessary to form six loops and a TM core with a sufficient size and versatility 
to offer an unusual number of specificities, regulatory mechanisms, and contact sites for 
G protein and other signal molecules. TM α-helices vary in sequence length and can 
extend beyond the lipid bilayer.
139
 Therefore, the boundaries between TMs and loops are 
likely to be uneven and may be dynamic. TMs 1, 4, and 7 are significantly more 
hydrophobic than TMs 2, 3, 5, and 6 that contain several ionic and/or neutral residues that 
are hydrophilic. Proline residues frequently found in TM α-helices kink the helix 
backbone by ~26° and impact the global structure. The seven TMs are arranged as a 
closed loop in the counterclockwise direction from TM 1 to TM 7 when viewed from the 
extracellular surface (Figure 8A). The orientation of the TMs imposes a steric and 
geometric specificity on a ligand‟s entry into and binding to the TM core.140 In this 
arrangement, the core is primarily comprised of TMs 2, 3, 5, 6, and perhaps 7, whereas 
TMs 1 and 4 are peripherally sequestered. This arrangement is consistent with the view 
that the more hydrophobic TMs 1, 4, and 7 are exposed more to the lipid bilayer than the 
less hydrophobic TMs 2, 3, 5, and 6. The high resolution 3D structure of 
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bacteriorhodopsin
141,142
 suggest that the TM core is tightly packed by hydrogen bonds 
and salt bridges between the residues of same TMs as well as other TMs. Disulfides 
linkages often play a major role in the structure and stability of proteins. Among 
numerous cysteine residues found in eukaryotic GPCRs, two conserved cysteine residues 
in EL2 are known to be linked by a disulfide bond in bovine rhodopsin and other GPCRs. 
This disulfide constrains the EL2 loop, preventing it from moving too far away from the 
TM helical bundle.
143,144
 
In contrast to the structural and functional similarity of GPCRs, the types of 
natural GPCR ligands interacting with them are structurally wide-ranging. The diverse set 
of ligands is comprised of small organic molecules, subatomic particles (e.g. photons), 
ions, peptides and proteins. The location of ligand binding domains for a few GPCRs has 
been determined and has been postulated for many others. While many small molecule 
agonists bind within the TM segments, peptide hormones and proteins often bind to the 
amino terminus and extracellular loop regions 
138,145
 (Figure 8B-F). 
 
2.4 Challenges in GPCR Research 
In spite of remarkable advances in the biology and pharmacology of GPCRs, 
progress in the area of protein structure has been more limited. Until the recent reports of 
the crystal structure of human β2-adrenergic receptor
130,146
 the only high resolution 
structure of a GPCR was that of the bovine rhodopsin.
142
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Figure 8. GPCRs structure and receptor-ligand interactions.
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2.4.1 Why are there only a few Experimental Structures of GPCRs?  
Some of the major obstacles to obtaining structures of GPCRs include protein 
expression, purification, and protein stability.
147
 Crystallization of membrane protein is 
often a very difficult and time consuming process. With the exception of rhodopsin, 
which is present in abundant amounts in rod outer segments, membrane proteins occur at 
relatively low concentration in cell membranes. Another problem associated with 
crystallization of these receptors is their conformational flexibility. To orchestrate the 
complex signaling pathways the helical bundle of GPCRs adopt various conformations 
(active and inactive states) leading to conformational heterogeneity. In addition, the polar 
surface area available for crystal contacts is limited because of the receptor residues that 
are predominantly nonpolar being buried in the membrane bilayer. Purified GPCRs are 
not stable in detergent compatible with crystallography.
148
 They tend to be more stable in 
non-ionic detergents with relatively long alkyl chains. These detergents may form large 
micelles that prevent the formation of crystal contacts.
149
 The successful addressing of 
these problems, with the recent advances in crystallographic techniques is accelerating 
the progress in this area of research. Meanwhile, to keep up with the rate of newly 
discovered GPCR sequences, one may rely on alternate solutions such as generation of 
3D models based on the available crystal structure data of a few GPCRs.  
 
2.5 Homology (Comparative) Modeling as a Workable Solution  
Given the scarcity of crystal structures for GPCRs, the study of this family of 
proteins has been greatly advanced through the use of structural models.
150
 These models, 
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combined with experimental testing, have proven to be successful tools to obtain a 
structural understanding of the GPCR function, and the characteristics of the ligand 
binding sites.
151
 Homology modeling is a method for constructing a three dimensional 
model of a protein sequence based on the structure of homologous proteins. Steps 
involved in building a homology model are 1) Identifying the homologous protein(s) and 
determining their sequence similarity with the unknown; 2) Alignment of the receptor 
sequence to be modeled with those of the template(s); 3) Identification and mutation of 
residues in the structurally conserved regions; 4) Generation of conformations for the 
structurally variable regions (primarily extracellular and intracellular loops); 5) Building 
and optimization of the side-chain conformation; 6) Evaluation and refinement of the 
generated model. 
 
2.5.1 Bovine Rhodopsin and β2-Adrenergic Receptor Structures as Suitable 
Templates for Homology Modeling 
The general observation that evolutionarily related proteins share a similar 3D 
structure inspite of the fact that they have different amino acid sequences has led to 
protein models from structurally different templates. By far the most common way the 
inactive state of a GPCR is modeled is based on the crystal structure of bovine 
rhodopsin.
142,152
 All rhodopsin-like GPCRs are likely to share a common topography with 
7TMs bundled together in a similar manner. Sequence comparison has revealed specific 
amino acid patterns characteristic of each TM that are highly conserved in class A 
GPCRs. These conserved amino acid residues are also the basis of a commonly used 
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GPCR residue indexing system introduced by Ballesteroes and Weinstein.
153
 (Briefly, the 
most conserved residue in a given TM is assigned the index X.50, where X is the TM 
number. The remaining residues are numbered relative to position 50). These specific 
conserved residues are 1) N1.50, D2.50, N7.50. They contribute to the stabilization of 3D 
structures of TM1, TM2, and TM7 and their mutation produces serious effects in function 
of the receptor.
154
 2) The D/ERY motif in TM3 and E6.30 in TM6. The central arginine 
(R3.50) of the D/ERY motif makes a hydrogen bond with the adjacent D3.49 and a 
highly conserved glutamic acid in TM6 (E6.30). For a number of GPCRs, mutations in 
this motif induce a constitutively active phenotype, and thus it is assumed that this motif 
holds the receptor constrained in the ground state.
52,155
 3) The aromatic cluster including 
highly conserved F6.44, W6.48, F6.51, and F6.52. UV absorbance studies and site 
directed mutagenesis have shown a conformational change of W6.48 upon rhodopsin 
activation, consistent with a change in the relative orientation of helices of TM3 and 
TM6.
156
 Computational studies have shown that the conformation of W6.48 and F6.52 
are highly correlated, and may constitute a rotamer “toggle switch” that may modulate 
the TM6 proline kink. W6.48 and P6.50 are likely to share a common functional role 
enabling the activation of receptor.
157
 4) The NPXXY motif in TM7. The crystal structure 
of rhodopsin reveals that this motif induces a large distortion in TM7 which is stabilized 
by hydrogen bond between polar N7.49 and a network of waters that connect it with 
D2.50. Studies have demonstrated that NPXXY motif and helix 8 play an important role 
in the activation process, binding of the G-proteins and may act as a conformational 
switch domain involved in activation.
158
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Recently a crystal structure of the β2-adrenergic receptor (3.4 Å) was reported as a 
receptor-antibody complex with carazolol (inverse agonist) bound in the helical region.
130
 
Although the β2AR structure represents the truncated versions, the overall topology of 
rhodopsin and β2AR are quite similar. The root mean square deviation (RMSD), which is 
measure of structural similarity between protein‟s structures for alpha carbon backbone 
of TM region between the two is 1.56 Å which indicates similar arrangement of TM 
helices. Also, a high resolution (2.4 Å) crystal structure of engineered β2-adrenergic 
receptor-lysozyme T4 fusion protein has been reported that is similar to the antibody- β2-
AR complex.
131,146
 Among the major differences which exist between rhodopsin and β2-
AR relevant to the ligand binding site are the disposition of the helical segments and the 
second extracellular loop (Figure 9). In case of β2AR the EL2 loop contains a short helix. 
This helix contains two disulfide bonds which appear to maintain the loop in a 
constrained state presumably providing space for diffusion of ligands into the binding site 
of the receptor, whereas in rhodopsin the second extracellular loop contains a buried β-
hairpin which forms a cap-like structure that isolates the retinal-binding site in a 
hydrophobic pocket. Another difference between two structures is in the state of “ionic 
lock” defined as the network of hydrogen bonding and charge interactions between R131 
in TM3 and E268 in TM6 for β2AR and R135 and E247 in rhodopsin. The ionic lock is 
proposed to maintain rhodopsin and other class A GPCRs in an inactive conformation. 
Disruption of this interaction is thought to allow formation of the active conformation. 
The crystal structure of inactive rhodopsin displays an ionic lock with a distance of 2.9 Å 
between E247 and R135. However in both β2AR structures the ionic lock is broken with 
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a R131-E268 distance of >6.0 Å. Evaluation of the ligand binding site, carazolol (in 
β2AR) and cis-retinal (in rhodopsin) reveals difference in their interaction with the highly 
conserved “rotamer toggle” (W265 in rhodopsin and W268 in β2AR). It has been 
proposed that a change in the rotameric state of this tryptophan in class A GPCRs serves 
as a second activation switch. Although carazolol does not directly interact with W286 in 
β2AR it appears to control the rotameric state of W286 indirectly via interaction with 
F289 and F290.  
In the absence of an experimentally-determined structure for either 5-HT2A or H1 
receptors, rhodopsin and β2-adrenergic receptor crystal structures were used to create 
homology models of these receptors. Each template has certain advantages and 
disadvantages which justifies its selection. For example it is not clear if the β2AR/T4 
lysozyme fusion protein is in the inactive or active state while the rhodopsin structure has 
been extensively studied (biophysical characterization) and crystal structures for both 
active and inactive states have been determined. On the other hand, β2AR is an aminergic 
GPCR that reversibly binds ligands whereas the rhodopsin ligand, retinal, is covalently 
linked to the receptor. Moreover the sequence homology is higher between 5-HT2A /H1 
and β2AR than between 5-HT2A/H1 and rhodopsin. The overall goal of this project was to 
determine ligand-receptor interactions for the serotonin 5-HT2A receptor for selected 
target compounds. 5-HT2A is a typical rhodopsin-like aminergic GPCRs consisting of two 
soluble domains (extracellular N-terminal, intracellular C-terminal) and seven 
hydrophobic regions corresponding to seven transmembrane-spanning (7TM) helices. In 
order to determine the receptor-structure based affinity and selectivity of ligands for the 
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5-HT2A and H1 receptors, homology models of the 5-HT2A  and H1 receptors were built 
using both bovine rhodopsin and the recently reported structure of the human β2-
adrenergic receptor as templates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. a) Superimposition of the 5-HT2A GPCR models based on β2-AR (orange: PDB 
2RH1) and rhodopsin (green: PDB 1U19) crystal structures. b) Conserved residues in 
rhodopsin based model and c) β2-AR based model. 
 
 
a 
 
b 
 
c 
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2.6 Construction of Homology Models  
Models of the 5-HT2A and H1 receptors were built using two primary homology 
modeling techniques.   
1) Manual approach. An alignment of the primary amino acid sequences was 
carried out using the ClustalX program.
159
 The adjustments to the alignments were made 
wherever necessary. In the structurally conserved regions (primarily TMs) there was a 
high degree of sequence similarity and no insertions or deletions. Hence the amino acids 
were directly mutated from bovine rhodopsin to the corresponding residues in the 
template receptor (5-HT2A and H1). Most of the loop regions connecting the TM helices 
were of varied length and low in sequence homology, so they were modeled using a loop 
search facility (selection of loops from a database of high resolution protein structures 
found in the PDB) in the SYBYL molecular modeling package.  
The N-terminal region of the 5-HT2A receptor is of different length and showed 
little sequence similarity to the templates. Deletion of N-terminus from the 5-HT2A 
receptor does not appear to affect receptor function
160
 so explicit consideration of the N-
terminal segment was not given for the generation of 5-HT2A and H1 models. The 
rhodopsin crystal structure consisted of only the first 18 residues in the C-terminus. A 
short α-helical segment (Helix 8) is present at the beginning of C-terminus following 
TM7. Helix 8 is perpendicular to the TM helix aggregate and is preceeded by the 
NPXXY motif of TM7 that is common to 5-HT receptor sequences. The side chains were 
then placed in the final model and checked for stereochemical integrity using the 
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PROCHECK
161
 and ProTable feature within the SYBYL. The final receptor model was 
then energy-minimized. 
 2) MODELLER-generated models. Based on ligand binding studies and 
generation of constitutively active receptors, it has been implied that the rhodopsin can 
exist in two receptor states. Thus a ligand can bind to and stabilize the receptor, which 
can exist in various different conformations. In order to consider this conformational 
flexibility of the receptor, MODELLER
162
 program was used in the generation of a 
population of receptor models, each with a slightly different conformation. MODELLER 
builds models of 3D structures of proteins by satisfaction of the spatial restraints. These 
restraints include the positions of the atoms in the template structures, distances and 
dihedral angles in the template structures. Stereochemical restraints such as bond length 
and bond angle are obtained from the CHARMM forcefield, and statistical preferences of 
dihedral angles and non-bonded atomic distances were obtained from a representative set 
of protein structures.  
The 5-HT2A (P28233) receptor sequence was aligned with a profile of several 
related class A GPCRs using the ClustalX program. Manual adjustment of the ClustalX 
alignment was required to properly align the disulfide-forming cysteine residues in the e2 
loop. The result was an unambiguous alignment in the transmembrane (TM) helical 
regions of both the H1 and 5-HT2A sequences with that of the bovine rhodopsin.  This 
alignment, along with a file containing the atomic coordinates of the inactive form of 
rhodopsin receptor (PDB ID = 1U19) or β2-AR receptor (PDB ID = 2RH1), was used as 
input to the MODELLER software package to generate a population of 100 different  
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5-HT2A homology models.  Each of these receptor models was subsequently energy-
minimized. The selection of the best fit model was done based on the observed 
interactions of the docked pose of the set of high affinity ligands (see experimental 
section), the reported site directed mutagenesis data for the respective receptors (H1 and 
5-HT2A) and the observed GOLD scores. In addition to using the GOLD score, HINT 
(Hydropathy Interaction)
163
 score was also used to characterize the nature of the binding 
site. An attempt was made to correlate the experimentally obtained binding affinity data 
with the GOLD scores and the HINT scores; however a very modest correlation was 
obtained.   
 
2.6.1 Docking and Scoring methods for ligands 
Following the generation of final models, the automated docking program 
GOLD
164
 (Genetic Optimization for Ligand Docking) was then used to optimally place 
the ligands in the binding site of receptor models. The GOLD program uses a genetic 
algorithm to sample the complete range of ligand conformational flexibility with partial 
flexibility of the protein, and satisfies the basic requirement that the ligand must displace 
loosely bound water on binding. It works as follows: A population of potential solutions 
(i.e. possible docked orientations and conformations of the ligand) is set up at random. 
Each member of the population is encoded as a chromosome, which contains information 
about the mapping of protein ligand interactions. Each chromosome is assigned a fitness 
score based on its scoring function and the chromosomes within the population are 
ranked according to fitness. The population of chromosomes is iteratively optimized. At 
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each step, a point mutation may occur in a chromosome, or two chromosomes may mate 
to give two children chromosomes. The selection of chromosomes is inclined towards 
fitter members of the population, i.e. chromosomes corresponding to ligand dockings 
with good fitness scores. The fittest chromosomes are then used as the starting point of 
the next iteration. The GOLD program provides three different scoring functions 1) Gold 
Score. The original scoring function provided with GOLD, which has been optimized for 
the prediction of ligand binding positions and takes into account factors such as H-
bonding energy (intra/inter molecular), van der Waals energy and ligand torsion strain. 2) 
ChemScore. It estimates the total free energy change that occurs on ligand binding and is 
trained by regression against binding affinity data. As the fitness scores are 
dimensionless, they cannot be used explicitly as values for binding energy or binding 
affinity 3) ASP (Astex Statistical Potential)165 is an atom-atom potential derived from a 
database of protein-ligand complexes. Assessment of the docking and scoring methods 
indicated that reasonable results were obtained with ChemScore function of GOLD. This 
docking/scoring combination was used in most of the studies. 
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STRUCTURE-AFFINITY RELATIONSHIP STUDIES OF 
AMDA AND ITS ANALOGS AT 5-HT2A AND H1 RECEPTORS 
 
 
 
 
3.1 Introduction 
The serotonin 5-HT2 and histamine H1 receptors have been implicated in various 
central nervous system (CNS) related disorders.
42,109,166
 In the absence of an 
experimentally-determined structure of a 5-HT family receptor, most structure-based 
drug design and optimization have relied on the information gained by structure-activity 
relationship (SAR) studies. Many SAR studies 
51,125,167
 for the 5-HT2 ligands and their 
potential therapeutic uses 
82,120,168
 have been reported which stress the importance for the 
development of subtype selective ligands. In addition, the recent reports of the role of 5-
HT2A receptors in non-rapid eye movement sleep (NREMS) regulation and respiratory 
control,
58
 suggest that selective antagonism of the 5-HT2A receptor may be a promising 
new mechanism for the treatment of sleep disorders.
169
  Thus, study of the 5-HT2 
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receptor‟s binding site and generation of 5-HT2 subtype-selective agents have been of 
considerable interest.  
Molecular modeling studies based on the 5-HT2A receptor sequence and high-
resolution crystal structure of bovine rhodopsin have been reported by Westkaemper et 
al. and others to envision ways in which the existing and new compounds may interact 
with the residues in the ligand binding site.
170,171
 Some of these studies suggested that the 
affinity of structures containing a phenylethylamine skeleton for the 5-HT2A receptor 
could be enhanced by a second aromatic moiety, perhaps by participating in the 
additional aromatic-aromatic interactions between the ligand and the receptor.
172
 This 
ultimately led to the design of 9-(aminomethyl)-9,10-dihydroanthracene (AMDA), which 
has proven to be a unique 5-HT2 antagonist.
5
 Although AMDA was structurally unique 
and simple, it became apparent that the AMDA structure bears general similarity to two 
classes of known drugs- tricyclic antidepressants and antipsychotic agents. Both of these 
classes are tricyclic amines consisting of two aromatic groups and a central non-aromatic 
ring that bears an alkylamine linker chain as in AMDA. Also, most clinically useful 
tricyclic amines are conformationally flexible. Since alkylamine chain length and N-
alkylation are two major structural features that distinguish AMDA from 
conformationally flexible classical tricyclic amines, our group investigated the influence 
of chain length and N-alkylation in a series of AMDA analogs and compared to 
imipramine.
173,174
 Also, a series of AMDA analogues were tested to determine the 
importance of the tricyclic ring system, and the effect of restricting the conformational 
freedom of the ammonium ion on 5-HT2A receptor affinity. This resulted in the synthesis 
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of spiro[9,10-dihydroanthracene]-9,3‟-pyrrolidine (SpAMDA), a conformationally 
constrained analog of AMDA.
175
 Both AMDA and SpAMDA proved to be high-affinity 
antagonists for 5-HT2A/2C receptors with better selectivity for these receptors as compared 
to the D2 receptor and serotonin and norepinephrine transporters, unlike the tricyclic 
antidepressants.  
Histamine released by tissue mast cells, basophils and histaminergic neurons is 
also known to impact the ability to fall asleep and stay asleep.
176
 Research and 
development of H1 ligands have focused largely on antagonists that are used for their 
antiallergic effects in the periphery. However, the first-generation H1 receptor antagonists 
(e.g. diphenhydramine, mepyramine, chlorpheniramine) also exhibit high H1 receptor 
occupancy in the CNS due in part to their lipophilicity, leading to sedative effects.
177,178
  
Recent reports of the clinical trial studies have indicated that compound acting at both 5-
HT2A and H1 receptor enhances sleep and should have low abuse potential.
123
 Thus the 
study of ligands acting at both 5-HT2A and H1 receptors could be therapeutically relevant. 
Binding studies conducted for the selectivity profile of AMDA and its analogues showed 
that SpAMDA had high affinity for H1 receptors (Ki = 4 nM), while AMDA showed 
moderate affinity (Ki = 197 nM). Given the potential therapeutic use of dual 5-HT2A/H1 
ligands in the treatment of sleep disorders we decided to continue our studies on the 
AMDA structure and carried out the systematic structure-affinity relationship (SAFIR) 
studies of AMDA and its analogs.  
 
 
   
 41 
3.2 Results and Discussion 
3.2.1 Structure-Affinity Relationship Studies 
Several reviews describing structure-activity relationship studies of 
diphenhydramine-like antihistamines have been reported.
178-180
 The features that have 
been systematically varied include the nature of the two required aromatic groups, the 
terminal basic amine and the aliphatic linker between these two features. We have 
examined similar structural variations with AMDA as the parent structure. Note that 
replacement of the ether oxygen of diphenhydramine by a methylene unit results in 
compound 18 (Table 5). Replacement of the pyridin-2-yl group of the H1 antagonist 
pheniramine with phenyl results in 15. Binding affinities of the compounds for the 5-
HT2A and H1 receptors are shown in Table 5 and displayed graphically in Figure 10. The 
most significant differences in affinity for both 5-HT2A and H1 receptors were observed 
between the 9-(aminoalkyl)-9,10-dihydroanthracene (DHA) compounds and their 
corresponding diphenylalkylamine (DPA) congeners. Ring-opening of the tricyclic 
system uniformly produced decreases in affinity for both 5-HT2A and H1 receptors. No 
DPA compound exhibited high affinity at 5-HT2A (Ki <100 nM) and only three showed 
high affinity for H1 receptors (14, Ki = 64 nM; 15, Ki = 75 nM; 18, Ki = 70 nM). In 
contrast, many of the DHA analogs were found to have high affinity at both receptors, 
demonstrating that rigid dihydroanthracene is a privileged structure.
181
  
For compounds interacting with the H1 receptor, progressively increasing either 
the number of methylene units in the linker or the number of N-methyl groups 
consistently retained or enhanced affinity in both the DHA and the DPA series. The H1 
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receptor affinity was insensitive to chain length for the unsubstituted amine analogs of 
AMDA (1, Ki = 197 nM; 4, Ki = 137 nM; 7, Ki = 175 nM). In contrast, H1 affinity 
increased with increasing chain length for both N-methylated (2, Ki = 189 nM; 5, Ki = 
47.5 nM; 8, Ki = 3 nM) and N,N-dimethylated analogs (3, Ki = 25 nM; 6, Ki = 6 nM; 9, Ki 
= 0.5 nM). For the DHA analogs, N,N-dimethylation and a three-methylene linker was 
optimum for H1 affinity (9, Ki = 0.5 nM). The trends in affinity at 5-HT2A are less 
uniform. However, increasing the linker length for the N,N-dimethylated DHA analogs 
did produce a successive increase in affinity (3, Ki = 540 nM; 6, Ki = 84 nM; 9, Ki = 22 
nM). 
Like the H1 receptor, the affinity of the DPA compounds for 5-HT2A generally 
increased with increasing linker size or degree of N-methylation though, as noted above, 
no DPA compound was found to have substantial affinity (Ki < 700 nM) for 5-HT2A. As 
observed previously
174
 for DHA compounds with a one-methylene linker, 5-HT2A affinity 
decreased as the degree of N-methylation increased (1, Ki = 20 nM; 2, Ki = 52 nM; 3, Ki = 
540 nM). This trend was not observed for the other linker lengths where N-methylation 
showed the tendency to increase affinity. Affinities were more uniform for compounds 
with one N-methyl group (2, Ki = 52 nM; 5 Ki = 92 nM; 8, Ki = 13 nM), and for those 
with two N-methyl groups, affinity increased with linker length by 25-fold (3, Ki = 540 
nM; 6, Ki = 84 nM; 9, Ki = 22 nM). In general, binding affinity for the 5-HT2A receptor is 
less sensitive to N-methylation and chain length variation than the H1 receptor. 
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Table 5. Observed binding affinities for 9-(aminoalkyl)-9,10-dihydroanthracene (DHA) 
and diphenylalkylamine (DPA) analogs at 5-HT2A and H1 receptors. 
 
 
X
N
R1
R2 n
 
 
 
     Ki (nM)
a 
Cpd X n R1 R2 5-HT2A H1 
1 —CH2— 1 —H —H 20
b 197 ± 67 
2 —CH2— 1 —H —CH3 52
b 189 ± 28 
3 —CH2— 1 —CH3 —CH3 540
b 25 ± 4 
4 —CH2— 2 —H —H 480
b 137 ± 47 
5 —CH2— 2 —H —CH3 92 ± 2.8 48 ± 7 
6 —CH2— 2 —CH3 —CH3 84 ± 9 6 ± 0.5 
7 —CH2— 3 —H —H 32
b 175 ± 59 
8 —CH2— 3 —H —CH3 13
b 3 ± 0.3 
9 —CH2— 3 —CH3 —CH3 22
b 0.5 ± 0.07 
10 —H, —H 1 —H —H 4480 ± 300 >10,000 
11 —H, —H 1 —H —CH3 >10,000 >10,000 
12 —H, —H 1 —CH3 —CH3 7360 ± 1691 5170 ± 750 
13 —H, —H 2 —H —H >10,000 2760 ± 310 
14 —H, —H 2 —H —CH3 1500 ± 163 60 ± 5 
15 —H, —H 2 —CH3 —CH3 1640 ± 172 75 ± 6 
16 —H, —H 3 —H —H 2590 ± 632 1670 ± 180 
17 —H, —H 3 —H —CH3 750 ± 79 390 ± 29 
18 —H, —H 3 —CH3 —CH3 1150 ± 120 70 ± 5 
.
             a
Standard errors typically range between 15-25% of the Ki value.
 b
From Runyon, et al., 2001.
174
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Figure 10. 3D bar graphs showing the affinities at 5-HT2A and H1 for the a) 9-(aminoalkyl)-9,10-dihydroanthracene (DHA) and b) 
diphenylalkylamine (DPA) analogs shown in table 5. 
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3.2.2 Modeling Receptor-Ligand Interactions: H1 and 5-HT2A Receptor Models  
When considering the selectivity of a particular ligand for one receptor versus 
another, it is useful to analyze the differences in amino acids that comprise the binding 
sites of the two receptors. The alignment of the human H1 and 5-HT2A receptor sequences 
with that of human 2-AR is presented in Figure 11. The H1 receptor is phylogenetically 
related to the 5-HT2 receptor subtypes, with high sequence homology specifically in the 
transmembrane region.
182
 Based on the primary sequences, binding site analysis of both 
5-HT2A and H1 receptors indicates that the major variations in amino acid constitution 
occur at positions 3.33, xl2.52, xl2.54, 5.39, 5.42, 6.55 and 7.35 (Figure 11). Differences 
in steric and electrostatic side chain properties at these and other positions are likely 
responsible for ligand selectivity of the two receptors. The H1 receptor amino acid residue 
K191
5.39
, not commonly found at this position among aminergic GPCRs, could be 
potentially exploited for the design of highly selective H1 ligands.  The three-dimensional 
arrangement of these residues is shown in Figure 12. The residues that are conserved 
between H1 and 5-HT2A are those that tend to be highly conserved among all aminergic 
GPCRs. These residues, primarily located in the inner region of the binding cavity, 
include W
3.28
, the amine counter-ion D
3.32
, S
3.36
 and T
3.37, the „aromatic cluster‟ residues 
W
6.48
, F
6.52
, and Y
7.43
 (an H-bonding partner for D
3.32
). 
Models of human H1 and 5-HT2A receptors were generated with the MODELLER 
program using a high-resolution crystal structure of the human β2-adrenergic receptor as a 
template. Inspection of putative receptor binding sites and ligand binding modes in our 
homology models (Figure 13) indicate two common interactions that occur for each of 
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the compounds at both 5-HT2A and H1 receptors: 1) The highly conserved aspartic acid 
residue at position
183
 3.32 (H1, D107
3.32
; 5-HT2A, D155
3.32
) is able to interact with the 
protonated amine of the docked ligand; and 2) Hydrophobic residues present in TM6 
comprising the aromatic cluster
184
 are able to interact with the aromatic rings of ligand. In 
other binding site locations, variability of amino acid residues at equivalent positions in 
the H1 and 5-HT2A influence the way the aromatic rings are oriented in the receptor, 
which in turn provide an explanation for the observed differences in affinity for AMDA 
and its analogs with varying chain lengths. The presence of hydrophobic residues 
surrounding the conserved D
3.32
 in H1 and in 5-HT2A, together with the aromatic cluster 
region in H1 and in 5-HT2A, provide sites of favorable interaction with the ligands for 
each receptor. 
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Figure 11. Alignment of the human β2-adrenergic, H1 and 5-HT2A receptor sequences. 
Sequence positions highlighted in pink indicate highly conserved amino acids among the 
Class A GPCR family which serve as reference positions in the Ballesteros-
Weinstein
153
numbering system. The traditional numbering shown corresponds to the H1 
(top) and 5-HT2A (bottom) sequences. β2-Adrenergic residues highlighted in purple 
indicate positions in the third intracellular loop that were mutated to glycine in the H1 and 
5-HT2A sequences; these were retained in subsequent H1 and 5-HT2A models. Other 
residues highlighted in the β2-AR sequence represent the binding site and are those which 
are within 5.0 Å of the carazolol ligand bound in the 2AR. The residue color indicates 
the degree of similarity at a particular position as defined by the Gonnet PAM250 
similarity matrix (green = identical; yellow = strong or weak conservation; red = no 
conservation). The figure was created using ALSCRIPT.
185
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3.2.3 Binding Mode Analysis  
Compounds listed in Table 5 were docked into the receptor binding sites of the H1 
and 5-HT2A receptor models using an automated docking routine GOLD. The GOLD 
scoring function (steric and electronic interactions) was used to select the favored ligand 
conformation. In addition, we carried out HINT
163
 (Hydropathic INTeraction) analysis to 
characterize the nature of the binding site interactions. HINT is a free-energy-based 
method that considers atom-atom interactions in a bimolecular complex using a 
parameter set derived from octanol/water partition coefficients.
186
 Modeling observations 
indicate that the compounds prefer to be oriented within the binding pockets of the two 
receptor models in similar but distinct binding modes (Figure 13). The well-known 
aspartate D
3.32
 residue was found to interact with the basic amine in both receptors for 
each docked ligand, and the ligand aromatic rings were consistently oriented in the 
binding site surrounded by TM4, TM5 and TM6. In general, for the short-chain linker 
ligands there is a relatively small amount of ligand surface area that may interact with the 
surrounding hydrophobic environment in the binding pocket, accounting for the observed 
decreased affinity of these compounds at both 5-HT2A and H1.  However, for AMDA (1), 
the observed high affinity could be due to the presence of an alternate binding mode.
170
  
The tricyclic DHA ring system in 9 showed strong hydrophobic interactions 
(Y108
3.33
, L163
4.61
, F168
xl2.38
, F190
5.38
 and F435
6.55
), with the phenyl rings oriented 
toward TM5 and the aliphatic linker located deep in the H1 binding pocket. In contrast, in 
the 5-HT2A model, 9 is oriented such that the phenyl rings are facing TM6 (F339
6.51
, 
F340
6.52
 and N343
6.55
) and the aliphatic linker is positioned closer to EL2 (Figure 13a and 
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13d). For both H1 and 5-HT2A, the compound with the longest linker and highest degree 
of methylation (9) was found to have the greatest (H1) or one of the highest (5-HT2A) 
affinities among the compounds tested. The methylene linkers in the H1 receptor are able 
to interact with residues L104
3.29
 and Y431
6.51
 which may explain the comparatively 
higher affinity of 9 for H1 than for 5-HT2A. Further, the observed differences in ligand 
orientation within the receptor binding site can account for the preference for N-
methylation at H1, with the methyl groups more closely surrounded by hydrophobic 
residues as compared to 5-HT2A (Figure 13a and 13d).  
For the unbridged DPA analogs, the increased conformational flexibility (as 
compared to DHA) and intramolecular steric repulsion produce a twisted ring orientation. 
This results in more unfavorable receptor-ligand interactions (steric clashes and polar-
nonpolar interactions) involving the ring system and the surrounding residues (Figure 13b 
and 13e) which may explain the generally low affinity of compound in DPA series as 
compared to DHA series. 
HINT hydropathy interaction analysis provided additional support for the 
proposed orientation of the ligands in the binding pocket. Figure 14 shows the HINT 
maps generated for compound 9 (which has highest affinity for both receptors) in the 
binding sites of the H1 and 5-HT2A receptors. In each case the tricyclic ring system fits 
into the hydrophobic „aromatic cluster‟ while the amine group faces D1073.32 and is 
stabilized by both ionic and hydrogen bonding interactions. However, both the aliphatic 
linker region and the N-methyl groups engage in more extensive hydrophobic interactions 
in H1 than in 5-HT2A. 
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In addition, the receptor-ligand complexes described here are in general 
agreement with other studies that have implicated residues that contribute to an 
antagonist binding site in H1 and 5-HT2A.
170,187,188
 Besides the several key residues that 
have been reported by site-directed mutagenesis studies in H1 receptor models
189
 
(W158
4.56
, F424
6.44
, W428
6.48
, F432
6.52
 and F435
6.55
) and 5-HT2A receptor models
190
 
(F243
5.47
, W336
6.48
, F339
6.51
, F340
6.52
), we found that Y108
3.33
 was oriented to favorably 
interact with ligands in the binding pocket of the H1 receptor, and the cognate residue 
V156
3.33
 for the 5-HT2A receptor. The differences in the stereoelectronic character of 
these residues likely contribute to the differences in the way the ligand binds to these 
receptors, and consequently the observed differences in binding affinity. 
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Figure 12.  Illustration of the differences in binding site residue composition of the H1 
and 5-HT2A receptors. Residues are truncated at the C

 carbon atom (ball-and-stick 
representation) and are colored based on residue similarity as described in figure 11. For 
those positions whose residue identity differs, the H1 residue is listed first, followed by 
the 5-HT2A residue. 
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a. b. c. 
d 
   
Figure 13. Docked receptor-ligand complexes. The H1 receptor model with compounds a) 9, b) 18 and c) 1. The 5-HT2A receptor model with compounds 
d) 9, e) 18 and f) 1. Residues within 5 Å of the bound ligand are displayed. 
e f d 
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a. 
 
      
b. 
 
Figure 14. HINT interaction maps for compound 9 in a) 5-HT2A and b) H1 binding sites. 
Regions of favorable hydrophobic (green) and polar (magenta) interactions are shown as 
contours. 
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3.2.4 Chemistry 
 9-Aminomethyl-9,10-dihydroanthracene (1) was reported by our group in the 
past.
173
 (9,10-Dihydroanthracen-10-yl)-N-methylmethanamine (2) and (9,10-
dihydroanthracen-10-yl)-N,N-dimethylmethanamine (3) were prepared by reduction 
(BH3•THF) of amides 44 and 45 obtained by the treatment of the acid chloride of 43 with 
methyl or dimethylamine
174
 (Scheme 1). 2-(9,10-Dihydroanthracen-9-yl)ethanamine (4) 
was prepared from 2-(anthracen-9-yl)ethanamine (48). The condensation of 9-
anthraldehyde (46) with nitromethane in methylene chloride gave 9-(2-
nitrovinyl)anthracene (47)
191
 which was reduced to 2-(anthracen-9-yl)ethanamine (48) 
using LiAlH4/THF. The target molecule i.e., 4 was then prepared through middle ring 
reduction using sodium metal in liquid ammonia
192
 (Scheme 2). 2-(9,10-
Dihydroanthracen-9-yl)-N-methylethanamine (5) was synthesized using 9-
hydroxymethylanthracene (49) as the starting material. Bromination
193
 followed by 
cyanation
194
 of the alcohol gave 2-(anthracen-9-yl)acetonitrile (51) which was further 
hydrolyzed to the corresponding acid 52. Anthracene ring reduction using sodium metal 
in 1-pentanol gave 2-(9,10-dihydroanthracen-9-yl)acetic acid (53). Sequential conversion 
of the acid 53 to its amide 54 via the chloride, followed by reduction gave the target 
molecule 5 (Scheme 3). 2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine (6) 
was prepared by reductive amination
195
 of 2-(9,10-dihydroanthracen-9-yl)acetaldehyde 
(57) obtained by the oxidation of 2-(9,10-dihydroanthracen-9-yl)ethanol (56)
196
 (Scheme 
4). 3-(9,10-Dihydroanthracen-9-yl)propan-1-amine (7), 3-(9,10-dihydroanthracen-9-yl)-
N-methylpropan-1-amine (8), 3-(9,10-dihydroanthracen-9-yl)-N,N-dimethylpropan-1-
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amine (9) were prepared by reduction (BH3•THF) of amides 63, 64 and 65 obtained by 
treatment of the acid chloride of 3-(9,10-dihydroanthracen-9-yl)propanoic acid (62)
197
 
with ammonia gas, methylamine and dimethylamine, respectively (Scheme 5). 2,2-
Diphenylethanamine (10) was commercially obtained. N-methyl-2,2-diphenylethanamine 
(11) was obtained by the N-methylation of the respective amine 66 as reported
198
 
(Scheme 6). Compounds N,N-dimethyl-2,2-diphenylethanamine (12) and N-methyl-3,3-
diphenylpropan-1-amine (14) were obtained commercially. 3,3-Diphenylpropan-1-amine 
hydrochloride (13) was obtained in salt form from commercially available 3,3-
diphenylpropan-1-amine. N,N-Dimethyl-3,3-diphenylpropan-1-amine (15)
199
 was 
synthesized by reductive amination of 3,3-diphenylpropanal (68) obtained by the 
oxidation of  commercially available 3,3-diphenylpropanol (67) using Dess-Martin 
reagent (Scheme 7). 4,4-Diphenylbutan-1-amine (16)
200
 was prepared by the BH3•THF 
reduction of 4,4-diphenylbutyronitrile (71) that was obtained from potassium 
amide/liquid ammonia solution of diphenylmethane (69) by alkylation with 
bromopropionitrile
201
 (Scheme 8). N-Methyl-4,4-diphenylbutan-1-amine (17) and N,N-
dimethyl-4,4-diphenylbutan-1-amine (18) were prepared by reduction (BH3•THF) of 
amides 75 and 76 obtained by treatment of the acid chloride of 4,4-diphenylbutyric acid 
(73)
202
 with methylamine and dimethylamine, respectively. The intermediate compound 
73 was obtained from treatment of commercially available lactone 72 with benzene in the 
presence of anhydrous aluminum chloride (Scheme 9). 
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3.3 Synthetic Schemes  
  44 R1 = H, R2 = CH3
  45 R1 = CH3, R2 = CH3
N
R1
R2
a db, c
HO O O N
R1
R2
2  R1 = H, R2 = CH3
3  R1 = CH3, R2 = CH3
42 43
 
Scheme 1. a) n-BuLi, diethyl ether, dry ice; b) SOCl2, reflux; c) methyl or dimethyl 
amine, THF, 25 ºC; d) BH3•THF, reflux. 
 
OH
NO2 NH2 NH2
4
a b c
46 47 48  
Scheme 2. (a) CH3NO2; (b) LiAlH4, THF; (c) Na, liquid ammonia. 
 
a b c
d
HO Br NC
e
O
N
H
CH3
f
HN
CH3
5
OH
O
OH
O
49 50 51 52
53 54
Scheme 3. (a) PBr3 , toluene; (b) KCN, DMSO; (c) ethylene glycol, KOH; (d) Na, 1-
pentanol; (e) SOCl2, benzene, methylamine (2M) THF; (f) BH3•THF, reflux. 
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N
CH3H3C
OH OH O
H
6
a b c
55 56 57   
 
Scheme 4. (a) Na2K silica gel, THF; (b) Dess-Martin (periodinane) reagent, CH2Cl2;  
(c) dimethylamine hydrochloride, Ti(O
i
Pr)4, NEt3, abs EtOH, NaBH4. 
 
O
N
R1
R2
a
b ec, d
  63  R1 = R2 = H
  64  R1 = H, R2 = CH3
  65  R1 = CH3, R2 = CH3
OHO N O
R1
R2
7  R1 = R2 = H
8  R1 = H, R2 = CH3
9  R1 = CH3, R2 = CH3
OK
i
a
ii
O
CN
COOH
a
iii
58 59 60 61
62
 
Scheme 5. (a) i. KOC(CH3)3  ii. acrylonitrile, t-butyl alcohol, iii. NH4OH, Zn dust, 
hydrochloric acid reflux; (b) Na, 1-pentanol, reflux, 10 min; (c) SOCl2, reflux, 2 hr; (d) 
NH3 or methylamine or dimethylamine, THF, 25 ºC; (e) BH3•THF, reflux, 6 hr. 
 
NHNH2
CH3
a
1166  
Scheme 6. (a) aqueous (37%) formaldehyde, CH3CN, NaBH3CN, glacial acetic acid,  
(2N) KOH, Et2O. 
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OH
CHO
N
CH3H3C
15
a b
67 68  
Scheme 7. a) Dess-Martin (periodinane) reagent, anhydrous CH2Cl2; (b) dimethylamine 
hydrochloride, Ti(O
i
Pr)4, NEt3, abs EtOH, NaBH4. 
 
+ Br
CN
16
a b
CN
NH2
69 70 71
 
Scheme 8. a) K metal, Fe(NO3)3, liq NH3, Et2O; (b) BH3•THF. 
 
O O
O
OH
O
Cl
O
N
R1
N
R1
a b
c d
R2 R2
  75  R1 = H, R2 = CH3
  76  R1 = CH3, R2 = CH3
17  R1 = H, R2 = CH3
18  R1 = CH3, R2 = CH3
72 73 74
  
 
Scheme 9.  a) anhydrous benzene, AlCl3; (b) SOCl2, benzene; (c) methylamine or 
dimethylamine (2M) THF; (d) BH3•THF. 
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3.4 Molecular modeling  
 Homology models were built using the automated software MODELLER (details 
in experimental section). The populations of 100 different H1 and 5-HT2A homology 
models were generated and subsequently energy minimized. The β2-adrenergic receptor 
was used as the template for the generation of models. The selection of the best fit model 
in each (H1 and 5-HT2A) case was based on the fitness function values obtained as a result 
of docking studies conducted using the automated docking program GOLD details in 
experimental). In addition to consistently observed GOLD score, steric and electronic 
interactions of the docked poses and reported site-directed mutagenesis data was 
considered for the selection of the best fit model. Further, HINT scoring function was 
used to characterize the nature of the binding site interactions (details in experimental 
section).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 60 
3.5 Conclusions 
 
 Within the matrix of compounds synthesized and tested, the N,N-dimethylated 
chain lengthened propylene analog of AMDA shows the highest affinity at both 5-HT2A 
and H1 receptors (9; 5-HT2A, Ki = 22 nM; H1, Ki = 0.5 nM) and the highest selectivity for 
the H1 receptor (44-fold). In addition, removing the conformational restriction of the 
dihydroanthracene tricyclic system is detrimental to the ligand affinity for both 5-HT2A 
and H1 receptors. Structure-affinity relationships among these compounds show that N-
alkylation either decreases or has little effect on 5-HT2A affinity. In the case of 
compounds with propylene linker (7, 8 and 9), all have relatively high affinity for the 5-
HT2A receptor and are less sensitive to the degree of N-alkylation. In addition, the ring-
opening of the dihydroanthracene system to diphenyl system is generally unfavorable for 
the affinity at both 5-HT2A and H1 receptors. Hydropathic analysis of the modeled 
complexes supports the proposed role of the TM6 aromatic cluster in directing binding. 
The proposed differences in the binding pocket of H1 (Y108
3.33
) and 5-HT2A (V156
3.33
) 
may determine the way ligands bind, which in turn determine the selectivity of the 
ligands for each of two receptors. These preliminary modeling results provide a 
qualitative understanding of how AMDA analogs might interact with the 5-HT2A and H1 
receptors. This study also provides potential insight into the mechanisms by which 
differences in the structures of the receptor and ligand determine the receptor selectivity. 
   
 61 
 
 
 
 
 
RING-ANNULATED AND N-SUBSTITUTED ANALOGS OF AMDA AS 
STRUCTURAL PROBES FOR 5-HT2A AND H1 RECEPTORS 
 
 
 
 
4.1 Introduction  
 
In the past few years, much information has been generated about the 5-HT2 
receptor and its subtypes.
3,49
 However, it is still not completely clear how serotonergic 
ligands (agonists, partial agonists and antagonists) including 5-HT itself interact with the 
receptors. In the absence of a crystal structure for the 5-HT2 receptor family, models 
generated from a representative GPCR such as rhodopsin or a β-adrenoceptor are used to 
study possible drug-receptor interactions.
51,171,203
 We have previously synthesized and 
tested many analogs of the selective 5-HT2 antagonist 9-aminomethyl-9,10-
dihydranthracene (AMDA). Modeling investigations of AMDA and its analogues have 
provided some insight into the possible ligand-receptor interactions responsible for their 
affinities at the 5-HT2A and H1 receptors.
170,204,205
 Literature studies involving H1 
antagonists show that diphenhydramine-like structures are the most investigated series of 
anti-H1 active structures.
107
 The results of the quantitative structure-activity relationship 
(QSAR)
206
 studies of these series of compounds suggest that the major characteristics for 
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H1 activity are high lipophilicity of an aromatic group, a given distance between a 
hydrophobic region and observed ammonium ion and a region of relatively large “bulk 
acceptance” around the ammonium ion. In order to further explore receptor binding site 
dimensions, we synthesized and tested N-substituted and ring-homologated analogues of 
AMDA which can in turn also serve as structural probes to determine the preferred ligand 
orientations, ligand-receptor interactions and predict the dimensions of the binding site. 
 
4.2 Substituted Phenylalkylamine Analogs of AMDA as Structural Probes 
 Molecular modeling studies conducted by us suggested that, all the AMDA 
analogs are oriented in a similar fashion but exhibit a different binding mode for 5-HT2A 
and H1 receptors.
205
 In both cases, the tricyclic ring system prefers a hydrophobic core 
surrounded by TM 4, 5, and 6 whereas the basic amine-bearing end is oriented toward 
TM3. In accordance with the existing trend for various class of antihistamines,
107
 it was 
observed that N-alkylation is favorable for the H1 receptor affinity among AMDA 
analogs. However, in case of 5-HT2A receptor an opposite trend was observed in which 
N-alkylation led to decreases in the binding affinity.  As mentioned above, we 
synthesized and tested N-phenylalkylamine analogs of AMDA (19-22, Figure 15) to 
further explore the bulk tolerance at this portion of the binding site. Compound 19 was 
previously synthesized in our group. The observed affinity data for these compounds 
showed that these compounds had low affinity (Ki = 365 to 710 nM) at 5-HT2A and H1 
(Ki = 223 to 964 nM) receptors. The slight variation in the binding affinity values for the 
5-HT2A receptor corresponded to the previously observed trend. However, it was 
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surprising that phenylalkyl substitution at the basic amine greatly reduces affinity at the 
H1 receptor (20, Ki = 242 nM, 21, Ki = 223 nM, 22, Ki = 964 nM), since both classical 
and tricyclic antihistamines often have very bulky amine substituents.
107
 The results 
obtained suggest the possibility that the basic amine in the N-phenylalkyl AMDA analogs 
bind in a different environment as compared to the diphenhydramine series and tricyclic 
antihistamines. The proposed orientation of the N-phenylalkyl substituent within the 5-
HT2A and H1 receptor binding site is shown in Figure 16a and 16b.  
In addition, the synthesis and testing of the quaternary ammonium salt of AMDA 
(23) showed substantially higher affinity for H1 receptor (Ki = 70 nM) as compared to 5-
HT2A receptor (Ki = 4000 nM). The observed affinity for the H1 receptor could be due to 
the presence of Y6.51 in the binding site that forms a π-cation bond207 with the 
quaternary ammonium ion in the H1 receptor but not in the 5-HT2A receptor (Figure 17), 
further suggesting the possibility of a more hydrophobic binding site environment in H1 
as compared to 5-HT2A 
 
4.3 Ring-annulated Analogs of AMDA as Dimensional Probes  
The concept of using ring-annulated or so called “stretched-out” analogues of 
high affinity ligands as dimensional probes has been reported but not widely 
employed.
208
 By carrying out systematic ring annulation and substitution one can infer 
information about the dimensions of the binding site.
209-211
 AMDA and its analogs 
contain a rigid tricycyclic scaffold. Previously conducted SAR studies
170
 of substituted 
AMDA analogs by us have indicated that there may be a great deal of steric tolerance 
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around this tricyclic ring system. However, the large substituents examined to date have a 
high degree of rotational freedom due to alkyl chain flexibility. In order to construct a 
rigid and elongated structure we decided to expand the tricyclic ring system with fused 
aromatic rings (Figure 15). The expansion of the AMDA pharmacophore by benzene 
fusion will provide dimensional probes which can extend beyond the existing site and 
may permit interactions with additional binding site residues. The initial compound that 
we attempted to synthesize and test was tetracene 25. However, the synthetic 
methodology chosen for 25 gave a mixture (75:25) of isomers of tetraphene 24 and 
tetracene 25 respectively (Scheme 12). The binding affinity data obtained for this mixture 
had the Ki value of 10 nM (5-HT2A). Thus it was concluded that at least one of the 
isomers binds with high affinity. Based on our previous SAR study experience we 
synthesized the ring substituted methoxy-analogue 26 of the expanded AMDA structure 
with a similar procedure. The attempted synthesis (Scheme 12) gave a mixture of two 
isomers 26 and 27. Due to the challenges faced in the final cyclization step and difficulty 
in the separation of products, the reaction gave a very low yield of the final product. The 
purification of the reaction mixture resulted in the separation of only the major isomer 
i.e., (26) whose binding affinity was determined. The binding affinity data showed that 
methoxy-substituted isomer 26 had reasonable affinity (Ki = 21 nM) for the 5-HT2A 
receptor while possessing very low affinity for H1 receptor (Ki = 2640 nM). In order to 
further confirm the possibility that a single isomer is responsible for high affinity at 5-
HT2A, the synthesis of compound 25 was carried out by another group member (S. Peddi) 
via an unambiguous cyclization route. The binding studies of compound 25 indicated that 
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it had no affinity for 5-HT2A receptor (Ki = >10,000 nM). These results indicate the 
possibility of an isomer having a pharmacophore features similar to 26 to be responsible 
for the affinity of the ligand. 
H
N
Ki (5-HT2A) - 365 ± 17 nM 
     (H1)        - 964 ± 150 nM
H2N
H2N
H2NH2N OCH3
OCH3
Ki (5-HT2A) - >10,000 nM Ki (5-HT2A) - 21 ± 0.5 nM 
     (H1)        - 2640 ± 530 nM
N
H3C CH3
CH3
23
Ki (5-HT2A)
a - 4000 nM 
     (H1)        - 70 ± 10 nM
Ki (5-HT2A)
a - 721 nM 
     (H1)        - NA
H
N
2
H
N
3
H
N
4
Ki (5-HT2A) - 400 ± 34 nM 
     (H1)        - 242 ± 27 nM
Ki (5-HT2A) - 422 ± 5 nM 
     (H1)        - 223 ± 128 nM
20 21
22 24
2625 27
19
 
Figure 15. Binding affinity data of AMDA analogs as molecular probes. 
a
From Runyon, 
et al., Biorg. Med. Chem. Lett. 2001, 11, 655-688.
174
 
 
4.4 Molecular Modeling studies 
The generation and refinement of the 5-HT2A and H1 receptor homology models 
used in the docking studies is described in the experimental section. A virtual library of 
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compounds shown in Figure 15 with explicit consideration of stereoisomers was built and 
energy-minimized. The structures were then docked into the receptor binding site using 
the automated docking program GOLD (experimental section). To begin with, the 
structures were docked into the homology model built using 2-adrenergic receptor as the 
template. However, the docked poses failed to show the optimum interactions between 
the ligand and the binding site residues hence we used the homology models built using 
bovine rhodopsin as the template. Visual inspection of docking poses in conjunction with 
the ChemScore fitness function was used to select the final solution for each isomer. The 
GOLD program used for docking was able to place all the ligands in the previously 
predicted binding site (Figures 16-18). In each solution, the ligand ammonium ion 
interacts with the D155
3.32
 residue in the binding site. The tetraphene isomer (24) showed 
lipophilic interactions with the hydrophobic residues in the binding pocket (Figure 18). In 
the case of the methoxy substituted analog 26, docked pose of both the (R)- and (S)- 
stereoisomer showed additional interactions with hydrogen-bond donating S159
3.36
 and 
S77
1.35 
residues respectively, in the 5-HT2A binding site. The vast difference in the affinity 
value of compound 25 (>10,000 nM) and mixture of 24 and 25 (Ki = 10 nM), combined 
with the observation that methoxy-substituted compound (26) showed higher affinity (Ki 
= 21 nM) suggest that the non-linear tetraphene analogs are responsible for the observed 
affinity.       
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                a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              b. 
 
 
 
Figure 16.  Proposed binding mode of phenylalkylamine analogs of AMDA in the 
binding site of the a) 5-HT2A and b) H1 receptors. Ligands are represented as capped stick 
model with compounds 19 (yellow), 20 (orange), 21 (cyan) and 22 (green) respectively. 
Residues within 4 Å of the bound ligands are displayed. 
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Figure 17. Proposed binding mode of quaternary ammonium salt of AMDA in the 
binding site of the H1 receptor. Compound 23 (magenta) is represented as capped stick 
model. Residues within 4 Å of the bound ligands are displayed. 
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 a.                                                                    b. 
  
 
 
c.      d. 
  
 
. 
Figure 18.  Proposed binding mode of isomers of ring-homologated AMDA analogs  
a) (R)-26 b) (S)-26 c) (R)-24 d) (S)-24 within the binding site of the 5-HT2A receptor. 
Residues within 4 Å of the bound ligands are displayed. 
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4.5 Chemistry  
Compound 9-(N-benzylaminomethyl)-9,10-dihydroanthracene (19) was reported 
by our group earlier.
174
 The phenylalkyl amines 20, 21 and 22 were prepared by reduction 
(BH3•THF) of amides obtained by the treatment of the acid chloride with phenylethyl-, 
phenylpropyl and phenylbutyl amine respectively (Scheme 10). Compound 23 was 
obtained by the N-methylation of previously synthesized compound 3 using iodomethane 
(Scheme 11). In case of ring-annulated analogs, commercially available -bromo-o-
tolunitrile (80) on treatment with DIBAL-H in anhydrous CH2Cl2 and work up using 
aqueous HBr gave the aldehyde 81 in quantitative yields.
212
 Palladium catalyzed cross-
coupling of 2-naphthylboronic acid and 6-methoxy-2-naphthylboronic acid with the 
aldehyde 81 gave the respective coupled aldehydes 82 and 83. Cyanosilylation of the 
aldehydes 82 and 83 using TMSCN gave the cyano trimethylsilyl ether as intermediates, 
which were reduced with LiAlH4 to give the respective amino alcohols 84 and 85. 
Cyclodehydration of aminoalcohols using methanesulfonic acid gave the isomers of 
cyclized products 24, 25 and 26, 27 respectively (Scheme 12). 
 
4.6 Synthetic Schemes 
O
H
N
H
N
R R
a
b
c
77  R = - (CH2)2C6H5 
78  R = - (CH2)3C6H5
79  R = - (CH2)4C6H5
O OH
20 R = - (CH2)2C6H5 
21 R = - (CH2)3C6H5
22 R = - (CH2)4C6H5
43
 
Scheme 10. (a) SOCl2, benzene; (b) phenylethylamine or phenylpropylamine or 
phenylbutylamine; (c) BH3•THF. 
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O N N
COOH CH3 CH3
a
b
c
CH3CH3
d
N
H3C CH3
CH3
2343 45 3  
 
Scheme 11. (a) SOCl2, reflux; (b) dimethylamine, THF, 25 ºC; (c) BH3•THF, reflux; (d) 
iodomethane, CH2Cl2. 
 
 
 
 
RNH2
82  R = H
83  R = OCH3
24 R = H
26 R = OCH3
a b
c
d
84  R = H
85  R = OCH3
R
H2N
25 R = H
27 R = OCH3
CN
Br
CHO
Br
RCHO
H2N
R
OH
80 81
 
 
Scheme 12. (a) DIBAL-H, CH2Cl2; (b) Pd(PPh3)4, K3PO4, 2-naphthylboronic acid/6-
methoxy-2-naphthylboronic acid; (c) TMSCN, ZnI2, CH2Cl2, LiAlH4, THF; (d) 
CH3SO3H. 
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4.7 Conclusions 
 
 
 Overall, our results imply that large rigid ring-annulated AMDA analogs can be 
sterically accommodated within the proposed 5-HT2A binding site. It is rather remarkable 
that compounds of the dimensions of 24 and 26 bind at all and in fact have very high 5-
HT2A affinity and a low H1 affinity. There are currently no known rigid ligands that show 
the affinity for 5-HT2A receptors and exceed the dimensions of these AMDA analogs. For 
example, in case of of tricyclic antidepressants, ergot alkaloids and apomorphine the 
longest dimension is equivalent to 3 linearly fused rings. We have chosen to carefully 
examine the dimensions of the binding site by elaboration of the tricyclic system with 
successive aromatic ring fusions which present a rigid obstacle. Further elaboration of the 
AMDA skeleton by benzfusion will create dimensional probes which will extend beyond 
AMDA itself and allow access to additional sets of binding site residues. Since both the 
tetracene and tetraphene isomers of the unsubstituted ring-annulated AMDA analog show 
remarkable differences in binding affinities, we would attempt synthesis of substituted 
tetraphen analogs of AMDA by a different synthetic method in the future. Based on the 
results obtained, we would also attempt the resolution of enantiomers by HPLC using 
chiral column supports. The dimensional probe concept can be exploited further by the 
design, synthesis of various substituted benzene fused AMDA analogs. Due to their large 
rigid structures these ligands can interact with subtype specific residues which can help to 
generate selective agents.  
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ENGINEERING A SELECTIVE NON-NITROGENOUS AMINERGIC GPCR 
LIGAND 
 
 
 
5.1 Introduction. 
 
Over the years, significant progress has been made in the development of novel, 
high-affinity ligands for several aminergic GPCRs including those activated by 
histamine,
107
 serotonin
213
 and dopamine.
214
 However, there is a lack of truly selective 
agonists and/or antagonists for most of these receptors. Development of a selective ligand 
in the case of aminergic GPCRs is especially challenging due to the presence of highly 
conserved structural features among the members of this class of receptors.
134,215,216
 In 
addition, it is also assumed that due to the presence of these common structural features 
the various subtypes exhibit a common mechanism of interaction with their ligands. 
Since most aminergic GPCR ligands have a basic amine moiety, this feature was 
identified as a crucial component for high-affinity receptor-ligand interaction.
57
 
Systematic mutagenesis studies by various groups have identified negatively charged 
Asp
3.32 
as a counter ion for the basic amine in both agonists and antagonists.
217-219
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 In the past Glennon et al.
213
 have reported several successful strategies for the 
development of selective serotonergic ligands. However, to-date very few cases are 
reported for the receptor structure-based design of a selective ligand. Recently, our group 
has reported
220
 homology modeling studies of the kappa-opioid receptor (KOR) with 
salvinorin A, a selective non-nitrogenous KOR agonist. The result of our modeling study 
suggests that one of the possible reasons for the salvinorin A‟s high KOR selectivity 
could be the absence of the highly conserved Asp
3.32
-amine interaction that is conserved 
among all GPCRs. In addition, the models also indicate the presence of a KOR specific 
interaction in the binding site. Also, there have been reports of the binding of some 
antagonists with reduced, but still significant, affinity at the Asp-mutated 5-HT1A,
221
 5-
HT2A
54
 and muscarinic acetycholine receptors
222
 suggesting that it may be possibile to 
design a GPCR ligand that does not interact with this aspartate.  
 As mentioned in our earlier studies, in order to understand how molecules bind 
at 5-HT2A and the H1 receptors, we conducted docking studies for AMDA and its analogs 
with the homology models of receptors. Continuing our efforts to understand the binding 
site interactions and test the utility of our models, we generated a testable hypothesis 
about the necessity of the interaction involving the highly conserved Asp
3.32
 and the basic 
amine containing ligands that could possibly lead to a selective GPCR ligand.       
 
 
5.2 Hypothesis based on the Homology Modeling and Reported Site-Directed 
Mutagenesis Studies 
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  Most of the second-generation H1 antagonists penetrate poorly into the CNS, and 
have an improved selectivity profile as compared to first-generation H1 antagonists. It is 
observed that the addition of a chemical group that is ionized at physiological pH will 
convert a potent sedating H1-antagonist into a less sedating one.
223
  For example the 
oxidation of the terminal alcohol group in hydroxyzine to a carboxylic acid group results 
in cetrizine, which is less sedating than the parent compound. However, the precise 
structural requirements that contribute to receptor selectivity and affinity are 
unknown.
224-226
 Site-directed mutagenesis studies have revealed that Asp 107
3.32
 in TM3 
is crucial for binding of histamine and nearly all H1 receptor antagonists.
6,219
 In addition, 
mutation analysis of the H1 receptor binding pocket has revealed several residues that are 
essential for agonist and antagonist interactions.
187,188,227
 Of these, Lys191
5.39
 appears to 
be unique to the H1 receptor.
189,228
  
 A multiple sequence alignment of TM5 for a set of aminergic GPCRs indicates 
that Lys191 is found in the histamine H1 receptor at a position (5.39) near the 
extracellular end of the TM5 domain where no charged residue is observed in other 
aminergic GPCRs.
229
  Lys191 is thought to interact with the proximal nitrogen (N
π
) of the 
imidazole ring of histamine.
229
 In addition, it may act as a specific anchor point for 
second-generation H1 antagonists containing a carboxylate moiety.
187,230
 Mutation of 
Lys191
5.39
 (human) and its counterpart Lys200
5.39
 (guinea pig) to alanine leads to 
decreased affinity for histamine (5-fold) and an even higher decrease in functional EC50 
value (50-fold). In addition, mutational analysis of the antagonist binding site reveals that 
the Lys200Ala mutation results in a 10- to 50-fold loss of affinity for zwitterionic 
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antagonists such as acrivastine and cetrizine. The affinities of structural analogs of these 
compounds lacking carboxylate group were unaffected by the mutation
189
 (Figure 19). 
 Studies involving tricyclic rigid analog olopatadine and its structural analog 
doxepin that lacks the carboxylic acid substituent, has shown that the presence of the 
carboxylic substituent has no significant effect on wild-type H1 receptor affinity 
(increases by ~ 2-fold). However, in the case of the mutant D107A H1 receptor, the 
affinity of doxepin deceases significantly (~ 60-fold) as compared to olopatadine (~ 12-
fold), suggesting that a cationic interaction exists in the binding site in addition to the 
hydrophobic interactions. Taking into consideration these findings, we carried out 
docking studies of a series of known first and second generation H1 antagonists and 
AMDA analogs synthesized in our lab. Binding site analysis from the docked poses of 
ligands reveal that AMDA and its analogs may bind in a similar manner to H1 
antagonists. The basic amine in each bound ligand is able to interact with the conserved 
Asp107.
3.32
 In addition, the carboxylic acid moiety present on the zwitterionic 
compounds (acrivastine and olopatadine) was in a favorable position to interact with 
Lys191
5.39
 in H1 receptor. Based on our docking observations and reported
228
 mutation 
study of Lys
5.39
, we predicted that in addition to the conserved Asp
3.32
 interaction and the 
overall fit of the ligand in the binding pocket, one of the key interactions for the observed 
affinities of the zwitterionic compounds could be the ionic interactions involving the 
Lys191
5.39
 that is unique to the binding site of H1 receptor. Thus we generated a 
hypothesis that either one of these two ionic interactions might be sufficient for ligand 
affinity. Further, the binding study results
6
 involving the mutant D107A H1 receptor and 
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the drug olopatadine suggested that inspite of mutating the highly conserved D107 
residue, olopatadine retains its affinity (Figure 19). Thus in order to test our hypothesis of 
possibly substituting the highly conserved Asp
3.32
 ionic interaction with an equivalent 
Lys
5.39 
interaction we decided to synthesize a compound without the basic amine but 
incorporate a carboxylic acid substituent in the compound. 
 
5.3 Strategy for the Design of a Selective H1 Ligand 
Taking into consideration our predicted anionic interaction of the carboxyclic acid 
substitution on the ligand with the specific Lys191
5.39 
residue in the binding site of H1 
receptor, we decided to synthesize the analog of our earlier obtained lead compound 
AMDA. Previously conducted SAR studies
170,204
 on the AMDA analogs had suggested 
that the C-3 position of the DHA core showed high stereo-electronic tolerance. Thus, 
initially 3-carboxy-AMDA (28) was synthesized in our laboratory by G. Dewkar and 
tested. Given the challenges faced in the cyclization and purification of compound 28, a 
parallel effort was made to synthesize carboxylic acid-substituted diarylalkyamine analog 
29 (Figure 19). Further in accordance with the affinity data obtained (SAR discussion 
below) we attempted the synthesis of the 3-carboxy-AMDA analog 30. In addition, we 
intended to synthesize a non-nitrogenous, carboxylic acid-containing analog 34 that could 
not interact with the conserved Asp
3.32
. It was also anticipated that such a compound 
would be highly selective for the H1 receptor having removed the one ligand-receptor 
interaction common to all aminergic GPCRs. Taking into consideration the difficulties 
faced in the synthesis of acid-substituted AMDA, we decided to use a different approach 
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for the design of high affinity and selective ligands. We used the “deconstruction” 
approach that is similar to the previously reported “deconstruction-reconstruction-
elaboration” approach for the design of selective 5-HT2 ligands.
213
 In our approach, we 
started with the structure of a lead compound olopatadine (35) and deconstructed its 
structure to determine the structural requirements for binding. Then we reintroduced each 
structural feature in a rational manner to determine how they influence affinity and 
selectivity. In doing so, we first synthesized and tested the tricyclic core of olopatadine 
with an acetic acid substitution at C-2 position i.e., compound 31. We then synthesized 
compound 32 by the reduction of the ketone functionality. Further, we replaced the 
ketone with an olefinic bond to obtain 33. However, we found that none of these 
compounds i.e., 31, 32 and 33 bind at 5-HT2A and H1 receptors. Comparing the structure 
and binding data of 33 (Figure 19) with lead compound olopatadine (35) and its analog 
doxepin (36), we concluded that an alkylamine chain is needed for high affinity at both 
receptor types and acid substitution might determine selectivity. Hence in the final step, 
we synthesized compound 34 that was structurally analogous to olopatadine with the 
exception of basic nitrogen atom.  
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NH2
Ki (5-HT2A) - 5460 ± 621 nM 
     (H1)        - 632 ± 71 nM
N
COOH
COOH
N
COOH
O
O
COOH
O
COOH
O
COOH
Ki (5-HT2A) - >10,000 nM 
     (H1)        - 5950 ± 1224 nM
Ki (5-HT2A) - >10,000 nM 
     (H1)        - >10,000 nM
Ki (5-HT2A) - > 10,000 nM 
     (H1)        - 8180 nM
Ki (5-HT2A) - > 10,000 nM 
     (H1)        - > 10,000 nM
O
COOH
Ki (5-HT2A) - > 10,000 nM 
     (H1)        - 251 ± 24 nM
2928
31 32 33
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O
COOH
N
Olopatadine (35)a
Ki (5-HT2A) -  630 nM 
     (H1)        -  1.8 nM
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O
N
Doxepin (36)a
Ki (5-HT2A) -  0.6 nM 
     (H1)        -  3.3 nM
1
2
3
4
For D107A (H1) -  25 nM For D107A (H1)  - 190 nM
N
N
COOH
Ki (H1) -  10 nM
For L200A (H1) - 548 nM
N
N
Acrivastine (37)b
Ki (H1) -  4 nM
For L200A (H1) - 2 nM
Triprolidine (38)b
1
2
3
4
1
2
3
4
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Figure 19. Probes for the design of a selective H1 ligand. 
a
From Nonaka, et al., Eur. J. 
Pharmacol. 1998, 345, 111-117.
6
 
b
From Weiland, et al., J. Biol. Chem.1999, 274, 29994-
30000.
189
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5.4 Results and discussion 
5.4.1 Structure-Affinity Relationship Studies 
 The modeled orientation of the ligand within the predicted binding site and the 
associated receptor-ligand interactions were consistent with the binding affinity data in 
Figure 19. The 3-carboxy-AMDA (28) exhibited some affinity for the H1 receptor, 
suggesting a possible interaction of the carboxylate substituent with a cationic residue 
Lys191
5.39
 in the H1 binding site. However, the affinity was very low (Ki = 632 nM). 
Observation of docked poses indicates that the relatively low affinity of 28 as compared 
to AMDA (Ki = 197 nM) could be due to the length of the short linker connecting the 
amine with the biaryl moiety, which would prevent compound 28 from adopting a high-
affinity conformation in the binding pocket so as to interact with both D(3.32) and 
K(5.39). The studies
189
 involving the H1 antagonist triprolidine (38) and its acid-
substituted analog acrivastine (37) suggest that the presence of a carboxylic group 
substituent has little effect on H1 affinity (decreases by 2.5-fold). However, the mutant 
K200A H1 receptor showed a decrease in affinity (~ 55-fold), suggesting the possible 
cationic interaction of K200
5.39
 with the carboxylate group of the ligand. Thus, in 
comparison to the acrivastine structure to test the possible effect of a larger amine linker 
length, we synthesized and tested diarylamine analog 29. Interestingly, it exhibited very 
low affinity (Ki = 5950 nM) for the H1 receptor.  
From our initial modeling studies, it was rationalized that one possible reason for 
the observed lack of affinity could be that the presence of the highly charged carboxylate 
group prevents the parent aromatic ring from taking full advantage of the aromatic cluster 
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located on and around the TM5 and 6. In addition, comparison of the docked poses of 
compound 29 with acrivastine (37) in our model suggests that in order to take advantage 
of the cationic interaction of K(5.39), the carboxylic group substituent should be located 
at the 4-position (29, Figure 19) with an extended ethylene linker as in acrivastine. As 
stated in our strategy, we then synthesized and tested structural analog of olopatadine 
lacking the nitrogen atom. None of the non-nitrogenous carboxylic acid-substituted 
analogs 31, 32 and 33 showed affinity for the 5-HT2A receptor, suggesting the importance 
of other pharmacophoric features (basic amine) on the molecule for the favorable 
interaction in the binding site. Among all of the tested non-nitrogenous compounds with a 
rigid tricyclic core, only compound 34 showed moderate affinity at the H1 receptor (Ki = 
250 nM) providing support for our proposed hypothesis. In accordance with a previously 
reported study
6
 investigating the binding site interactions of H1 receptor antagonists, one 
of the possible reasons for the observed binding affinity of 34 at the H1 receptor is that 
the conserved ammonium ion interaction is not essential for the binding. The anionic 
interaction of the carboxylate group with K191
5.39
 on TM5 likely provides an equivalent 
electrostatic interaction to that of D107
3.32 
on TM3. The modest affinity values for 
compound 34 can be due to multiple reasons, one of them being the replacement of the 
functionally relevant nitrogen atom. Studies relating functional group contributions to 
drug-receptor interactions have shown that replacement of a critical charged nitrogen 
atom with a neutral carbon atom would result in an average decrease in the actual binding 
energy of 11.5 kcal/mol, suggesting that the charged nitrogen group shows a stronger 
interaction than the neutral group
231
 or even a carboxylate group (8.2 kcal/mol) and 
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providing a partial explanation for the modest observed affinity of 34. Furthermore, the 
proposed K191
5.39
 residue in the binding site possesses a flexible butylene side-chain 
linker providing more rotational degrees of freedom than D107
3.32
 or most other naturally 
occurring amino acids. Thus its interaction with a flexible carboxyl group substituent on 
34 is entropically disfavored, leading to decrease in binding affinity. 
 
5.4.2 Modeling interactions 
The histamine H1 receptor model was generated by using a β2-adrenergic receptor 
crystal structure (β2AR) as the homology modeling template and used to study the ligand-
receptor interactions involving acid substituted ligands.  The lead compound olopatadine 
and its non-nitrogenous analog 34 with precise consideration of stereoisomers, was 
sketched, energy-minimized and docked into the receptor binding site (see Experimental 
Methods). Visual inspection of docked poses, the GoldScore fitness function and 
information from site-directed mutagenesis studies were used to select a solution for each 
isomer. The GOLD
232
 program used for docking was able to place all the ligands in the 
previously predicted binding site (Figure 20). In case of olopatadine, both E and Z 
isomers show a similar binding mode in the binding site of H1 receptor. The protonated 
amine exhibits strong ionic interaction with the D107
3.32
, while the carboxylate group 
simultaneously showed extensive hydrogen bonding/ionic interaction with K191
5.39
. 
Binding site residues T194
5.42
 and Y108
3.33 
also form putative hydrogen bonds with the 
ligand carboxylate moiety. Both isomers of compound 34 bind in a similar fashion to 
olopatadine in the binding cavity with the exception of the ammonium ion interaction.  
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The HINT (Hydropathic INTeraction) scoring function was used to further 
support the receptor-ligand interactions predicted by the generated conformations of the 
ligand using the GOLD docking program. A HINT map was generated (details in 
experimental). Figure 21 illustrates the interactions with a HINT map, where the size of 
the displayed contour represents the extent of the interaction, and the color represents the 
type of interaction between the molecule 34 and the histamine binding site. The tricyclic 
ring system of compound 34 with the aliphatic linker fits in the predominantly 
hydrophobic pocket formed by Y108
3.33
, F190
3.38
, N198
5.46
, S111
3.36
 and Y458
7.43
. In 
addition, there is a region of favorable polar interactions surrounding the carboxylate 
substituent on the aromatic ring. This carboxylate group engages in favorable polar 
interaction with the residue K191
5.39
 and the neighboring residues Y108
3.33
 and T194
5.42
. 
The relatively large number of favorable polar and nonpolar interactions could be 
responsible for the significant observed affinity of compound 34 for the H1 receptor, 
despite the absence of a basic amine moiety. 
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a.      b. 
 
 
 
 
c.      d. 
 
 
 
Figure 20.  Docked poses of a. (E)-olopatadine, b. (Z)-olopatidine, c. (E)-34,  d. (Z)-34 
in H1 model.
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Figure 21. HINT interaction maps for compound 34 in H1 binding sites. Regions of 
favorable hydrophobic (green) and polar (magenta) interactions are shown as contours. 
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5.4.3 Chemistry 
Compound 28 was synthesized by G. Dewkar in our laboratory. Synthesis of 
compound 29 was carried out by standard Wittig reaction following the reported 
procedure
233
 (Scheme 13). The keto ester 87 obtained by the esterification of 4-
benzoylbenzoic acid (86) was reacted with phosphonium salt followed by the hydrolysis 
of the ester side-chain to give intermediate 89. This was further subjected to 
hydrogenation to give the final product 29. We were not able to synthesize compound 30 
(Figure 19). To begin, an attempt was made to synthesize 34 from dibenz[b,e]oxepin-2-
acetic acid (31) and the corresponding phosphonium salt prepared from 1-bromo-4-
methylpenatane and triphenylphosphine.
234
 A substituted ethyl o-toluate (90) was 
brominated with N-bromosuccinimide to provide 91. This intermediate was then 
condensed with ethyl 2-(4-hydroxyphenyl)acetate to give crude ester 92 which was 
hydrolyzed to the diacid 93. The diacid obtained was cyclized using polyphosphoric acid-
acetic acid mixture to obtain the product 31 (Scheme 14). Compound 32
235
 was obtained 
by the reduction of ketoacid 31 using Zn-AcOH (Scheme 15). Compound 33 was 
obtained by the hydrolysis of 94
236
, which was obtained by the Wittig reaction using the 
reported method
236
 (Scheme 16). Synthesis of compound 34 turned out to be much more 
challenging than expected.  As shown in Scheme 18, initial attempts of carrying out 
Wittig reaction on the keto acid 31
237
 and the corresponding ester 35
235
 failed. Further 
attempts to use the Wittig reaction with the oxazoline-protected compound failed due to 
the low yield of compound 36
236
 obtained utilizing 2-methyl-2-aminopropanol for the 
formation of oxazole.
238
 The in situ esterification of the keto acid 31 following the Wittig 
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reaction resulted in compound 37; however, the yield was drastically low. The synthetic 
Scheme utilized in the preparation of the desired (E,Z)-(11-[4-methylpentylidene]-6,11-
dihydrobenz[b,e]oxepin-2-acetic acid (34) is illustrated in Scheme 17. In this method, 
using 4-(2-hydroxyethyl)phenol instead of 4-hydroxyphenylacetate as the starting 
material, the alcohol substituted ketone (98)
239
 was obtained. The alcohol was protected 
using TBDMS
240
 to give 99 which was then subjected to the Wittig reaction using 
LHMDS as a base.
241
 The deprotection of the  compound 100 by TBAF
234
 followed by 
the TEMPO
242
 oxidation of the alcohol side-chain gave the final product 34.  
 
5.5 Synthetic Schemes 
O O
a b
N
N
c d
N
29
COOH CO2CH3 CO2CH3
COOH COOH
86 87 88
89
H
 
 
Scheme 13. (a) CH3OH, H2SO4; (b) Ph3P
+
-CH2(CH2)2-N(CH3)2Br
-
, THF, 1.6M n-BuLi; 
(c) 1N NaOH, CH3OH; (d) 10% Pd/C, HCl, CH3OH. 
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O
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CO2CH2CH3
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CO2CH2CH3
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c d
O
CO2CH2CH3
COOH
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CO2CH2CH3
90 91
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93
  
 
Scheme 14. (a)  NBS, benzoyl peroxide, CCl4; (b) K2CO3, KI,  
ethyl 2-(4-hydroxyphenyl)acetate, butanone; (c) aq NaOH, MeOH; (d) PPA, acetic acid. 
 
 
O
O
COOH
O
COOH
a
31 32  
Scheme 15. (a) Zn-AcOH. 
 
 
O
O COOH
a
O
CO2CH3
O
COOH
b
3331 94  
Scheme 16. (a) Ph3P
+
-CH3Br, n-BuLi, THF, p-TsOH, MeOH; (b) 10% NaOH, MeOH. 
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Scheme 17. (a) n-BuLi, THF, Ph3P
+
-CH2(CH2)3-CH(CH3)2 Br
-
; (b) abs ethanol, H2SO4;  (c) (i) 
Pyridine, SOCl2, CH2Cl2; (ii) NH2C(Me)2CH2OH , toluene; (iii) SOCl2, CH2Cl2; (d) p-TsOH, 
MeOH. 
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Scheme 18. (a) NBS, benzoyl peroxide, CCl4; (b) K2CO3, KI, 4-(2-hydroxyethyl)phenol 
butanone; (c) aq NaOH, MeOH; (d) acetyl chloride; (e) TFAA, BF3·OEt2, DCM, NaOH;(f) 
TBDMS, imidazole, DMF; (g) LHMDS, Ph3P
+
-CH2(CH2)3-CH(CH3)2 Br
-
, THF; (h) TBAF, THF; 
(i) NaClO2/TEMPO, NaOCl, MeCN. 
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    5.6 Conclusions 
The results obtained from the binding data and site-directed mutagenesis studies, 
supported by the homology modeling studies show that the compound (E,Z)-(11-[4-
methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid (34) is a lead for the 
design of selective H1 receptor antagonists. The moderate affinity (Ki = 250 nM) and high 
selectivity for the H1 vs. 5-HT2A receptor without a basic amine moiety in the ligand 
structure imply that the presence of an ionizable functional group (e.g. carboxylate) as a 
substituent can replace the basic nitrogen atom essential for the interaction with D3.32 in 
H1, and these results may be used in the further development of selective high-affinity H1 
ligands. Further, the general approach reported here can be used in the design of selective 
GPCR ligands. In continuation of our work, we also would attempt the synthesis of 
analog of compound 34 without the carboxylic acid substituent which could serve as a 
reference for our proposed hypothesis and also study the effect of Lys
5.39 
mutation on our 
tested ligands. 
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SUMMARY 
 
Based on our investigation of the binding site interactions of serotonin 5-HT2A 
and histamine H1 receptors with various ligands, we conclude that homology modeling 
and ligand docking studies, supported by binding affinity and site-directed mutagenesis 
data, can be used to understand the possible ligand-receptor interactions and to generate 
reasonable leads for the development of selective high-affinity ligands. Rational SAFIR 
studies around the early lead compound AMDA (9-aminomethyl-9,10-dihydroanthacene) 
led us to identify a molecule 3-(9,10-dihydroanthrace-9-yl)-N, N-dimethylpropan-1-
amine (9) with high affinity at both 5-HT2A (Ki = 22 nM) and H1 Ki = 0.5 nM) receptors.. 
However, the selectivity of this compound with respect to other 5-HT subtypes (5-HT2B, 
5-HT4-7) remains to be tested. Further, the molecular modeling indicates the presence of 
differing residues at position 3.33 within the binding site of 5-HT2A (V156
3.33
) and H1 
(Y108
3.33
) receptors and that this difference could play a role in determining the affinity 
and selectivity of ligands among these two receptors. SAFIR and modeling observations 
suggest that AMDA and its chain-lengthened analogs can serve as effective probes to 
investigate the 5-HT2A and H1receptor binding sites. 
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 The modeling investigations supported by the binding data show that ring-
annulated AMDA analogs with a methoxy substituent can be used as dimensional probes 
to explore the additional binding site interactions. Using this technique (7, 12-dihydro-3-
methoxytetraphen-12-yl)methanamine (26), a compound with high affinity and 
selectivity was identified (5-HT2A Ki = 21 nM; H1 Ki = 2640 nM). In addition, 
comparison of the binding site residues between 5-HT2A and H1 receptors and the 
reported sequence alignment studies among aminergic GPCRs show that Lys191
5.39
 is 
unique to the H1 receptor. Lys191
5.39
 is proposed to be able to form an ionic interaction 
with the carboxylate group of zwitterionic H1 antagonists (acrivastine and olopatadine) 
and the designed compound (E,Z)-(11-[4-methylpentylidene]-6,11-
dihydrobenz[b,e]oxepin-2-acetic acid (34). Our compound 34 could act as a lead for the 
development of non-nitrogenous H1-selective receptor ligands. However, the selectivity 
of this compound with respect to other 5-HT subtypes (5-HT2B/2C and 5-HT4-7) remains to 
be tested. 
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EXPERIMENTALS  
 
7.1 Chemistry 
Melting points were determined using a Thomas-Hoover melting point apparatus 
and are uncorrected. Nuclear magnetic resonance (
1
H NMR and 
13
C NMR) spectra were 
obtained with a Varian Gemini 300 MHz spectrometer and chemical shifts are reported in 
parts per million (δ), using tetramethylsilane (TMS) as an internal standard. Unless 
otherwise mentioned the spectral data corresponds to the free amine using chloroform as 
the internal standard. In case of the salt form the respective solvent is mentioned. The 
oxalate salts were prepared by dissolving the respective amine in anhydrous acetone; this 
mixture was then added to a solution of oxalic acid in anhydrous acetone. Hydrochloride 
salts were prepared similarly by addition of anhydrous HCl solution. Elemental analysis 
was performed by Atlantic Microlab Inc. (Norcross, GA), and determined values are 
within 0.4% of theory (except where indicated). Column chromatography was performed 
on silica gel, grade 62, 60-200 mesh, 150 Å (Sigma-Aldrich, MO). Routine thin-layer 
chromatography (TLC) was performed on silica gel GHFL (250 microns, 2.5 × 10 cm; 
Analtech Inc., Newark, DE). Unless otherwise mentioned, all the reagents and chemicals 
were obtained from Sigma-Aldrich, MO. 
 
(9,10-Dihydroanthracen-10-yl)-N-methylmethanamine hydrochloride (2).
174
 
BH3•THF complex (1.0 M in THF, 0.51 g, 6.0 mmol) was added in a dropwise manner to 
a stirred solution of 44 (0.3 g, 1.2 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  
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The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture 
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture 
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduced pressure. Water was added and the residue was extracted with ether (25 mL). 
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
mL). The organic layer was washed with water, brine and dried (MgSO4). Removal of 
solvent under reduced pressure afforded 2. It was then purified by medium pressure 
column chromatography, CH2Cl2/MeOH (9:1) (0.267g, 85%). HCl salt: mp 250 - 252 °C. 
1
H NMR (CDCl3): 2.44 (s, 3H), 3.07 (d, J = 7.2 Hz, 2H), 3.97 (d, J = 18.6 Hz, 1H), 4.16 
(d, J = 18.6 Hz, 1H), 4.54 (t, J = 8.1 Hz, 1H), 7.27 - 7.50 (m, 8H); 
13
C NMR (CDCl3):  
34.15, 35.01, 44.16, 52.91, 127.27, 127.92, 128.70, 129.08, 136.51, 137.57. Anal. Calcd 
for (C16H17N·HCl·0.25 H2O) C, 72.71; H, 7.05; N, 5.29 Found: C, 72.77; H, 6.98; N, 
5.30. 
 
(9,10-Dihydroanthracen-10-yl)-N,N-dimethylmethanamine hydrochloride (3).
174
 
BH3•THF complex (1.0 M in THF, 0.51 g, 6.0 mmol) was added in a dropwise manner to 
a stirred solution of 45 (0.3 g, 1.19 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture 
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture 
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduced pressure. Water was added and the residue was extracted with ether (25 mL). 
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
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mL). The organic layer was washed with water and brine, dried (MgSO4), and 
concentrated under reduced pressure to give 3. It was then purified by medium pressure 
column chromatography, CH2Cl2/MeOH (9:1) (0.248 g, 88%). HCl salt: mp 248 - 250 °C  
1
H NMR (DMSO): 2.72 (s, 6H), 3.36 (d, J = 7.5 Hz 2H), 3.96 (d, J = 18.3 Hz, 1H), 4.21 
(d, J = 18.3 Hz, 1H), 4.67 (t, J = 8.1 Hz, 1H); 
13
C NMR (DMSO):  35.21, 43.06, 44.20, 
60.73, 127.23, 128.01, 128.76, 129.08, 136.87, 138.05. Anal. Calcd for (C17H19N·HCl· 
0.25 H2O) C, 74.57; H, 7.36, N; 5.11 Found: C, 73.36; H, 7.42; N, 5.03. 
 
2-(9,10-Dihydroanthracen-9-yl)ethanamine oxalate (4).
174
 Anhydrous ammonia (15 
mL) was added to a well stirred solution of compound 48 (0.2 g, 0.9 mmol) dissolved in 
THF (5 mL) by using a cold finger under N2 at -78 °C. Sodium metal (0.05 g) was then 
added in pieces and the reaction was stirred for 25 min. The mixture was then allowed to 
cool to rt and poured into a large excess of NH4Cl solution, then extracted with EtOAc (3 
× 25 mL). The combined EtOAc extracts were washed with water, brine and dried 
(MgSO4). The solvent was removed under reduced pressure to yield the amine 4 that was 
purified by medium pressure column chromatography, CH2Cl2/MeOH (9:1) (0.1 g, 
50.0%). Oxalate salt: mp 193-195 °C. 
1
H NMR (CDCl3): 2.02 (q, J = 7.8 Hz, 2H), 2.7 (t, 
J = 7.8 Hz, 2H),  4.02 (t, J = 7.2 Hz, 1H), 3.89 (d, J = 18.3 Hz, 1H) 4.0 (d, J = 18.3 Hz, 
1H), 7.1 - 7.3 (m, 8H). 
13
C NMR (CDCl3):  34.8, 39.5, 40.1, 45.6, 126.3, 128.1, 136.4, 
140.6. Anal Calcd for (C16H17N·C2H2O4) C, 68.99; H, 6.11; N, 4.47 Found C, 68.72; H, 
6.26; N; 4.45. 
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2-(9,10-Dihydroanthracen-9-yl)-N-methylethanamine oxalate (5).  BH3•THF complex 
(1.0 M in THF, 0.33 g, 3.96 mmol) was added in a dropwise manner to a stirred solution 
of 54 (0.25 g, 0.99 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  The mixture was 
slowly warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool 
to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h) 
and allowed to cool to rt, and the solvent was removed under reduced pressure. Water 
was added and the residue was extracted with ether (25 mL). The aqueous portion was 
made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer 
was washed with water and brine, dried (MgSO4), and concentrated under reduced 
pressure to give the amine as an oil. The oil obtained was purified by medium pressure 
column chromatography, CH2Cl2/MeOH (9:1) to yield 17 as an oil (0.2 g, 85%). Oxalate 
salt: mp 202 - 205 °C. 
1
H NMR (CDCl3): 1.81 (q, J = 7.5 Hz, 2H), 2.38 (s, 3H), 2.56 (t, J 
= 7.5 Hz, 2H),  3.99 (d, J = 18.3 Hz, 1H), 4.09 (d, J = 18.3 Hz, 1H), 4.0 (t, J = 7.8 Hz, 
1H), 7.16 - 7.3 (m, 8H). 
13
C NMR (CDCl3):  35.3, 36.7, 37.4, 45.4, 50.2, 126.4, 128.1, 
136.4, 140.6. Anal Calcd for (C17H19N·C2H2O4·0.25 H2O) C, 68.76; H, 6.52; N, 4.22 
Found: C, 68.43, H, 6.35, N, 4.22. 
 
2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine oxalate (6).  To a stirred 
solution of triethylamine (0.18 g, 1.79 mmol) in absolute ethanol was added 
dimethylamine hydrochloride (0.14 g, 1.79 mmol), titanium isopropoxide (0.51 g, 1.79 
mmol) and compound 57 (0.2 g, 0.89 mmol). The reaction mixture was stirred at rt for 12 
h. Sodium borohydride (0.1 g, 2.68 mmol) was added to this mixture and stirring was 
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continued for a further 12 h. The reaction was quenched by pouring the mixture into 
aqueous ammonia (20 mL, 2 N) and the resulting precipitate was filtered and washed 
with CH2Cl2 (3 × 20 mL). The filtrate was collected and the mixture was extracted with 
CH2Cl2. The CH2Cl2 portion was dried (MgSO4) and concentrated under reduced pressure 
to obtain viscous yellow oil that was purified by medium pressure column 
chromatography, CH2Cl2/MeOH (9:1) to yield 6 (0.12 g, 55%). Oxalate salt: mp 184 - 
186 °C. 
1
H NMR (CDCl3): 1.83 (q, J = 7.5 Hz, 2H), 2.26 (s, 6H), 2.33 (m, 2H), 3.94 (d, J 
= 18.6 Hz, 1H), 4.14 (d, J = 18.6 Hz, 1H), 4.1 (t, J = 7.2 Hz, 1H), 7.1 - 7.3 (m, 8H). 
13
C 
NMR (CDCl3):  32.3, 40.4, 45.3, 52.2, 56.2, 126.8, 128.7, 138.4, 140.1. Anal Calcd for 
(C18H21N·C2H2O4·0.5 H2O) C, 68.55; H, 6.90; N, 3.99 Found: C, 68.76, H, 6.72, N, 3.96.  
 
3-(9,10-Dihydroanthracen-9-yl)propan-1-amine oxalate (7). BH3•THF complex (1.0 
M in THF, 0.17 g, 1.98 mmol) was added in a dropwise manner to a stirred solution of 63 
(0.1 g, 0.397 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  The mixture was slowly 
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt, 
and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h) and 
allowed to cool to rt, and the solvent was removed under reduced pressure. Water was 
added and the residue was extracted with ether (25 mL). The aqueous portion was made 
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was 
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to 
give 7 as an oil. It was then purified by medium pressure column chromatography, 
CH2Cl2/MeOH (9:1) (0.07 g, 75%). Oxalate salt: mp 210 - 212 °C. 
1
H NMR (DMSO): 
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1.49 (m, 2H), 1.56 (m, 2H), 2.69 (t, J = 7.2 Hz, 2H), 3.92 (t, J = 6.3 Hz, 1H), 3.89 (d, J = 
18.6 Hz, 1H), 4.0 (d, J = 18.6 Hz, 1H), 7.1 - 7.3 (m, 8H). 
13
C NMR (DMSO):  25.92, 
34.35, 35.02, 35.08, 46.48, 50.1, 128.3, 128.5, 136.7, 140.6. Anal Calcd for 
(C17H19N·C2H2O4) C, 69.71; H, 6.47; N, 4.28 Found: C, 69.47; H, 6.35; N, 4.22 
 
3-(9,10-Dihydroanthracen-9-yl)-N-methylpropan-1-amine oxalate (8). BH3•THF 
complex (1.0 M in THF, 0.161 g, 1.88 mmol) was added in a dropwise manner to a 
stirred solution of 64 (0.1 g, 0.376 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture 
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture 
was heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduced pressure. Water was added and the residue was extracted with ether (25 mL). 
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
mL). The organic layer was washed with water and brine, dried (MgSO4), and 
concentrated under reduced pressure to give 8 as an oil. It was then purified by medium 
pressure column chromatography, CH2Cl2/MeOH (9:1) (0.075 g, 80%). Oxalate salt: mp 
148 - 150 °C.
 1
H NMR (DMSO): 1.53 (m, 4H), 2.44 (s, 3H), 2.78 (t, J = 7.2 Hz, 2H), 3.92 
(t, J = 7.4 Hz, 1H), 4.02 (d, J = 18.6 Hz, 1H), 3.8 (d, J = 18.6 Hz, 1H), 7.1-7.3 (m, 8H). 
13
C NMR (DMSO):  24.3, 33.1, 34.25, 35.01, 46.37, 48.66, 128.38, 128.55, 136.72, 
140.5. Anal Calcd for (C18H21N·C2H2O4) C, 70.36; H, 6.79; N, 4.10 Found: C, 70.44; H, 
6.87; N, 4.11. 
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3-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylpropan-1-amine oxalate (9).  BH3•THF 
complex (1.0 M in THF, 0.15 g, 1.75 mmol) was added in a dropwise manner to a stirred 
solution of 65 (0.1 g, 0.35 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  The 
mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture was 
allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture was 
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduced pressure. Water was added and the residue was extracted with ether (25 mL). 
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
mL). The organic layer was washed with water and brine, dried (MgSO4), and 
concentrated under reduced pressure to give 9 as an oil. It was then purified by medium 
pressure column chromatography, CH2Cl2/MeOH (9:1) (0.078g, 85%). Oxalate salt: mp 
 
1
H NMR (CD3OD): 1.63 (s, 4H), 2.71 (s, 6H), 2.94 (s, 2H), 3.87 (d, J = 18.6 Hz, 1H), 
3.89 (t, J = 7.2 Hz, 1H), 4.1 (d, J = 18.6 Hz, 2H), 7.14 -7.28 (m, 8H). 
13
C NMR 
(CD3OD):  22.5, 33.8, 34.7, 42.1, 57.5.2,  126.2, 127.8, 136.3, 139.9. Anal Calcd for 
(C19H23N·C2H2O4) C, 70.96; H, 7.09; N, 3.94 Found: C, 70.77; H, 7.05; N, 4.04.     
  
N-Methyl-2,2-diphenylethanamine oxalate (11). Sodium cyanoborohydride (0.5 g, 8 
mmol) was added to a stirred solution of 2,2-diphenylethanamine 66 (1 g, 5.0 mmol) and 
37% aqueous formaldehyde (2.0 mL, 25 mmol) in acetonitrile (15 mL). A vigorous 
exothermic reaction followed and a dark residue was separated. The reaction mixture was 
stirred for 15 min, and then glacial acetic acid was added dropwise until the solution 
tested neutral on wet pH paper. Stirring was continued for an additional 45 min, glacial 
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acetic acid being added occasionally to maintain the pH near neutrality. The solvent was 
evaporated at reduced pressure, and 2 N KOH (20 mL) was added to the residue. The 
resulting mixture was extracted with ether (3 × 20 mL). The combined ether extracts 
were washed with 0.5 N KOH (20 mL) and then extracted with 1N HCl (3 × 10 mL). The 
acid extracts were combined and neutralized with solid KOH and then extracted with 
ether (3 × 20 mL). The combined ether extracts were dried (MgSO4) and evaporated in 
vacuum to provide yellow oil. The resulting yellow oil was purified using medium 
pressure chromatography, CH2Cl2/MeOH (9:1) to yield 11 (0.45 g, 40%). Oxalate salt: 
mp 150 - 152 °C.
 1
H NMR (CDCl3): 2.36 (s, 3H), 3.01 (d, J = 8.1 Hz, 2H), 4.28 (t, J = 8.1 
Hz, 1H), 7.2 - 7.4 (m, 10H). 
13
C NMR (CDCl3):  40.3, 51.8, 62.3, 123.0, 123.8, 124.2, 
141.5. Anal Calcd for (C15H17N·C2H2O4) C, 68.29; H, 6.67; N, 4.50 Found: C, 67.89; H, 
6.35; N, 4.64.     
 
3,3-Diphenylpropan-1-amine hydrochloride (13). Commercially available 3,3-
diphenylpropan-1-amine (0.1 g) was dissolved in anhydrous acetone (4 mL). Anhydrous 
HCl (1.2 mL) was added to this solution and refrigerated. The solution was filtered and 
dried under vacuum to yield 13 (0.08 g, 90%). HCl salt: mp 216 - 218 °C. (lit
246
 218 - 
219 °C).  
1
H NMR (CDCl3): 2.36 (q, J = 7.8 Hz, 2H), 2.63 (t, J = 8.4 Hz, 2H), 4.13 (t, J = 
7.8 Hz, 1H), 7.17 - 7.30 (m, 10H). 
13
C NMR (CDCl3):  33.1, 38.37, 48.0, 127.0, 128.2, 
129.2, 144.6. Anal Calcd for (C15H17N·HCl) C, 72.71; H, 7.32; N, 5.65 Found: C, 72.75; 
H, 7.36; N, 5.60.     
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N,N-Dimethyl-3,3-diphenylpropan-1-amine oxalate (15). To a solution of 
triethylamine (0.96 g, 9.5 mmol) in absolute ethanol (10 mL) was added dimethylamine 
hydrochloride (0.77 g, 9.5 mmol), titanium isopropoxide (2.69 g, 9.5 mmol), and 
compound 68 (1 g, 4.7 mmol). Reaction mixture was stirred at rt for 12 h. To this mixture 
NaBH4 (0.266 g, 7.05 mmol) was added and stirring was continued for 12 h. The reaction 
was quenched by pouring the mixture into ammonia (30 mL, 2 N) solution. The resulting 
precipitate was filtered and washed with CH2Cl2 (3 × 20 mL). The filtrate was collected 
and the mixture was extracted. The CH2Cl2 portion was dried (MgSO4) and concentrated 
under reduced pressure to give viscous yellow oil. The resulting yellow oil was purified 
using medium pressure chromatography, CH2Cl2/MeOH (9:1) to obtain 15 (0.25 g, 22%). 
Oxalate salt: mp 150 - 152 °C. 
1
H NMR (CDCl3): 2.52 (m, 2H), 2.85 (s, 6H), 3.0 (m, 2H), 
4.2 (t, J = 7.4 Hz, 1H), 7.2 - 7.4 (m, 10H). 
13
C NMR (CDCl3):  32.2, 45.8, 50.6, 58.3, 
126.3, 128.2, 129.1, 143.1. Anal. Calcd for (C17H21N·C2H2O4·0.25 H2O) C, 67.43; H, 
7.14; N, 4.13 Found: C, 67.73; H, 6.97; N, 4.11. 
 
4,4-Diphenylbutan-1-amine hydrochloride (16).
247
 A 1.0 M solution of BH3•THF 
complex (0.386 g, 4.5 mmol) was added at 0
 
°C to a well stirred solution of compound 71 
(0.2 g, 0.9 mmol) in anhydrous THF (5 mL). The solution was brought to rt and then 
heated to reflux (8 h) and cooled. 6.0 M HCl (2 mL) solution was added cautiously to the 
reaction mixture, and continued to reflux (1 h). The reaction mixture was cooled and the 
solvent was removed under reduced pressure resulting in a white residue. Water (10 mL) 
was added to this residue followed by extraction with EtOAc (2 × 15 mL). The aqueous 
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phase was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The 
combined CH2Cl2 extracts were washed with water, brine and dried (MgSO4). The 
solvent was removed under reduced pressure to give the amine 16 (0.17 g, 85%) as oil. 
HCl salt: mp 198 - 200 °C. 
1
H NMR (CDCl3): 1.45 (m, 2H), 2.1 (m, 2H), 2.7 (t, J = 7.8 
Hz, 2H),  4.0 (t, J = 7.8 Hz, 1H ), 7.1 - 7.3(m, 10H). 
13
C NMR (CDCl3):  31.2, 36.2, 
42.5, 53.5, 126.5, 128.3, 129.3, 143.0. Anal Calcd for (C16H19N·HCl) C, 73.40; H, 7.70; 
N, 5.35 Found: C, 72.30; H, 7.51; N, 5.24. 
 
N-Methyl-4,4-diphenylbutan-1-amine oxalate (17). BH3•THF complex (1.0 M in THF, 
0.335 g, 3.9 mmol) was added in a dropwise manner to a stirred solution of 75 (0.2 g, 
0.78 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  The mixture was slowly 
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt, 
and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h) and 
allowed to cool to rt, and the solvent was removed under reduced pressure. Water was 
added and the residue was extracted with ether (25 mL). The aqueous portion was made 
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was 
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to 
give 17 as an oil. It was then purified by medium pressure column chromatography, 
CH2Cl2/MeOH (9:1) (0.148 g, 80%). Oxalate salt: mp 163 - 165 °C. (lit
247
 mp 162 - 164
 
o
C. 
1
H NMR (CDCl3): 1.49 (q, J = 7.8 Hz, 2H), 2.1 (q, J = 8.1 Hz, 2H ), 2.4 (s, 3H), 2.61 
(t, J = 7.5 Hz, 2H)  3.9 (t, J = 7.5 Hz, 1H), 7.1 - 7.31 (m, 10H). 
13
C NMR (CDCl3):  
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27.2, 36.2, 36.8, 50.8, 51.1, 126.2, 128.2, 129.3, 143.0. Anal Calcd for (C17H21N· 
C2H2O4) C, 69.28; H, 7.03; N, 4.25; Found: C, 69.02; H, 7.11; N, 4.26. 
 
N,N-Dimethyl-4,4-diphenylbutan-1-amine oxalate (18).
247
 BH3•THF complex (1.0 M 
in THF, 0.317 g, 3.7 mmol) was added in a dropwise manner to a stirred solution of 76 
(0.2 g, 0.74 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  The mixture was slowly 
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt, 
and HCl (6.0 M, 3 mL) was added with caution. The mixture was heated at reflux (1 h) 
and allowed to cool to rt, and the solvent was removed under reduce pressure. Water was 
added and the residue was extracted with ether (25 mL). The aqueous portion was made 
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was 
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to 
give 18 as an oil. It was then purified by medium pressure column chromatography, 
CH2Cl2/MeOH (9:1) (0.155 g, 83%). Oxalate salt. mp 149 - 151 °C. (lit
247
 mp 152 – 154 
°C). 
1
H NMR (CDCl3): 1.54 (q, J = 7.5 Hz 2H), 2.1 (q, J = 7.8 Hz, 2H), 2.3 (s, 6H), 2.49 
(t, J = 7.8 Hz, 2H), 3.9 (t, J = 7.5 Hz, 1H), 7.1-7.3 (m, 10H). 
13
C NMR (CDCl3):  24.7, 
36.3, 44.8, 51.6, 59.3, 126.3, 128.2, 129.1, 143.1. Anal Calcd for (C18H23N·C2H2O4·0.25 
H2O) C, 69.04; H, 7.38; N, 4.02 Found: C, 69.32, H, 7.20, N, 4.12. 
 
N-((9,10-Dihydroanthracen-10-yl)methyl)-2-phenylethanamine hydrochloride (20). 
BH3•THF complex (1.0 M in THF, 1.0 g 12.2 mmol) was added in a dropwise manner to 
a stirred solution of 77 (0.8 g, 2.44 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  
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The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture 
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture 
was heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduce pressure. Water was added and the residue was extracted with ether (25 mL). The 
aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
mL). The combined CH2Cl2 extracts were washed with water and brine, dried (MgSO4), 
and concentrated under reduced pressure to give the amine as an oil. It was then purified 
by medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 20 (0.57 g, 
75%). HCl salt: mp 188 – 190 °C. 1H NMR (CDCl3): 2.4 (m, 2H), 2.93 (m, 2H), 3.07 (d, 
J = 8.1 Hz, 2H), 3.95 (d J = 18.6 Hz, 1H), 4.09 (d, J = 18.6 Hz, 1H), 4.5 (t, J = 7.8 Hz, 
1H), 7.1 - 7.4 (m, 13H). 
13
C NMR (CDCl3):  36.6, 40.3, 48.7, 50.5, 57.5, 126.2, 126.8, 
127.7, 128.7, 138.2, 138.6, 139.7. Anal Calcd for (C23H23N·HCl·0.25 H2O) C, 77.94; H, 
6.96; N, 3.95; Found: C, 78.19; H, 6.87; N, 4.0. 
 
N-((9,10-Dihydroanthracen-10-yl)methyl)-3-phenylpropan-1-amine oxalate (21). 
BH3•THF complex (1.0 M in THF, 0.25 g 2.92 mmol) was added in a dropwise manner 
to a stirred solution of 78 (0.2 g, 0.58 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.  
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture 
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture 
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under 
reduced pressure. Water was added and the residue was extracted with ether (25 mL). 
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 
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mL). The combined CH2Cl2 extracts were washed with water and brine, dried (MgSO4), 
and concentrated under reduced pressure to give amine as an oil. It was then purified by 
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 57 (0.15 g, 
80%). Oxalate salt: mp 208 - 210 °C. 
1
H NMR (CDCl3): 1.94 (m, 2H), 2.63 (t, J = 7.5Hz, 
2H), 2.9 (m, 2H), 3.1 (d, J = 8.1 Hz, 2H), 3.97 (d, J = 18.6 Hz, 4.1 (d, J = 18.6 Hz, 2H), 
4.3 (t, J =  8.1 Hz, 2H), 7.1 - 7.4 (m, 13H). 
13
C NMR (CDCl3):  29.6, 30.3, 35.7, 40.5, 
49.5, 49.2, 58.6, 126.1, 126.8, 128.1, 128.7, 128.9, 138.2, 138.6, 139.7. Anal Calcd  
(C24H25N·HCl·0.25 H2O) C, 73.99; H, 6.59; N, 3.31 Found: C, 74.11; H, 6.49; N, 3.33. 
 
N-((9,10-Dihydroanthracen-9-yl)methyl)-4-phenylbutan-1-amine hydrochloride 
(22). BH3•THF complex (1.0 M in THF, 0.6 g 7.0 mmol) was added in a dropwise 
manner to a stirred solution of 79 (0.5 g, 1.4 mmol) in anhydrous THF (4 mL) under N2 
at 0 °C.  The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction 
mixture was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The 
mixture heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed 
under reduced pressure. Water was added and the residue was extracted with ether (25 
mL). The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 
× 25 mL). The combined CH2Cl2 extracts were washed with water and brine, dried 
(MgSO4), and concentrated under reduced pressure to give amine as an oil. It was then 
purified by medium pressure column chromatography, CH2Cl2/MeOH, (9:1) to yield 22 
(0.38 g, 80%). HCl salt: mp 198 - 200 °C. 
1
H NMR (CDCl3): 1.63 (m, 4H), 2.61 (m, 2H), 
2.9 (m, 2H), 3.1 (m, 2H), 3.97 (d, J = 18.2 Hz, 1H), 4.1 (d, J = 18.2 Hz, 1H), 4.4 (t, J = 
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8.1 Hz, 2H), 7.1 - 7.4 (m, 13H). 
13
C NMR (CDCl3):  28.6, 30.1, 35.7, 40.4, 49.5, 50.2, 
58.6, 126.0, 126.8, 128.1, 128.6, 128.7, 138.2, 138.6, 139.7. Anal Calcd for 
(C25H27N·HCl·0.25 H2O) C, 77.59; H, 7.55; N, 3.61 Found: C, 77.75; H, 7.56; N, 3.62. 
 
[(9,10-Dihydro-9-anthryl)methyl]trimethyl ammonium iodide (23).
248
  To a solution 
of compound 3 (0.2 g, 0.79 mmol) in anhydrous CH2Cl2 (4 mL) was added iodomethane 
(0.168 g, 3.95 mmol). The reaction mixture was stirred at rt for 3 h. Ethyl acetate (3 mL) 
was then added to the mixture in a dropwise manner resulting in the formation of white 
turbid solution. The reaction mixture was then cooled, refrigerated to obtain a white solid. 
The solid was then purified by medium pressure column chromatography, CH2Cl2/MeOH 
(10:1) to obtain 23 (0.22 g, 70%). mp 148 - 150 °C. 
1
H NMR (DMSO): 3.04 (s, 9H), 3.54 
(d, J = 7.2 Hz, 2H), 4.79 (t, J = 7.2 Hz), 3.97 (d, J = 18.3 Hz, 1H), 4.01 (d, J = 18.3 Hz, 
1H), 4.28 (m, 8H). 
13
C NMR (DMSO):  35.5, 42.6, 53.5, 68.5, 127.2, 127.9, 138.1, 
138.6. Anal Calcd for (C18H22N) C, 56.33; H, 5.90; N, 3.64 Found: C, 56.15, H, 5.87; N, 
3.63. 
 
(7,12-Dihydrotetraphen-12-yl)methanamine fumarate (24). Methanesulfonic acid (20 
ml) was added to compound 84 (0.5 g, 1.8 mmol) and was stirred for 1 h. The reaction 
mixture was allowed to cool and then added to a cold solution of 10% NaOH until basic. 
The mixture was then extracted with CH2Cl2 (75 ml). Combined extracts were washed 
with brine, water, and dried (MgSO4). Evaporation of solvent gave a mixture of 24 
(major) and 25 (minor) as the products. Further purification was carried out by medium 
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pressure column chromatography, CH2Cl2/MeOH (10:1) to obtain product as a light 
brown oil (0.040 g, 20%). However, the final mixture obtained was mixture of 24 and 25. 
Fumarate salt: mp 148 – 150 °C. 1H NMR (CDCl3): 3.1 (m, 1H), 3.18 (m, 1H), 4.1 (d, J = 
18.6 Hz, 2H), 4.21 (d, J = 18.6 Hz, 2H), 4.6 (t, J = 7.2 Hz), 7.2 - 8.1 (m, 9H); 
13
C NMR 
(CDCl3):  37.2, 44.1, 47.84, 105.3, 117.8, 125.2, 134.7, 157.1. Anal.Calcd 
(C19H17NO·C4H6O4) C, 73.58; H, 5.63; N, 3.73. 
 
(7,12-Dihydro-3-methoxytetraphen-12-yl)methanamine fumarate (26).  
Methanesulfonic acid (20 ml) was added to the compound 85 (0.5 g, 1.62 mmol) and was 
stirred for 1 h. The reaction mixture was allowed to cool and then added to a cold 
solution of 10% NaOH until basic, and extracted with CH2Cl2 (75 ml). Combined 
extracts were washed with brine, water, and dried (MgSO4). Evaporation of solvent gave 
a mixture of 26 (major) and 27 (minor) as the products. Further purification was carried 
out by medium pressure column chromatography, CH2Cl2/MeOH (10:1). Only the major 
product was separated (0.040 g, 26%) as light brown oil. Fumarate salt: mp 132 – 135 °C. 
1
H NMR (CDCl3): 2.97 (m, 1H,) 3.05 (m, 1H) 3.94 (s, 3H), 3.98 (d, J = 18.6 Hz, 2H), 
4.24 (d, J = 18.6 Hz, 2H), 4.75 (t, J = 7.2 Hz), 7.17 - 8.1 (m, 9H); 
13
C NMR (CDCl3):  
35.99, 45.9, 47.84, 55.53, 106.3, 118.8, 125.6, 134.7, 156.4. Anal. Calcd for 
(C20H19NO·C4H6O4·0.5 H2O) C, 68.0; H, 5.95; N, 3.30 Found: C, 67.49, H, 5.54; N, 3.52. 
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4-(4-(Dimethylamino)-1-phenylbutyl)benzoic acid (29).
249
 Compound 89 (0.4 g, 1.35 
mmol) was dissolved in a solution of MeOH:CH2Cl2 (5:1) (10 mL). Pd/C (0.2 g 10%) 
was added and the mixture was stirred overnight under a hydrogen atmosphere. The 
reaction mixture was filtered with celite and the filtrate was concentrated under reduced 
pressure. The residue was triturated with diethyl ether and the precipitate was collected 
by filtration to obtain product. Recrystallization from ethanol and petroleum ether 
afforded 29 as a faint yellow powder (0.38 g, 95%). mp 233 – 235 °C. 1H NMR (DMSO): 
1.56 (m, 2H), 2.13 (m, 2H), 2.6 (s, 6H), 3.05 (t, J = 7.2 Hz, 2H), 4.07 (t, J = 7.2 Hz, 1H), 
7.22 -7.88 (m, 9H); 
13
C NMR (DMSO):  23.07, 32.11, 42.6, 50.9, 56.8, 127.0, 128.4, 
129.6, 144.7, 150.4, 167.89. Anal Cacld for (C19H23NO2·HCl·H2O) C, 64.85; H, 7.44; N, 
3.98 Found: C, 64.18; H, 7.08; N, 3.70. (ESIMS (-ve) calcd for C19H23NO2 [(M-H)
-
] 
298.17 Found 298.22. 
 
6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid (31).
237
 A mixture of compound 
93 (1.43 g, 5.0 mmol), polyphosphoric acid (9.0 g) and 7 mL of acetic acid was stirred at 
80 °C for 6 h. After hydrolyzing the mixture with 75 mL of water, 10% NaOH was added 
until basic and the aqueous mixture was extracted with ether. Acidification of the ice-
cooled aqueous phase with concentrated HCl provided a solid which was purified by 
medium pressure column chromatography, CH2Cl2/MeOH (10:1) to obtain 31 (0.53 g, 
40%). mp 134 - 136 °C. (lit
237
 135 - 136 °C).  
1
H NMR(CDCl3): 3.70 (s, 2H), 5.21 (s, 
2H), 7.0 - 8.1 (m, 7H); 
13
C NMR(CDCl3):  39.48, 73.19, 120.74, 124.69, 126.65, 
127.39, 128.86, 129.07, 132.17, 132.38, 135.04, 135.98, 139.96, 160.16, 176.77, 190.45; 
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Anal Calcd for (C16H12O4) C, 71.63; H, 4.50; O, 23.85 Found: C, 71.18; H, 4.46; O, 
23.58. 
 
6,11-Dihydrodibenz[b,e]oxepin-2-acetic acid (32).
237
 To a stirred solution of compound 
31 (0.1 g, 0.37 mmol) in acetic acid (3 mL) was added Zn powder (0.3 g, 4.46 mmol) and 
the mixture was refluxed for 2 h, cooled and filtered. The filtrate was concentrated in 
vacuum to obtain syrupy residue. After addition of water to the syrupy residue, the 
mixture was extracted with CHCl3 (3 × 25 mL) which was washed with water, dried 
(MgSO4) and concentrated. The residue obtained was purified by crystallization from 
benzene to yield product 32 (0.055 g 60%). mp 156 - 158 °C. (lit
237
 155 – 157 °C).  1H 
NMR(CDCl3): 3.57 (s, 2H), 4.24 (s, 2H), 5.32 (s, 2H), 6.8 - 7.3 (m, 7H); 
13
C 
NMR(CDCl3):  38.47, 39.69, 70.27, 119.68, 125.27, 125.40, 125.64, 126.65, 127.58,  
127.65, 127.81, 128.20, 128.28, 128.46, 128.63, 131.32, 135.26, 139.32, 155.74, 179.21. 
Anal. (C16H14O3·0.75 H2O) C, 71.76; H, 5.83 Found: C, 71.87; H, 5.45. 
 
11-Methylene-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid (33). To a solution of 
compound 94 (0.1 g) in absolute ethanol was added 10% NaOH and refluxed for 3 h.  
The reaction mixture was then cooled and concentrated. HCl was added to the mixture 
and extracted with CH2Cl2 (3 × 25 mL). The solvent was concentrated in vacuum to 
obtain the product 33 as a pale white solid (0.085 g, 90%). mp 162 - 164 °C. 
1
H 
NMR(CDCl3): 3.62 ( s, 2H), 5.2 ( s, 2H), 5.32 (s, 1H), 5.74 (s, 1H), 6.86 (d, J = 8.4 Hz 
1H), 7.14 (d, J = 8.4 Hz 1H), 7.33 - 7.38 (m, 4H); 
13
C NMR(CDCl3):  39.72, 70.39, 
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117.20, 119.62, 125.41, 126.48, 127.11, 127.71, 128.73, 130.14, 130.65, 133.69, 143.36, 
147.53, 154.85, 177.62. Anal Calcd for (C17H14O3·H2O) C, 69.61; H, 5.84 Found: C, 
69.87; H 5.84. ESIMS (-ve) m/z calcd for C17H13O3 [(M-H)
-
] 265.09, Found 264.963.  
 
(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid (34). In a 
two-necked round-bottomed flask equipped with a stirrer was added compound 101 (0.1 
g, 0.31 mmol), acetonitrile (4 mL), TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy free 
radical (0.0339 g, 0.0217 mmol), sodium chlorite (0.056 g, 0.62 mmol) and 0.67 M 
sodium phosphate buffer (1.2 mL) and kept for stirring. A dilute bleach solution (0.15 
mL) was added to this mixture in a dropwise manner. The resultant mixture was heated to 
35 °C and stirring was continued until reaction was completed (6 h). After cooling the 
reaction mixture to 25 
°
C, water (5 mL) was added and the pH was adjusted to 8.0 by 
addition of 2N NaOH. The reaction mixture was than poured into ice-cold sodium sulfite 
solution (30 mL) maintained below 20 
°
C. After stirring for 30 min at rt, methyl t-butyl 
ether (MTBE) was added and the rapidly stirred mixture was acidified with 2 N HCl to 
pH 3-4. The organic layer was separated and washed with water, brine, dried (MgSO4) 
and concentrated to give 34 as a mixture of geometrical isomers (E/Z = 3/7) as an oil 
(0.041 g, 40%). 
1
H NMR(CDCl3): 0.91 (d, J = 6.6 Hz, 6H), 1.40 (q, J = 7.2 Hz, 2H), 1.62 
(m, 1H), 2.42 (q, J = 7.2 Hz, 2H), 3.58 (s, 2H), 5.71 (t, J = 7.8 Hz, 1H), 6.1 (t, J = 7.8 Hz, 
1H), 6.8 - 7.3 (m, 7H); 
13
C NMR(CDCl3):  22.07, 27.06, 27.29, 38.63, 39.68, 69.95, 
119.31, 123.60, 124.43, 125.86, 126.92, 127.04, 128.68, 129.42, 131.91, 133.21, 133.54, 
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137.84, 145.44, 154.28, 177.43; Anal Calcd for (C22H24O3) C, 78.54, H, 7.19 Found: C, 
78.1; H, 9.7. ESIMS (-ve) calcd for C22H24O3 [(M-H)
-
] 335.16, found 335.23. 
 
6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid ethyl ester (35).
237
 A mixture of 
compound 31 (1.0 g), absolute ethanol (10 mL) and concentrated sulfuric acid (2 mL) 
was refluxed for 6 h. The solution was then cooled and concentrated. The crude product 
obtained was dissolved in ether, washed with 5% NaOH solution, water and dried 
(MgSO4) to yield solid. The solid was purified by medium pressure column 
chromatography, CH2Cl2/MeOH (9:1) to obtain 35 (0.99 g, 90%). mp 90 - 92 °C. (lit
237
 
89 – 91 °C).  1H NMR(CDCl3): 1.26 (t, J = 7.2 Hz, 3H), 3.60 (s, 2H), 4.14 (q, J = 7.2 Hz, 
2H), 5.17 (s, 2H), 7.0 - 7.57 (m, 7H); 
13
C NMR(CDCl3):  14.44, 40.48, 61.22, 73.84, 
121.26, 125.33, 128.04, 128.17, 129.49, 129.70, 132.65, 133.0, 135.77, 136.60, 140.69, 
160.67, 171.69, 191.11. 
 
11-Oxo-2-[4,4-dimethyl-2-oxazolin-2-yl)methyl]-6,11-dihydrobenz[b,e]oxepin (36). 
To a solution of compound 31 (0.3 g, 1.18 mmol) in CH2Cl2 (8 mL) and pyridine (1 mL) 
was added SOCl2 (0.214 g, 1.8 mmol) at 0 °C, and the mixture was stirred at rt for 2 h. 
The reaction mixture was concentrated and the residue obtained was treated with 2-
amino-2-methylpropanol (0.77 g, 8.73 mmol) in toluene (5 mL) at 50 °C for 3 h. The 
reaction mixture was then diluted with EtOAc, washed with brine, dried (MgSO4) and 
concentrated. The residue obtained was recrystallized from toluene to obtain 
carboxamide (0.2 g, 0.58 mmol) which was suspended in CH2Cl2 (8 mL). To this 
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suspension was added SOCl2 (0.082 g 0.69 mmol) at 0 °C, and the mixture was stirred at 
rt for 1 h. The reaction mixture was diluted with CH2Cl2, washed with brine, dried 
(MgSO4) and concentrated to obtain product which was purified by medium pressure 
column chromatography, hexane/EtOAc (2:1) to yield 36 as an oil (0.05g, <5%).  
1
H 
NMR(CDCl3): 1.31 (s, 6H), 3.63 (s, 2H), 3.95 (s, 2H), 5,21 (s, 2H), 7.0 - 8.1 (m, 7H); 
13
C 
NMR(CDCl3):  27.94, 33.51, 66.72, 73.17, 78.94, 120.67, 124.72, 127.34, 128.63, 
128.81, 129.04, 131.55, 132.29, 135.09, 135.30, 140.06, 157.81, 159.91, 163.57, 175.87, 
186.23, 190.42. 
 
(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid methyl 
ester (37). To a suspension of 4-(methylpentane) triphenylphosphonium bromide (0.79 g, 
1.86 mmol) in anhydrous THF (5 mL) under N2 atmosphere at 0 °C was added a 2.5 M 
solution of n-BuLi (0.35 g, 5.58 mmol) in hexane. The solution was stirred under the 
same condition for 1 h. A solution of 31 (0.1 g, 0.37 mmol) in THF (2 mL) was added 
and the resulting mixture was stirred at rt for 2 h. After being concentrated, the reaction 
mixture was diluted with water, washed with ether, and than neutralized. The resulting 
solution was concentrated and the residue obtained was dissolved in methanol (10 mL) 
containing p-TsOH·H2O (0.1 g, 0.55 mmol) and refluxed for 2 h. The reaction mixture 
was concentrated, diluted with EtOAc (50 mL) and washed with water. The organic layer 
was dried (MgSO4) and concentrated in vacuum to obtain product which was purified by 
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 37 as an oil. The 
product obtained was in very low yield (<5%). 1H NMR(CDCl3): 0.91 (d, 6H), 1.28 (m, 
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2H), 1.65 (m, 2H), 2.44 (m, 1H), 3.5 (s, 2H), 3.71 (s, 3H), 5.17 (bs, 2H), 5.67 (t, J = 7.5 
Hz, 1H), 6.0 (t, J = 7.5 Hz 1H), 6.7 - 7.3 (m, 7H). 
 
9,10-Dihydroanthracene-10-carboxylic acid (43). To a well-stirred suspension of 9,10-
dihydroanthracene 42 (4.5 g, 25.0 mmol) in anhydrous ether (40 mL) was added n-BuLi 
(1.6 g, 25 mmol) under N2 at 0 °C. The resulting dark solution was stirred at rt for 2 h and 
then heated to reflux for 45 min. The reaction mixture was then poured over an excess of 
dry ice slurry, extracted with water and acidified with HCl. The precipitate obtained was 
collected by vacuum filtration and recrystallized from 2-propanol to yield 43 (2.5 g, 45%) 
as white solid. mp 200 - 202 °C. (lit
243
 200 - 207 °C).
 1
H NMR (CDCl3): 3.9 (s, 1H), 4.2 
(s, 1H), 4.9 (s, 1H), 7.26 (s, 4H), 7.42 (s, 4H).  
 
2-(9,10-Dihydroanthracen-10-yl)-N-methylacetamide (44). Thionyl chloride (2.65 g, 
22.2 mmol) was added under N2 to a stirred solution of compound 43 (l.0 g, 4.45 mmol) 
in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool 
and the excess benzene and thionyl chloride were removed under reduced pressure to 
provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an 
ice bath (0 °C). Methylamine/THF (2 M, 0.276 g, 8.9 mmol) solution was added 
dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was 
removed under reduced pressure to give a white solid. Water (20 mL) was added, and the 
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed 
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave 
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crude amide as viscous oil. The resulting amide was purified using medium pressure 
chromatography, petroleum ether/EtOAc (6:4) to yield 44 (0.756 g, 72%). 
1
H NMR 
(CDCl3): 2.65 (s, 3H), 3.95 (d, J = 18.3 Hz, 1H), 4.12 (d, J = 18.3 Hz, 1H), 4.85 (s, 1H), 
7.25 - 7.46 (m, 8H).  
 
2-(9,10-Dihydroanthracen-10-yl)-N,N-dimethylacetamide (45).
243
 Thionyl chloride 
(2.65 g, 22.3 mmol) was added under N2 to a stirred solution of compound 43 (1.0 g, 4.45 
mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to 
cool and the excess benzene and thionyl chloride were removed under reduced pressure 
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in 
an ice bath (0 °C). Dimethylmethylamine/THF (2 M, 0.4 g, 8.9 mmol) solution was 
added dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The 
solvent was removed under reduced pressure to give a white solid. Water (20 mL) was 
added, and the suspension was extracted with EtOAc (3 × 25 mL). The combined extracts 
were washed with water, brine and dried (MgSO4). Removal of solvent under reduced 
pressure gave crude amide as oil. The resulting oil was purified using medium pressure 
chromatography, petroleum ether/EtOAc (6:4) to yield 45 (0.83 g, 75%).
 1
H NMR 
(CDCl3): 3.06 (s, 6H), 4.0 (d, J = 18.6 Hz, 1H), 4.51 (d, J = 18.6 Hz, 1H), 5.34 (s, 1H), 
7.20 - 7.37 (m, 8H).  
 
9-(2-Nitrovinyl)anthracene (47).
191
 Ammonium acetate (0.56 g, 7.27 mmol) was added 
to a well stirred solution of nitromethane (30 mL) and 9-anthraldehyde 46 (1.5 g, 7.27 
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mmol). The reaction mixture was heated to reflux for 40 min. The red solution obtained 
was evaporated under reduced pressure to remove nitromethane. The oily red solid was 
then dissolved in EtOAc and washed with water and brine. The EtOAc was removed 
under reduced pressure to yield nitrostyrene product 47 (95%). 
1
H NMR (CDCl3): 7.5 - 
7.6 (m, 4H), 7.68 (s, 1H), 7.7 - 7.8 (m, 4H), 7.78 (d, J = 14 Hz, 1H) 7.9 (d, J = 14 Hz, 
1H). 
 
2-(Anthracen-9-yl)ethanamine (48). Compound 47 (0.5 g, 2.2 mmol) was added to an 
ice-cold solution of THF (25 mL) and LiAlH4 (0.22 g, 6.0 mmol). The reaction was 
heated to reflux for 5 h and then cooled. To this was added 1 ml water and 1 mL 10% 
NaOH. Celite was then added to the mixture and filtered. The mixture was washed with 
CH2Cl2. The filtrate was washed with water, dried (MgSO4), and the solvent was 
removed under reduced pressure to yield crude product as oil that was purified by 
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to obtain 48 (0.3 g, 
80%). 
1
H NMR (CDCl3): 2.8 (t, J = 7.8 Hz, 2H), 3.0 (t, J = 7.8 Hz, 2H), 7.4 - 7.5 (m, 
4H), 7.56 (s, 1H), 7.6 - 7.7(m, 4H).  
 
9-Bromomethylanthracene (50).
193
 A suspension of 9-hydroxymethylanthracene (49, 
1.5 g, 7.2 mmol) in toluene (40 mL) was cooled to 0 
o
C followed by addition of 
phosphorus tribromide (0.8 mL, 8.4 mmol) via syringe. The mixture was stirred at 0 °C 
for 1 h and then warmed to rt, during which the reaction became homogeneous. Saturated 
Na2CO3 solution (15 mL) was added slowly and the reaction was stirred until it cooled to 
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rt. The phases were separated, and the organic phase was washed with water (10 mL), 
brine (10 mL) and dried over MgSO4. The yellow filtrate was concentrated to minimum 
volume, and then stored at 0 °C for crystallization. The yellow needle-like solid was 
collected and dried in vacuum (1.24 g). The mother liquid was concentrated and purified 
using medium pressure column chromatography (0.6 g). The two parts were combined to 
give the product 50 (total 1.84 g, 94%) as yellow needles. mp 145 -148 °C. 
1
H NMR 
(CDCl3): 5.5 (s, 2H), 7.2 - 8.4 (m, 9H). 
 
2-(Anthracen-9-yl)acetonitrile (51). A solution of compound 50 (1.5 g, 5.53 mmol) in 
DMSO (15 mL) was added over 10 min to a rapidly stirred suspension of KCN (0.54 g, 
8.29 mmol) in DMSO (30 mL) at 70 °C under N2. The mixture was stirred for an 
additional 40 min, cooled to rt and then diluted with water. The aqueous layer was 
saturated with sodium chloride and then extracted with ether (3 × 25 mL). The combined 
extracts were washed with water, dried (MgSO4,), filtered, and concentrated to yield 
product 51 (0.96 g, 80%) as a pale white solid. mp 154 - 156 °C. 
1
H NMR (CDCl3): 4.61 
(s, 2H), 7.2 - 8.5 (m, 9H). 
 
2-(Anthracen-9-yl)acetic acid (52). To a suspension of compound 51 (0.95 g, 4.37 
mmol) in ethylene glycol (50 mL) was added KOH (0.97 g, 17.48 mmol) in 10 ml of 
water. The mixture was heated to reflux for 24 h until the entire solid was completely 
dissolved. The hot solution was filtered, and the filtrate was acidified with dilute HCl to 
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obtain precipitate of product 52 (1.08 g, 100%). mp 212 - 214 °C. (lit
244
 208 - 212 
o
C). 
1
H 
NMR (CDCl3): 4.63 (s, 2H), 7.4 - 8.5 (m, 9H). 
 
2-(9,10-Dihydroanthracen-9-yl)acetic acid (53). To a refluxing solution of compound 
52 (0.375 g, 1.58 mmol) in 1-pentanol (10 mL) were added sodium pieces (0.36 g, 10 
equiv) slowly. The reaction mixture was stirred for 10 min until all the sodium dissolved. 
Water (10 mL) was added to the cooled mixture and then made acidic with 5% HCl. The 
reaction mixture was dried under high vacuum and the oily solution obtained was 
extracted with chloroform, dried (MgSO4) and concentrated to yield pure product 53 (0.3 
g, 80%) as white solid. mp 168 - 170 °C. (lit
245
 167 - 169 °C) 
1
H NMR (CDCl3): 2.63 (s, 
2H), 4.48 (t, J = 6.9 Hz, 1H), 3.91 (d, J = 18.6 Hz, 1H) 4.06 (d, J = 18.6 Hz, 1H),  7.4 - 
8.4 (m, 9H). 
 
2-(9,10-Dihydroanthracen-9-yl)-N-methylacetamide (54). Thionyl chloride (0.86 g, 
7.3 mmol) was added under N2 to a stirred solution of compound 53 (0.35 g, 1.45 mmol) 
in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool 
and the excess benzene and thionyl chloride were removed under reduced pressure to 
provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an 
ice bath (0 °C). Methylamine/THF (2 M, 0.09 g, 2.9 mmol) solution was added dropwise 
into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed 
under reduced pressure to give a white solid. Water (20 mL) was added, and the 
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed 
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with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave 
the crude amide as yellow oil. The resulting amide was purified using medium pressure 
chromatography, CH2Cl2/Acetone to yield 54 (0.27g, 76%). 
1
H NMR (CDCl3): 2.16 (s, 
3H), 2.41 (d, J = 7.5 Hz, 2H), 3.93 (d, J = 18.3 Hz, 1H), 4.05 (d, J = 18.3 Hz, 1H), 4.56 
(t, J = 7.5 Hz, 1H), 7.1 -7.3 (m, 8H). 
 
2,(9,10-Dihydroanthracene-9-yl)ethanol (56). Na2K silica gel (2 g) was added to a well 
stirred solution of 2-(anthracen-9-yl)ethanol 55 (0.75 g, 4.4 mmol) in anhydrous THF (10 
mL) under N2 at rt. The reaction mixture was refluxed for 15 min then allowed to cool to 
rt and quenched with water (50 mL). The solid precipitate obtained was filtered and 
washed with EtOAc (3 × 25 mL). The filtrate was collected and the mixture was 
extracted. The EtOAc portion was dried (MgSO4) and concentrated under reduced 
pressure to obtain viscous yellow oil. This was purified using medium pressure column 
chromatography, CH2Cl2/MeOH (9:1) to give 56 (0.65 g, 86%). 
1
H NMR (CDCl3): 1.76 
(q, J = 6.3 Hz, 2H), 3.49 (t, J = 6.3 Hz, 2H), 3.93 (d, J = 18.2 Hz, 1H), 4.15 (d, J = 18.2 
Hz, 1H), 4.08 (t, J = 7.2 Hz, 1H), 7.1 - 8.3 (m, 8H). 
13
C NMR (CDCl3):  31.5, 35.4, 
38.5, 42.3, 60.1, 62.3, 130.1, 131.2, 136.2, 140.2. 
 
2-(9,10-Dihydroanthracene-9-yl)acetaldehyde (57). A solution of compound 56 (0.50 
g, 2.2 mmol) in anhydrous CH2Cl2 (10 mL) was added to a stirred mixture of Dess-Martin 
(periodinane) oxidant (1.39 g, 3.3 mmol) in CH2Cl2. The reaction mixture was stirred for 
1h then diluted with ether (50 mL) and poured into 1.3 M NaOH (50 mL). The ether layer 
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was separated and extracted with 1.3 M NaOH (3 × 15 mL). The ether portion was 
washed with water (2 × 20 mL), brine (20 mL), dried (MgSO4) and concentrated under 
reduced pressure to yield product as oil. The resulting oil was purified by medium 
pressure column chromatography, Petroleum ether/EtOAc (9:1) to give 57 (0.391 g, 80%) 
as an oil. 
1
H NMR (CDCl3): 2.76 (d, J = 7.5 Hz, 2H), 3.86 (d, J = 18.3 Hz, 1H), 4.05 (d, J 
= 18.3 Hz, 1H), 4.59 (t, J = 6.9 Hz, 1H), 7.0 - 7.2 (m, 8H), 9.7 (s, 1H). 
13
C NMR 
(CDCl3): 34.85, 40.77, 50.0, 126.19, 127.35, 137.21, 138.5, 200.0. 
 
3-(Anthracen-9-yl)propanoic acid (61).
197
 Anthrone 58 (3.0 g, 15.5 mmol) was added 
to a well stirred solution of potassium t-butoxide (2.17 g, 19.38 mmol) dissolved in 
anhydrous t-butyl alcohol (30 mL). The solution was stirred for 1h at rt. Acrylonitrile (0.9 
g, 17.05 mmol) dissolved in 10 mL of anhydrous t-butyl alcohol was added dropwise 
over a period of 1 h to this reddish-brown solution of potassium anthranolate. During the 
addition of the nitrile a bright red precipitate separated. The reaction mixture was 
refluxed for 2 h and a clear deep red-colored solution was obtained. 5% HCl (2 mL) was 
added to the cooled mixture and t-butyl alcohol was removed under vacuum to yield a 
brown solid. Concentrated HCl (20 mL) was added to the residue which was refluxed for 
12 h. After cooling, HCl was removed with the aid of a sintered glass filter and the solid 
remaining in the flask was washed with water. The solid acid was dissolved in a mixture 
of concentrated ammonium hydroxide (50 mL) and water (30 mL) and the resulting 
solution was heated at 90 °C for 4 h with 9.5 g of zinc dust. The cooled reaction mixture 
was filtered to remove excess zinc and the filtrate was extracted with ether. The aqueous 
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layer was acidified with HCl to yield a crude acid which was filtered and dried. 
Recrystallization of the crude acid with 2-propanol gave 61 (1.96 g, 51% yield) as pale 
yellow crystals. mp 194 - 195 °C. (lit
197
 194 – 195 °C). 1H NMR (CDCl3): 2.85 (t, J = 6.9 
Hz, 2H), 4.01 (t, J = 6.9 Hz, 2H), 7.4 - 8.3 (m, 9H).
  
 
3-(9,10-Dihydroanthracen-9-yl)propanoic acid (62).
197
 To a refluxing solution of 
compound 61 (0.5 g, 2.0 mmol) in 1-pentanol (15 mL) was added sodium pieces (0.46 g, 
20 mmol) slowly. The reaction mixture was then stirred for 10 min until all the sodium 
dissolved. The reaction mixture was cooled, water (10 mL) was added to the mixture and 
made acidic with 5% HCl. The reaction mixture was dried under high vacuum and the 
oily solution obtained was extracted with chloroform, dried (MgSO4,) and concentrated 
to give crude product. The crude product obtained was purified by medium pressure 
chromatography, CH2Cl2/MeOH (9:1) to give 62 (0.4 g, 85%) as a white solid. mp 138 - 
140 °C. (lit
197
 137 - 140 °C). 
1
H NMR (CDCl3): 1.96 (q, J = 6.9 Hz, 2H), 2.32 (t, J = 7.2 
Hz, 2H), 3.95 (t, J = 7.2 Hz, 1H), 3.9 (d, J = 18.6 Hz, 1H), 4.0 9 (d, J = 18.6 Hz, 1H), 7.1 
- 7.29 (m, 8H).
  
 
3-(9,10-Dihydroanthracen-9-yl)propanamide (63). Thionyl chloride (0.14 g, 1.18 
mmol) was added under N2 to a stirred solution of compound 62 (0.15 g, 0.59 mmol) in 
anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and 
the excess benzene and thionyl chloride were removed under reduced pressure to provide 
an oil. The brown oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an 
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ice bath (0 °C). Anhydrous ammonia was slowly bubbled into the stirred solution for 0.5 
h, and the mixture was stirred at rt (2 h). The solvent was removed under reduced 
pressure to give oil. Water (20 mL) was added, and the suspension was extracted with 
EtOAc (3 × 25 mL). The combined extracts were washed with water and brine and dried 
(MgSO4). Removal of solvent under reduced pressure gave the crude amide. The 
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone 
(9:1) to yield 63 (0.11 g, 75%). mp 131 - 133
 
°C.
 1
H NMR (CDCl3): 1.96 (t, J = 7.2 Hz, 
2H), 2.18 (q, J = 7.2 Hz, 2H), 3.97 (t, J = 7.5 Hz, 1H), 3.90 (d, J = 18.2 Hz, 1H), 4.08 (d, 
J = 18.2 Hz, 1H), 7.2 - 8.3 (m, 8H).   
 
3-(9,10-Dihydroanthracen-10-yl)-N-methylpropanamide (64). Thionyl chloride (0.14 
g, 1.18 mmol) was added under N2 to a stirred solution of compound 62 (0.15 g, 0.59 
mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to 
cool and the excess benzene and thionyl chloride were removed under reduced pressure 
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in 
an ice bath (0 °C). Methylamine/THF (2 M, 0.036 g, 1.18 mmol) solution was added 
dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was 
removed under reduced pressure to give a white solid. Water (20 mL) was added, and the 
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed 
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave 
crude amide. The resulting amide was purified using medium pressure chromatography, 
CH2Cl2/Acetone (9:1) to yield 64 (0.12 g, 78%). mp 148 - 150 °C.
 1
H NMR (CDCl3): 
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1.94 (t, J = 8.1 Hz, 2H), 2.12 (q, J = 7.2Hz, 2H), 2.73 (d, J = 4.8Hz, 3H), 3.95 (t, J = 
7.5Hz, 1H), 3.89 (d, 18.6 Hz, 1H), 4.07 (d, J = 18.6 Hz, 1H), 7.1 - 7.3 (m, 8H).
 13
C NMR 
(CDCl3):  25.8, 32.5, 33.7, 34.7, 46.0, 125.8, 127.5, 135.6, 139.2, 172.6. 
 
3-(9,10-Dihydroanthracen-10-yl)-N,N-dimethylpropanamide (65). Thionyl chloride 
(0.14 g, 1.18 mmol) was added under N2 to a stirred solution of compound 62 (0.15 g, 
0.59 mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), 
allowed to cool and the excess benzene and thionyl chloride were removed under reduced 
pressure to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and 
cooled in an ice bath (0 °C). Dimethylmethylamine/THF (2 M, 0.053 g, 1.18 mmol) 
solution was added dropwise into the stirred solution, and the mixture was stirred at rt (2 
h). The solvent was removed under reduced pressure to give a white solid. Water (20 mL) 
was added, and the suspension was extracted with EtOAc (3 × 25 mL). The combined 
extracts were washed with water, brine and dried (MgSO4). Removal of solvent under 
reduced pressure gave the crude amide. The resulting amide was purified using medium 
pressure chromatography, CH2Cl2/Acetone (9:1) to yield 65 (0.124 g, 76%) as an oil. 
1
H 
NMR (CDCl3): 1.98 (t, J = 7.5 Hz, 2H), 2.26 (m, 2H), 2.87 (s, 3H), 2.92 (s, 3H), 4.04 (t, 
J = 7.2 Hz, 1H), 3.85 (t, J = 18.6 Hz, 1H), 4.11 (d, 18.6 Hz, 1H), 7.20 - 7.29 (m, 8H).
 13
C 
NMR (CDCl3):  25.5, 33.5, 32.2, 34.8, 45.7, 125.7, 127.4, 135.6, 139.5, 172.0. 
 
3,3-Diphenylpropanal (68). A solution of 3,3-diphenylpropanol 67 (1.5 g, 7.0 mmol) in 
anhydrous CH2Cl2 (15 mL) was added to a stirred mixture of Dess-Martin (periodinane) 
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oxidant (3.2 g, 7.7 mmol) in CH2Cl2 (30 mL). After 50 min, the reaction mixture was 
diluted with ether (50 mL) and poured into 1.3 M aqueous NaOH (50 mL).  The ether 
layer was separated and extracted with 1.3 M NaOH (30 mL). The ether layer was 
washed with water, dried (MgSO4), and the solvent was removed under reduced pressure 
to give the 68 (1.11 g, 75%) as an oil.
 1
H NMR (CDCl3): 3.1 (m, 2H), 4.2 (t, J = 7.5 Hz, 
1H), 7.1 - 7.3 (m, 10H), 9.2 (s, 1H). 
13
C NMR (CDCl3):  52.2, 55.8, 126.3, 128.2, 129.3, 
143.1, 202.0. 
 
4,4-Diphenylbutyronitrile (71). To a suspension of potassium metal (0.69 g, 17.76 
mmol) and catalytic amount of ferric nitrate in liquid ammonia (50 mL, -70
 
°C) was 
added diphenylmethane 69 (2.5 g, 14.8 mmol) dissolved in ether (15 mL) over 15 min. 
The deep red suspension obtained was stirred for 30 min. To this reaction mixture was 
added bromopropionitrile 70 (1.98 g, 14.8 mmol) in ether. After the disappearance of 
deep red color, NH3 was allowed to evaporate. The organic layer was separated and 
residue was extracted twice with ether (40 mL). The combined ether extracts were 
washed with 0.1 N HCl (2 × 30 mL) water (50 mL), brine (50 mL) and dried (MgSO4). 
The solvent was removed under reduced pressure and resulting oil 71 (1.14 g, 35%) was 
purified by medium pressure chromatography, CH2Cl2/petroleum ether (2:3). 
1
H NMR 
(CDCl3): 2.27 (t, J = 7.5 Hz, 2H), 2.38 (q, J = 7.8 Hz, 2H), 4.06 (t, J = 7.8 Hz 1H), 7.1 -
7.3 (m, 10H). 
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4,4-Diphenylbutyric acid (73).
202
 A solution of -phenyl--butyrolactone 72 (1.62 g, 
10.0 mmol) in anhydrous benzene (50 mL) was added in small proportions to anhydrous 
aluminum chloride (1.46 g, 11.0 mmol). The mixture was stirred at rt for 5 h, and then 
quenched with 2 N HCl. The benzene layer was extracted with ether (3 × 25 mL). 
Combined extracts were washed with water and dried (MgSO4) after filtration, 
evaporation of the solvent afforded the compound 73 (2.0 g, 84%) as colorless crystals: 
mp 88 - 90
 
°C. (lit
202
 mp 89 - 91
 
°C) 
1
H NMR (CDCl3): 2.3 (q, J = 7.8 Hz, 2H), 2.6 (t, J = 
7.5 Hz, 2H), 4.1 (t, J = 7.8 Hz, 7.1 - 7.3 (m, 10H). 
13
C NMR (CDCl3): 25.1, 27.2, 50.2, 
126.2, 128.3, 129.3, 143.0, 178.2. 
 
N-Methyl-4,4-diphenylbutanamide (75). Thionyl chloride (1.18 g, 10.0 mmol) was 
added under N2 to a stirred solution of compound 73 (0.5 g, 2.0 mmol) in anhydrous 
benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and the excess 
benzene and thionyl chloride were removed under reduce pressure to provide an oil. The 
oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath (0 °C). 
Methylamine/THF (2 M, 0.31 g, 10 mmol) solution was added dropwise into the stirred 
solution, and the mixture was stirred at rt (2 h). The solvent was removed under reduced 
pressure to give a white solid. Water (20 mL) was added, and the suspension was 
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine 
and dried (MgSO4). Removal of solvent under reduced pressure gave the crude amide. 
The resulting amide was purified using medium pressure chromatography, 
CH2Cl2/Acetone (9:1) to yield 75 (0.42 g, 80%). 
1
H NMR (CDCl3): 2.1 (t, J = 7.5 Hz, 
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2H), 2.38 (q, J = 7.8 Hz, 2H), 2.74 (d, J = 5.1Hz 3H), 3.9 (t, J = 7.8 Hz 1H),  7.1 - 7.3 (m, 
10H).   
 
N,N-Dimethyl-4,4-diphenylbutanamide (76)
247
. Thionyl chloride (1.18 g, 10.0 mmol) 
was added under N2 to a stirred solution of compound 73 (0.5 g, 2.0 mmol) in anhydrous 
benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and the excess 
benzene and thionyl chloride were removed under reduce pressure to provide an oil. The 
oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath (0 °C). 
Dimethylmethylamine/THF (2 M, 0.45 g, 10.0 mmol) solution was added dropwise into 
the stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed 
under reduced pressure to give a white solid. Water (20 mL) was added, and the 
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed 
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave 
crude amide as an oil. The resulting oil was purified using medium pressure 
chromatography, CH2Cl2/Acetone (9:1) to yield 76 (0.43 g, 85%). 
1
H NMR (CDCl3): 
2.24 (t, J = 7.5 Hz, 2H), 2.39 (q, J = 7.2 Hz, 2H), 2.82 (d, J = 5.7 Hz, 3H), 3.97 (t, J = 7.2 
Hz, 1H), 7.1 - 7.3 (m, 10H).  
 
9,10-Dihydro-N-phenethylanthracene-10-carboxamide (77). Thionyl chloride (2.6 g, 
22.0 mmol) was added under N2 to a stirred solution of compound 43 (1g, 4.4 mmol)  in 
anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to cool and 
the excess benzene and thionyl chloride were removed under reduce pressure to provide 
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an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath 
(0 °C). Phenylethylamine (1.0 g, 8.8 mmol) was added dropwise into the stirred solution, 
and the mixture was stirred at rt (2 h). The solvent was removed under reduced pressure 
to give a white solid. Water (20 mL) was added, and the suspension was extracted with 
EtOAc (3 × 25 mL). The combined extracts were washed with water, brine and dried 
(MgSO4). Removal of solvent under reduced pressure gave a crude solid.  The resulting 
amide was purified using medium pressure chromatography, CH2Cl2/Acetone (9:1) to 
yield 77 (1.05 g, 73%). mp 140 - 143 °C. 
1
H NMR (CDCl3): 2.63 (t, J = 7.2 Hz, 2H) 3.43 
(q, J = 7.2 Hz, 2H), 3.85 (s, 2H), 4.82 (s, 1H), 6.9 - 7.4 (m, 13H). 
13
C NMR (CDCl3):  
35.62, 39.70, 41.74, 54.53, 126.10, 127.8, 128.6, 138.2, 143.4, 170.9. 
 
9,10-Dihydro-N-(3-phenylpropyl)anthracene-10-carboxamide (78). Thionyl chloride 
(2.6 g, 22.0 mmol) was added under N2 to a stirred solution of compound 43 (1 g, 4.4 
mmol) in anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to 
cool and the excess benzene and thionyl chloride were removed under reduced pressure 
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in 
an ice bath (0 °C). Phenylpropylamine (1.0 g, 8.8 mmol) was added dropwise into the 
stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed under 
reduced pressure to give a white solid. Water (20 mL) was added, and the suspension was 
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine 
and dried (MgSO4). Removal of solvent under reduced pressure gave a crude solid.  The 
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone 
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(9:1) to yield 78 (1.15 g, 75%). 
1
H NMR (CDCl3): 1.63 (m, 2H), 2.46 (t, J = 7.2Hz, 2H), 
3.15 (q, J = 7.2 Hz, 2H), 3.96 (d, J = 18.6 Hz, 1H), 4.16 (d, J = 18.6 Hz, 1H), 4.82 (s, 
1H), 6.9 - 7.4 (m, 13H). 
13
CNMR (CDCl3):  29.2, 33.2, 40.20, 41.7, 54.2, 126.1, 126.8, 
128.1, 128.7, 128.9, 138.0, 138.2, 143.4, 170.9. 
 
9,10-Dihydro-N-(4-phenylbutyl)anthracene-10-carboxamide (79). Thionyl chloride 
(2.6 g, 22.0 mmol) was added under N2 to a stirred solution of compound 43 (1 g, 4.4 
mmol) in anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to 
cool and the excess benzene and thionyl chloride were removed under reduced pressure 
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in 
an ice bath (0 °C). Phenylbutylamine (1.0 g, 8.8 mmol) was added dropwise into the 
stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed under 
reduced pressure to give a white solid. Water (20 mL) was added, and the suspension was 
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine 
and dried (MgSO4). Removal of solvent under reduced pressure gave a crude solid.  The 
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone, 
(9:1) to yield 79 (1.13 g, 72%). 
1
H NMR (CDCl3): 1.48 (m, 4H), 2.5 (t, J = 7.2 Hz, 2H), 
2.7 (t, J = 6.9 Hz, 2H), 3.91 (d, J = 18.3 Hz, 1H),  4.12 (d, J = 18.3 Hz, 1H), 7.0 - 8.4 (m, 
13H). 
13
C NMR (CDCl3):  28.2, 29.2, 35.7, 40.60, 41.7, 54.2, 126.1, 126.8, 128.1, 
128.7, 128.6, 138.0, 138.2, 143.4, 170.9. 
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 2-(Bromomethyl)benzaldehyde (81).
212
 A solution of 2-(bromomethyl)benzonitrile 80 
(5.0 g, 25.5 mmol) in dried CH2Cl2 (75 ml) was cooled in an ice-water bath and 
maintained under an inert atmosphere. A 1.0 M solution of diisobutyl aluminum hydride 
(26.0 mL, 26.0 mmol) in heptane was added in a dropwise manner over a period of 30 
min. The resulting solution was then allowed to warm slowly to rt with stirring in a 
period of 3 h by removing the ice-water bath. The reaction mixture was cooled again with 
an ice-bath, and then directly poured into a 1000 mL beaker containing ice (100 g) and a 
precooled HBr aqueous solution (6.0 N, 100 mL). The resulting mixture was vigorously 
stirred for 1 h and then extracted with CH2Cl2. The combined extracts were washed with 
1 N NaHCO3, water, and dried (MgSO4). Evaporation of solvent gave product 81 (4.9 g, 
97% yield) as a clear brown liquid. 
1
H NMR (CDCl3): 4.91 (s, 2H), 7.45 (d, J = 5.4 Hz 
1H ), 7.52 (d, J = 5.7 Hz, 1H), 7.56 (d, J = 5.4 Hz, 1H),   7.83 (d, J = 5.7 Hz, 1H), 10.23 
(s, 1H). 
 
2-((Naphthalen-2-yl)methyl)benzaldehyde (82). 2-naphthylboronic acid (1.5 g, 8.7 
mmol) was added to a well stirred solution of 81 (1.0 g, 5.0 mmol) with potassium 
phosphate (21.2 g, 10.0 mmol) and palladium tetrakistriphenyl (5mol % 0.288 g) in dry 
THF (20 ml). The reaction mixture was stirred for a while at rt and heated to reflux for 8 
h. The reaction mixture was cooled to rt, filtered and washed with CH2Cl2 (50 ml). The 
filtrate was evaporated to obtain a brown oily liquid as product 82 which was further 
purified by medium pressure column chromatography, petroleum ether/EtOAc (9:1) to 
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give semi-solid 82 (0.85 g, 62%). 
1
H NMR (CDCl3): 4.0 (s, 2H), 7.1 - 7.8 (m, 10H), 10.3 
(s,1H). 
 
2-((6-Methoxynaphthalen-2-yl)methyl)benzaldehyde (83).  
6-methoxy-2-napthylboronic acid (1.5 g, 7.5 mmol) was added to a well stirred solution 
of 81 (1.0 g, 5.0 mmol) with potassium phosphate (21.2 g, 10.0 mmol) and palladium 
tetrakistriphenyl (5mol % 0.288 g) in dry THF (20 ml). The reaction mixture was stirred 
for a 15 min at rt and heated to reflux for 8 h. The reaction mixture was cooled to rt, 
filtered and washed with CH2Cl2 (50 ml). The filtrate was evaporated to obtain a brown 
oily liquid as product 63 which was further purified by medium pressure column 
chromatography, petroleum ether/EtOAc (9:1) to give a pale yellow solid (0.9 g, 65%). 
mp 67 - 70 °C. 
1
H NMR (CDCl3): 3.9 (s, 3H), 4,58 (s, 2H), 7.1 - 7.9 (m, 10H), 10.3 
(s,1H). 
 
2-Amino-1-(2-((naphthalen-2-yl)methyl)phenyl)ethanol (84). Trimethylsilylcyanide 
(1.05 g, 10.6 mmol) was added dropwise to a well stirred solution of 82 (1.75 g, 7.1 
mmol) and ZnI (0.054 g, 0.28 mmol) cooled in an ice bath. The reaction mixture was 
allowed to warm to rt and then heated to 60 °C for 30 min. The reaction mixture was 
cooled back to 0 °C and lithium aluminum hydride (0.96 g, 25.32 mmol) was added in a 
dropwise manner. The reaction mixture was further refluxed for 12 h, cooled to rt, and 
1ml water and 1ml NaOH were added. The reaction mixture was then diluted with 
CH2Cl2 (50 ml) and filtered through celite. The filtrate evaporated under reduced pressure 
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to obtain a red oily liquid which was further purified by medium pressure column 
chromatography, CH2Cl2/MeOH (9:1) to get 84 (0.8 g, 45%). 
1
H NMR (CDCl3): 1.8 (bs, 
2H), 2.64 (m, 2H), 4.1 (s, 2H), 4.7 (m, 1H), 7.0 - 7.8 (m, 10H). 
 
2-Amino-1-(2-((6-methoxynaphthalen-6-yl)methyl)phenyl)ethanol (85). 
Trimethylsilylcyanide (0.94 g, 9.49 mmol) was added dropwise to a well stirred solution 
of 83 (1.75 g, 6.33 mmol) and ZnI (0.048 g, 0.253 mmol) cooled in an ice bath. The 
reaction mixture was allowed to warm to rt and than heated to 60 °C for 30 min. The 
reaction mixture was cooled back to 0 °C and lithium aluminium hydride (0.96 g, 25.32 
mmol) was added in a dropwise manner. The reaction mixture was further refluxed for 12 
h, cooled to rt, and 1 ml water and 1ml NaOH were added. The reaction mixture was then 
diluted with CH2Cl2 (50 ml) and filtered using celite. The filtrate evaporated under 
reduced pressure to obtain red oily liquid which was further purified by medium pressure 
column chromatography, CH2Cl2/MeOH (9:1) to get 85 (0.75 g, 40%). mp 150 - 153 °C. 
1
H NMR (CDCl3): 1.75 (bs, 2H), 2.64 (m, 2H), 3.9 (s, 3H), 4.16 (s, 2H), 4.82 (m, 1H), 
7.0 - 7.66 (m, 10H). 
 
Methyl 4-benzoylbenzoate (87). To a solution of 4-benzoylbenzoic acid 86 (0.5 g, 2.2 
mmol) in methanol (10 mL) was added 0.5 ml of concentrated H2SO4 and refluxed for 4 
h. The reaction mixture was cooled to rt and solvent was evaporated under vacuum. 
Water was added to the residue which was extracted with EtOAc (3 × 20 mL). The 
combined EtOAc extracts were washed with water, brine, and dried (MgSO4). The 
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solvent was evaporated under reduced pressure to give a yellow oil 87 (0.5 g, 95%).
 1
H 
NMR(CDCl3): 3.97 (s, 3H), 7.23 - 7.81 (m, 9H); 
13
C NMR(CDCl3):  51.8, 60.2, 128.2, 
129.2, 130.2, 132.5, 165.8. 
 
(E,Z)-Methyl 4-(4-(dimethylamino)-1-phenylbut-1-enyl)benzoate (88).  
3-Dimethylaminopropyl triphenylphosphonium bromide (0.847 g, 1.9 mmol) was 
dissolved in 10 ml of THF and 1.6M n-butyllithium (0.133 g, 2.09 mmol) was added 
dropwise under cooling in a dry ice-acetone bath at -78 °C.  The mixture was then stirred 
for 30 min under ice cooling. A solution of compound 87 (0.475 g, 1.9 mmol) in 10 ml 
THF was added to the mixture and stirring was continued for 30 min. The reaction 
mixture was brought to rt and was stirred for another 1h. Brine was added to the reaction 
mixture and extracted with EtOAc (3 × 20 mL). Extract was washed with water, brine 
and dried (MgSO4). The solvent was evaporated under reduced pressure to give pale 
brown oily substance 88 as a mixture of geometrical isomers (E/Z = 1/2) which was 
further purified by medium pressure column chromatography, CH2Cl2/MeOH (9:1) to 
obtain  88 (0.53 g 90%).
 1
H NMR(CDCl3): 2.3 (q, J = 7.8 Hz, 2H), 2.20 (s, 6H), 2.44 (t, J 
= 6.8 Hz, 2H), 3.92  (s, 3H), 6.19 (t, J = 7.8 Hz, 1H), 6.22 (t, J = 7.8 Hz, 1H),  7.17 - 
7.8.0 (m, 9H); 
13
C NMR(CDCl3):  25.06, 44.11, 51.8, 60.2, 126.4, 128.6, 129.2, 165.4. 
 
(E,Z)-4-(4-(Dimethylamino)-1-phenylbut-1-enyl)benzoic acid (89).
249
 Compound 88 
(0.5 g, 1.6 mmol) was dissolved in methanol (5 mL), 1 N NaOH (3 mL) was added and 
resulting mixture was stirred overnight at rt. 1 N HCl was added to the reaction mixture 
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and concentrated to dryness. After a CHCl3:MeOH (5:1) mixture (10 mL) was added to 
the residue, the resulting mixture was stirred for 30 min and filtered with celite. The 
filtrate was concentrated and purified by column chromatography to obtain a yellow 
gummy solid. The solid obtained was triturated with ether to yield  precipitate of 89 (0.42 
g, 89%) which was collected by filtration. 
1
H NMR (CD3OD): 1.86 (m, 2H), 2.13 (s, 6H), 
2.52 (m, 2H), 6.19 (t, J = 7.2 Hz 1H), 6.24 (t, J = 7.2 Hz 1H), 7.17 - 7.8.0 (m, 9H); 
13
C 
NMR(CD3OD):  25.07, 48.11, 60.8, 115.3, 126.4, 128.6, 130.2, 169.4. 
 
Ethyl 2-(bromomethyl)benzoate (91).
237
 A mixture of ethyl 2-methylbenzoate 90 (1.0 g, 
6.0 mmol), N-bromosuccinimide (1.12 g, 6.3 mmol) and benzoyl peroxide (0.145 g, 0.6 
mmol) in 40 mL carbon tetrachloride was heated under reflux for 4 h. The reaction 
mixture was then cooled to rt with additional cooling using an ice bath for 1 h. The 
succinimide was separated by filtration and the filtrate was evaporated under vacuum to 
give 91. The crude product (purity > 95%) obtained was in quantitative yield and was 
used as such in next step.
 1
H NMR(CDCl3): 1.45 (t, J = 7.5 Hz, 3H), 4.40 (q, J = 7.5 Hz, 
2H), 4.98 (s, 2H), (7.2 - 8.2 (m, 4H); 
13
C NMR(CDCl3):  15.1, 30.9, 62.9, 129.2, 129.6, 
130.3, 130.6, 133.8, 139.6, 170.2. 
 
2-(3-Carboxybenzyloxy)phenylacetic acid (93).
237
 A mixture of ethyl 2-(4-
hydroxyphenyl) acetate (0.73 g, 4.1 mmol), compound 91 (1.0 g, 4.1 mmol), potassium 
carbonate (2.26 g, 16.4 mmol) and potassium iodide (0.068 g, 0.41 mmol) in 50 mL of 
butanone was refluxed for 16 h, cooled, and filtered and the filtrate concentrated to one 
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third its original volume. Water was added to the mixture which was extracted with ether 
(3 × 25 mL). The ether extract was washed with 5% NaOH and water, dried (MgSO4), 
filtered and concentrated in vacuum to give an oil (92) which was refluxed with 
potassium hydroxide (3.67 g, 65.6 mmol) in 40 mL of ethanol for 12 h. The mixture was 
concentrated and the residue was dissolved in water and extracted with ether. 
Acidification of the aqueous layer provided a yellow solid which was purified by medium 
pressure column chromatography, Petroleum ether/EtOAc (9:1) to obtain product 93 
(0.49 g, 58%). mp 176 - 178 °C. (lit
237
 176 – 178 °C). 1H NMR(CDCl3): 3.51 (s, 2H), 
5.44 (s, 2H), 6.9 - 8.0 (m, 8H); 
13
C NMR(CDCl3):  39.8, 68.1, 114.6, 126.1, 126.1, 
127.2, 127.4, 128.8, 130.2, 130.7, 132.2, 139.5, 158.0, 169.1, 174.8.  
 
11-Methylene-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid methyl ester (94).
236
 To a 
suspension of methyltriphenylphosphonium bromide (0.6 g, 1.68 mmol) in anhydrous 
THF (2 mL) was added 2.5 N n-BuLi (0.023 g, 0.37 mmol) solution in hexane under N2 
atmosphere at 0 °C, and the mixture was stirred under same conditions for 1 h. A solution 
of compound 31 (0.1 g, 0.37 mmol) in THF (2 mL) was added and the resulting mixture 
was stirred at rt for 2 h. After being concentrated, the reaction mixture was diluted with 
water, washed with ether and then neutralized (10% HCl). The solution was concentrated 
and the residue was dissolved in MeOH (10 mL) containing p-TsOH·H2O (0.091 g, 0.48 
mmol) and refluxed for 2 h. After being concentrated, the reaction mixture was diluted 
with EtOAc, washed with water and dried (MgSO4). The solvent was evaporated in 
vacuum to obtain 94 which was purified by medium pressure column chromatography, 
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hexane/EtOAc (2:1) to obtain 94 as an oil (0.045 g, 45%). 
1
H NMR(CDCl3): 3.60 (s, 2H), 
3.73 (s, 3H), 5.19 (s, 2H), 5.32 (s, 1H), 5.74 (s, 1H), 6.82 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 
8.4Hz, 1H), 7.31 - 7.39 (m, 5H); 
13
C NMR(CDCl3):  39.85, 51.64, 70.39, 117.09, 
119.52, 125.10, 126.14, 126.46, 127.09, 127.68, 128.70, 130.04, 130.48, 133.74, 143.38, 
147.61, 154.70, 171.79. 
 
2-[(4-(2-Hydroxyethyl)phenoxy)methyl]benzoic acid (96). A mixture of 4-(2-
hydroxyethyl)phenol (3.12 g, 22.62 mmol), ethyl α-bromo-o-toluate 91 (5.0 g, 20.56 
mmol), potassium carbonate (8.52 g, 61.68 mmol) and potassium iodide (0.34 g, 2.056 
mmol) in 75 mL of butanone was refluxed for 16 h, cooled and then filtered. The filtrate 
was concentrated to one third its original volume. Water (50 mL) was added to the 
mixture and extracted with ether (3 × 25 mL). Ether extracts were washed with 5% 
NaOH, water and dried (MgSO4). The ether layer was concentrated in vacuum to obtain 
the intermediate compound 95 which was refluxed with sodium hydroxide (0.79 g, 19.97 
mmol) in 30 ml of methanol for 12 h. The resulting mixture was concentrated and the 
residue obtained was dissolved in water and extracted with ether (3 × 25 mL). 
Acidification of aqueous layer provided 96 as an oil (2.0 g, 57%).
 1
H NMR(CDCl3): 2.76 
(t, J = 7.2 Hz, 2H), 3.72 (t, 7.2 Hz 2H), 5.4 (s, 2H), 6.89 - 8.05 (m, 8H); 
13
C 
NMR(CDCl3):  37.43, 62.50, 67.33, 113.83, 126.39, 126.62, 127.97, 129.02, 130.01, 
130.68, 131.44, 138.99, 156.71, 168.34. 
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2-((4-(2-Acetoxyethyl)phenoxy)methyl)benzoic acid (97). Anhydrous acetyl chloride 
(0.034 g, 0.44 mmol) was added dropwise to a solution of compound 96 (0.1 g, 0.367 
mmol) in anhydrous THF (4 mL). The reaction mixture was stirred at rt overnight. THF 
was evaporated and the residue obtained was washed with water and extracted with 
CH2Cl2 to obtain the acetylated product 97 (0.109 g, 95%). 
 1
H NMR(CDCl3): 2.09 (s, 
3H), 2.92 (t, J = 7.8 Hz, 2H), 4.29 (t, J = 7.8 Hz, 2H), 5.58 (s, 2H), 6.97 - 8.23 (m, 8H); 
13
C NMR(CDCl3):  20.57, 33.81, 64.85, 67.82, 114.52, 114.63, 114.70, 126.10, 126.87, 
126.91, 129.50, 129.79, 131.27, 133.14, 140.37, 157.01, 170.02, 171.75. 
 
2-(6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-yl)ethanol (98).
239
 Compound 97 (0.2 g, 
0.63 mmol) was dissolved in CH2Cl2 (4 mL) and trifluroacetic anhydride (0.2 g, 0.95 
mmol) was added followed by a catalytic amount of borontrifluoride etherate. The 
reaction mixture was heated to 40 °C for 4 h and then washed with sat NaHCO3 and 
water. The organic phase was dried (MgSO4), filtered and concentrated in vacuum to oil. 
The crude product obtained was subjected to hydrolysis under basic conditions to get an 
oil that was purified by medium pressure column chromatography, CH2Cl2/CH3OH (9:1) 
to obtain 98 as an oil (0.145 g, 90%).
 1
H NMR(CDCl3): 2.90 (t, J = 6.6 Hz 2H), 3.89 (t, J 
= 6.6 Hz, 2H), 5.18 (s, 2H), 7.0 - 8.1 (m, 7H); 
13
C NMR(CDCl3):  37.68, 63.02, 73.16, 
120.44, 124.71, 127.36, 128.80, 129.01, 131.29, 131.94, 132.34, 135.19, 135.94, 140.0, 
159.58, 190.77. 
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6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-ethyloxy(tert-butyl)dimethylsilane (99). To 
a solution of compound 98 (0.1 g, 0.398 mmol) in DMF (4 mL) at 0 °C under N2, tert-
butyldimethylsilyl chloride (0.065 g, 0.437 mmol) and imidazole (0.040 g, 0.597 mmol) 
was added. The reaction mixture was then allowed to warm to rt and stirred overnight. 
Resulting mixture was diluted with an equal volume of chloroform, washed with water 
and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuum to 
give the product 99. The product obtained was purified by medium pressure column 
chromatography, 3%CH3OH/CH2Cl2 to yield compound 99 as an oil (0.13 g, 90%). 
1
H 
NMR(CDCl3): 0.04 (s, 6H), 0.92 (s, 9H), 2.88 (t, J = 6.6 Hz, 2H), 3.85 (t, J = 6.6 Hz, 
2H), 5.2 (s, 2H), 7.0 - 8.1(m, 7H); 
13
C NMR(CDCl3):  -5.76, 17.91, 25.52, 38.07, 63.82, 
73.20, 119.99, 124.57, 127.32, 128.77, 129.0, 131.44, 132.22, 132.66, 135.25, 136.23, 
140.16, 159.45, 190.73. 
 
(E,Z)-11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-ethyloxy(tert-
butyl)dimethylsilane (100). To a suspension of 4-(methylpentane) 
triphenylphosphonium bromide (0.927 g, 2.17 mmol) in anhydrous THF (5 mL) was 
added lithium bis(trimethylsilyl)amide (0.726 g, 4.34 mmol) in a dropwise manner. The 
resulting orange colored solution was stirred for 30 min at 0 °C and slowly brought to rt 
and stirring was continued for 1 h. To the deep orange colored solution was then added 
the compound 99 (0.4 g, 1.085 mmol) dissolved in THF (3 mL) and the reaction mixture 
was stirred for 12 h at rt. The reaction was then quenched by adding NH4Cl solution to 
the mixture. The THF was evaporated and residue was extracted with ethyl acetate (3 × 
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25 mL). The solvent was dried (MgSO4), filtered and concentrated in vacuum to yield an 
oil. This was purified by medium pressure column chromatography, CH2Cl2/Petroleum 
ether (7:3) to give compound 100 as a mixture of geometrical isomers (E/Z = 3/7)  as an 
oil (0.25 g, 53%). 
1
H NMR(CDCl3): 0.06 (s, 6H), 0.93 (s, 9H), 1.44 (d, J = 7.8 Hz, 6H), 
1.65 (m, 1H), 2.23 (q, J = 8.1 Hz, 2H), 2.48 (q, J = 8.1 Hz, 2H), 2.80 (t, J = 6.9 Hz, 2H), 
3.83 (t, J = 6.9 Hz, 2H), 5.2 (s, 2H), 5.72 (t, J = 7.5 Hz, 0.7H), 6.06 (t, J = 7.5 Hz, 0.3H), 
6.8 - 7.4 (m, 7H); 
13
C NMR(CDCl3):  -5.71, 17.99, 22.14, 25.59, 27.18, 27.32, 38.33, 
38.69, 64.42, 70.01, 118.87, 123.54, 125.87, 127.11, 127.62, 128.30, 129.31, 131.45, 
133.4, 136.83, 138.34, 145.45, 153.43. 
 
(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-ethyl alcohol (101). 
To a solution of Compound 100 (0.170 g, 0.389 mmol) in anhydrous THF (4 mL), tert-
butyl ammonium fluoride (0.203 g, 0.778 mmol) was added in a dropwise manner at 0 °C 
under N2. The resultant mixture was stirred for 1 h then allowed to warm to rt and stirring 
was continued for another 1 h. The reaction mixture was then concentrated in vacuum 
and the residue obtained was washed with water and extracted with EtOAc (3 × 25 mL) It 
was purified by medium pressure column chromatography, hexane/EtOAc (1:1) to yield 
product 101 as an oil (0.119 g, 95%). 
1
H NMR(CDCl3): 0.92 (d, J = 6.6 Hz, 6H), 1.44 (q, 
J = 7.8 Hz, 2H), 2.21 (m, J = 7.5 Hz, 1H), 2.45 (q, J = 7.5 Hz, 2H), 2.81 (t, J = 6.3 Hz 
2H), 3.84 (q, J = 6.3 Hz, 2H), 5.2 (bs, 2H), 5.7 (t, J = 7.8 Hz, 0.7H), 6.04 (t, J = 7.8 Hz, 
0.3H), 6.7 - 7.3 (m, 7H); 
13
C NMR(CDCl3):  22.10, 26.75, 27.30, 37.84, 38.43, 63.41, 
69.98, 118.27, 123.76, 125.85, 127.01, 127.59, 127.97, 128.61, 129.12, 129.49, 131.43, 
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133.16, 138.12, 145.38, 153.66. Anal Calcd for (C22H26O2·0.25 H2O) C, 80.82; H, 8.16 
Found: C, 80.49, H, 8.48. ESIMS (+ ve) calcd for C22H26O2 [(M+H)
+
] 323.19, found 
323.26 
 
7.2 Molecular Modeling 
Molecular modeling investigations were conducted using the SYBYL 7.1 
molecular modeling package (Tripos International, St. Louis, MO) on MIPS R14K- and 
R16K-based IRIX 6.5 Silicon Graphics Fuel and Tezro workstations. Molecular 
mechanics-based energy minimizations were performed using the Tripos Force Field with 
Gasteiger-Hückel charges, a distance-dependent dielectric constant  = 4 D/Å and a non-
bonded interaction cutoff = 8 Å and were terminated at an energy gradient of 0.05 
kcal/(mol×Å). The H1 (P35367) and 5-HT2A (P28233) receptor sequences were retrieved 
from the ExPASy Proteomics Server (http://www.expasy.org/) and aligned with a profile 
of several related class A GPCRs (human, dopamine D3 (P35462), muscarinic cholinergic 
M1 (P11229), vasopressin V1a (P37288), adrenergic 2 (P07550), -opioid (P41143), 5-
HT2A (P28223), dopamine D2 (P14416), bovine rhodopsin (P02699) using the ClustalX
159
 
program. Within ClustalX, the slow-accurate alignment algorithm was used, the 
BLOSUM matrix series was employed and the gap opening penalty was increased from 
10.0 to 15.0 to help maintain the continuity of the transmembrane helical segments. The 
alignment was carried out in two separate steps as reported by Bissantz, et al.
250
 Manual 
adjustment of the ClustalX alignment was required to properly align the disulfide-
forming cysteine residues in the e2 loop. The result was an unambiguous alignment in the 
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transmembrane (TM) helical regions of both the H1 and 5-HT2A sequences with that of the 
2–adrenoceptor. This alignment, along with a file containing the atomic coordinates of 
the adrenergic 2 receptor (PDB ID = 2RH1), was used as input to the MODELLER
162
 
software package to generate a population of 100 different H1 or 5-HT2A homology 
models. Each of these receptors was subsequently energy-minimized. An analogous 
method was used in the case of homology models generated from bovine rhodopsin as the 
template. In this case, atomic coordinates of the bovine rhodopsin receptor (PDB ID = 
1U19), were used as input to the MODELLER software package. 
 The automated docking program GOLD version 3.01 (Cambridge 
Crystallographic Data Centre, Cambridge, UK) was then used to dock diphenhydramine, 
AMDA (1) and the high-affinity matrix compounds 9 and 18 into each of the 100 
receptor models. In the case of modeling investigations for the carboxylate- substituted 
compounds, olopatadine and acrivastine were added to the above set of compounds. 
Based on the fitness function values, steric and electronic interactions of the docked 
poses and reported site-directed mutagenesis data, one receptor model was selected to 
represent the ligand binding site of the H1 and 5-HT2A receptors. These models were 
subsequently analyzed using PROCHECK
161
 and the ProTable facility with in SYBYL to 
assess the geometric integrity of various structural elements (bond lengths, torsion angles, 
etc.) within each receptor. After checks for stereochemical integrity, the receptor models 
were used for the docking of all the target compounds. Ligand molecules were sketched 
using SYBYL and energy-minimized using the same parameters as were used for the 
receptor models. Basic amines were protonated to form ammonium ions. GOLD was 
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used to dock each ligand structure (using the parameter set defined by the “standard 
default settings” option) into the final receptor model. Each receptor-ligand complex was 
then energy-minimized with its best-ranked docking pose.  
 The HINT scoring function (version 3.11S β) was utilized to explore and visualize 
hydropathic interactions by analyzing the ligand-receptor complexes generated by the 
automated docking program GOLD. The interaction scores were calculated for the 
energy-minimized highest-ranked ligand conformation. The receptors (5-HT2A and H1) 
and ligands were partitioned using the “dictionary” and “calculated” methods 
respectively. The „All‟ hydrogen treatment option was employed in the H-bonding 
model, and hydrogen atoms at unsaturated positions as well as alpha to a heteroatom 
were considered to participate in H-bonding interactions. The inferred solvent model, 
which considers the partition of each residue based on its hydrogen count, was selected. 
The „+20 -NH- SASA‟ chain H-bond correction option was selected. Intermolecular 
HINT Tables were calculated for all (hydrophobic and polar) interactions with an 
interaction output cutoff value of 1.0. Finally, hydrophobic and polar interaction HINT 
maps were generated separately for a region extending 8 Å beyond the docked ligands. 
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